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Summary
1
Summary
The pituitary gland is a key regulator of growth, metabolism and sexual development. The
pituitary gland integrates signals from the hypothalamus and from peripheral endocrine glands
and responds to changing physiological needs by secreting a series of hormones that regulate
the activity of various endocrine glands as well as acting directly on many tissues. Tumours of
the pituitary gland are relatively frequent possibly due to the plasticity of the gland. Pituitary
gland tumours occur both sporadically and as part of inherited multiple endocrine neoplasia
(MEN) syndromes. MEN1 is one of these inherited syndromes. People suffering from MEN1
develop tumours of the pituitary gland, the parathyroid glands, the pancreatic islets and the
adrenal glands. MEN1 is caused by a loss of function mutation in the tumour suppressor gene
MEN1. Men1 expression is found in all tissues in the mouse and not only in the endocrine
system. Menin the protein encoded by Men1, shares no homology with any known proteins
and contains no recognisable protein domains. Menin is believed to function as a regulator of
transcription through binding to several specific transcription factors. These include Smad
transcription factors, JunD and members of the NF-kB family of proteins.
To investigate the phenotype of Men1 deficiency and to elucidate the mechanism of MEN1
tumourigenesis I have generated a conditional Men1 mouse model that enables me to
specifically delete Men1  in the pituitary gland. Men1  deficient pituitary glands are
hyperplastic as early as 7 weeks of age. The hyperplasia often develops into massive
adenomas by 40 weeks of age. Both hyperplasia and adenoma formation shows a gender
difference and is more pronounced in female mice. Analysis of the Men1 deficient pituitary
glands revealed pituitary gland overproliferation by 12 weeks of age before the development
of adenomas. Microarray analysis of the Men1 deficient pituitaries identified two growth
factors that were significantly overexpressed in Men1 deficient pituitary glands. Both of these
factors also showed a clear gender difference in their expression levels. The overexpression of
these growth factors in the Men1 deficient pituitaries was confirmed by in situ hybridisation.
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1 Introduction
1.1 Growth control in the pituitary gland
1.1.1 The pituitary gland
The pituitary gland is the master gland of the endocrine system. It integrates signals from the
hypothalamus, to which it is connected to by the pituitary stalk and regulates the activity of
the thyroid gland, the adrenal gland and the gonads.
The pituitary gland has three anatomical and functional parts, the posterior pituitary gland,
which is of neuroectodermal origin, and the intermediate and anterior pituitary gland, which
derives from the oral ectoderm. The posterior pituitary gland contains axons from neurons in
the hypothalamus that secrete Vasopressin and Oxytoxin. The intermediate gland (which is
not present in humans) secretes Melanocyte Stimulating Hormone (MSH). The anterior
pituitary gland consists of five major cell types, the lactotropes (10-25 percent), corticotropes
(15-20 percent), thyrotropes (3-5 percent), gonadotropes (10-15 percent) and somatotropes
(40-50 percent). In response to specific releasing hormones secreted from the hypothalamus
each cell type secretes their distinct hormone. Thyrotropin Releasing Hormone (TRH)
stimulates Thyroid Stimulating Hormone (TSH) release from the thyrotropes. Gonadotropin
Releasing Hormone (GnRH) stimulates release of Luteinising Hormone (LH) and Follicle-
Stimulating Hormone (FSH) from gonadotropes. Growth hormone releasing hormone
(GHRH) stimulates Growth Hormone (GH) release from the somatotropes and finally
Corticotropin Releasing Hormone (CRH) stimulates Adrenocorticotropin (ACTH) release
from the corticotropes. A hypothalamic Prolactin Releasing Hormone (PRRH) has been
characterised that binds to the G-protein coupled receptor hGR3 (Hinuma et al., 1998),
although subsequent studies have suggested that PRRH is only functional in females and only
at high concentrations (Samson et al., 1998) and that much of its function may be mediated by
the hypothalamus (Seal et al., 2000).
TSH, LH, FSH and ACTH exert their effects through peripheral endocrine organs whereas
Prolactin and GH act directly on their target organs to regulate reproduction and growth
respectively.
During adult life, the activity and size of the pituitary gland changes with age and in response
to certain physiological events such as pregnancy. Accordingly the pituitary gland is subjected
to a very complex regulation consisting of hormonal regulation from the hypothalamus, as
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well as feedback control from the peripheral target glands and other endocrine glands that
regulate the activity and growth of the pituitary gland directly and indirectly through the
hypothalamus. This plasticity of the pituitary gland, which is a consequence of the necessity
to adapt to changing physiological needs, may be the reason why pituitary gland neoplasias
are more frequent than tumours of other tissues. To elucidate the mechanism of pituitary gland
tumourigenesis in both sporadic cases and in the context of inherited tumour syndromes like
MEN1, I will in the following sections discuss the development of the pituitary gland and the
factors that control its growth as well as what is known about factors contributing to
tumourigenesis of the pituitary gland and other endocrine glands.
1.1.2 Development of the pituitary gland
A schematic representation of the development of the pituitary gland is shown on Figure 1.1.
The pituitary gland and the hypothalamus develop from a close association between two
embryonic tissues, the neural ectoderm and the oral roof ectoderm. At embryonic day E8.5 of
mouse development, the oral ectoderm comes into contact with the neural ectoderm from
which it receives inductive signals, mainly BMP4. These signals induce the onset of pituitary
gland organogenesis (Treier et al., 1996)(Dasen et al., 1999). Shh and Hnf3ß, a winged helix
transcription factor, which were previously uniformly expressed in the oral ectoderm, are now
excluded from the contact region with the ventral diencephalon. This creates a molecular
compartment within the oral ectoderm, which later becomes the anterior pituitary gland. At
the same time, Lhx3, a member of the LIM homeodomain family of transcription factors, is
expressed in this molecular compartment and commits the oral ectoderm to the pituitary gland
fate. Subsequently at E9.0, the oral ectoderm invaginates to form a structure called Rathke's
pouch which is the pituitary gland primordium (Figure 1.1 A). The formation of Rathke’s
pouch is followed by proliferation of cells from the ventral part of the pituitary gland. This
proliferation is blocked in the absence of Lhx3 or FGF8 from the ventral diencephalon. In the
definitive Rathke’s pouch, BMP2 is induced at the boundary between Rathke’s pouch and the
oral ectoderm and a ventral to dorsal BMP2 activity gradient is created. Concomitant with the
invagination of the oral ectoderm, a portion of the ventral diencephalon (the infundibulum)
evaginates and contacts the dorsal portion of Rathke's pouch directly. FGF8 originating from
the infundibulum establishes a dorsal to ventral activity gradient that functions
antagonistically to the opposing ventral to dorsal BMP2 gradient (Figure 1.1 B) (Treier et al.,
1998). These two transient gradients establish patterns of overlapping expression of several
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transcription factors in Rathke’s pouch. Many of these transcription factors exhibit temporally
and spatially restricted domains of expression within the developing pituitary gland resulting
in the appearance of the different hormone secreting cell types (Figure 1.1 C) (Treier et al.,
1998).
A series of mice with pituitary gland phenotypes have contributed to the identification of
factors involved in specifying the different pituitary gland cell types. The Ames dwarf mouse
has a hypoplastic pituitary gland. In the Ames mouse, somatotropes, lactotropes and
thyrotropes are specified but fail to proliferate. Accordingly the number of these cell types is
less than 1 percent of wildtype numbers (Sornson et al., 1996). The gene responsible for this
phenotype was cloned by positional cloning and named Prop-1. Prop-1 is a homeodomain
transcription factor that is exclusively expressed in the pituitary. Its expression can be
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detected from E10.5 on in a dorsal to ventral gradient. The phenotype of the Ames mouse is
associated with an absence of expression of the transcription factor Pit-1 which is the reason
for the name Prop-1 (Prophet of Pit). Prop-1 binds directly to the Pit-1 promoter to initiate
transcription (Sornson et al., 1996). Pit-1 was originally isolated as a transcription factor
binding to elements in both the GH and Prolactin promoters (Nelson et al., 1988) and was
subsequently identified as the gene responsible for the phenotype of the Snell and Jackson
dwarf mice, which completely lack three lineages of pituitary gland cell types, the
somatotropes, the lactotropes and the thyrotropes. Pit-1 expression begins at E13.5 and drives
differentiation and maintenance of these three lineages. The Gata-2 transcription factor on the
other hand is necessary for the deveolpment of the thyrotrope and gonadotrope lineages
(Dasen et al., 1999).
1.1.3 Control of pituitary gland growth
Once the different pituitary gland cell types have been specified at E16 in the mouse, they
proliferate until 7 to 8 weeks after birth to form the adult pituitary gland. The proliferation of
the differentiated pituitary gland cell types is under the control of hypothalamic hormone
releasing hormones. This has been best illustrated by the regulation of somatotrope growth.
The “little” dwarf mouse is characterised by anterior pituitary gland hypoplasia and
significantly decreased GH secretion associated with a dramatic reduction in the number of
somatotropes. The "little” mouse carries a mutation in the GHRH receptor, which renders the
receptor unable to bind GHRH (Lin et al., 1993). Conversely, overexpression of GHRH leads
to somatotrope hyperplasia (Mayo et al., 1988). These findings suggest that the activity of
GHRH not only regulates the secretion of GH, but also the proliferation of the GH secreting
cells. Likewise it has been shown that CRH, TRH and GnRH are also able to stimulate
proliferation of their target cells (Ezzat, 2001) and importantly, that disruption of the gene
encoding TRH leads to a significant reduction in TSH positive cells of the pituitary gland
(Yamada et al., 1997). Furthermore, in the absence of GnRH, gonadotropes are specified but
fail to proliferate (Mason et al., 1986). In contrast corticotropes develop normally in the
pituitary gland of CRH deficient mice (Muglia et al., 1995), possibly suggesting the existence
of other Corticotropin Releasing Hormones.
The action of GHRH on hormone secretion from and proliferation of somatotropes is
counteracted by Somatostatin secreted from the hypothalamus. Likewise the growth of
lactotropes is repressed by dopamine secreted from the hypothalamus. On the other hand the
secretion of ACTH, TSH, LH and FSH and the proliferation of corticotropes, thyrotropes and
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gonadotropes is blocked by Cortisol, Thyroid Hormone and Sex Hormones respectively,
secreted from the peripheral endocrine glands, constituting negative feedback mechanisms
(Melmed, 2003).
The GHRH receptor is a G-protein coupled receptor that couples to the adenylate cyclase
activating G-protein Gαs (Mayo, 1992). The same is true for the other hypothalamic releasing
hormone receptors.
The striking effect of cAMP on pituitary gland cell proliferation has been illustrated by two
examples. Ectopic expression of a dominant negative form of the Cyclic AMP Binding
Element (CREB) in somatotropes results in pituitary gland hypoplasia and a GH deficiency
caused by a significant reductions in cell number. Thus disruption of the cAMP responsive
pathway blocks proliferation of somatotropes. (Struthers et al., 1991). Conversely activating
mutations to the Gαs subunit induces hyperproliferation of somatotropes (Landis et al., 1989).
After normal growth ceases, the pituitary gland recedes somewhat in size. The largest
pituitary glands are thus found in adolescent females where they measure up to 9 mm in
height in humans (Chanson et al., 2001). There is however one significant exception and that
is pregnancy. In pregnant women the pituitary gland more than doubles in size. Interestingly,
after pregnancy and lactation the pituitary gland reverts to near normal size within 6 months
(Dinc et al., 1998). Expansion of the lactotrope population is responsible for most of the gain
in size of the pituitary gland, but there is also evidence that somatotropes can be induced into
secreting Prolactin (Melmed, 2003). The proliferation of the lactotrope lineage is induced by
Estrogen, a very potent mitogen for lactotropes (Heaney et al., 1999). The dramatic regression
of pituitary gland size upon normalisation of Estrogen levels illustrates the very strict growth
control normally active in the pituitary gland.
1.1.4 Pituitary gland tumours
Tumours are the result of failed growth control. The development of a tumour is a dynamic
process that involves sequential acquisition of tumourigenic traits driven by selectional
pressure. Accordingly tumour development often involves a series of changes to pathways
providing growth signals or mediating growth inhibitory signals as well as controlling cell
survival. Advanced tumour progression also requires increased angiogenesis and the
acquisition of limitless replicative potential (Hanahan et al., 2000).
In the pituitary gland, tumour development is often a gradual progression from hyperplasia,
which is a general increase tissue size due to higher cell numbers, to neoplasia, which can be
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defined as an abnormal mass of cells produced by an autonomous growth of a tissue.
Neoplasias can be benign or malignant depending on their growth rate and invasiveness. A
benign tumour which originates from glandular epithelium is called an adenoma, whereas a
malignant tumour of the same origin is termed a carcinoma.
Pituitary gland tumours are very common. Unselected autopsies have revealed that up to 25
percent of the population may develop pituitary gland adenomas, however most tumours are
never diagnosed (Burrow et al., 1981). The vast majority of pituitary gland tumours are
sporadic. Pituitary gland tumours are almost inevitably benign, but can nevertheless lead to
death due to of their localisation under the brain (Melmed, 2003). Pathology from pituitary
gland tumours normally arises from an excess of hormone secretion. The most frequent
pituitary gland tumour is a prolactinoma, but GH secreting, ACTH secreting and non-
secreting tumours also occur with high incidence (Melmed, 2003).
It has traditionally been debated whether pituitary gland tumours arise because of an intrinsic
pituitary gland defect or because of aberrant hormonal stimulation. It is now apparent, that
most tumours are of clonal origin, which would favour the intrinsic pituitary gland defect, but
it is very likely that external factors also play a role (Melmed, 2003).
Considering that the proliferation of the pituitary gland cells as well as hormone secretion
from the pituitary gland is regulated by releasing factors secreted by the hypothalamus, as
well as by feedback regulation from peripheral endocrine glands, it is perhaps not surprising
that some of these hormones have been implicated in pituitary gland tumourigenesis.
In humans, long lasting hypothyroidism, hypogonadism or hypoadrenalism leads to loss of
hormonal feedback inhibition and to pituitary gland hyperplasia caused by expansion of
thyrotropes, corticotropes or gonadotropes respectively (Melmed, 2003). Likewise, hyper-
secretion of GHRH, CRH or TRH from the hypothalamus is associated with hyper-
proliferation of gonadotropes, corticotropes and thyrotropes respectively in humans (Ezzat,
2001). Also high Estrogen levels or too low Dopamine levels induce lactotrope proliferation
(Ezzat, 2001). Activating mutations of the pituitary gland cell growth factor receptors are
rarely seen in human pituitary gland tumours. Interestingly, there appears to be no correlation
between multiple births and increased prolactinoma formation in women despite the dramatic
pituitary gland hyperplasia induced by pregnancy (Coogan et al., 1995).
In rodent models, prolonged overexpression of GHRH (Mayo et al., 1988)(Asa et al., 1992a),
CRH (Asa et al., 1992b), Estrogen (Heaney et al., 1999) or disruption of the Dopamine D2
receptor (Asa et al., 1999) leads to pituitary gland hyperplasia and eventually to adenomas.
Overexpression of other growth factors such as FGF-β (Heaney et al., 1999) FGF4 (Gonsky
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et al., 1991), TGF-α (McAndrew et al., 1995), and NGF (Borrelli et al., 1992) has also been
implicated in hyperplasia and prolactinoma formation in mouse models and in human
tumours. While these growth factors are sufficient to induce hyperplasias and may increase
the likelihood of adenomas, the clonal nature of most adenomas suggests that additional
mutations have to occur for progression from hyperplasias (Melmed, 2003). For GH secreting
tumours, activation of cAMP responsive pathways appears to be important for pituitary gland
tumourigenesis since 30 percent of sporadic tumours carry activating mutations to one of the
alpha subunits of the trimeric G proteins, Gαs (Vallar et al., 1987). The association between
high hypothalamic releasing hormone levels and hyperproliferation in corticotropes,
thyrotropes and gonadotropes in both mouse models and in humans suggests that deregulated
cAMP signalling can contribute to the formation of all pituitary gland tumours.
A series of mouse models have implicated genes involved in the Retinoblastoma (Rb)
pathway in pituitary gland hyperplasia and adenoma formation. The Rb pathway mediates
growth repressive signals and controls the onset of S-phase (Hanahan et al., 2000). These
mouse models include mice heterozygous for Rb itself (Jacks et al., 1992) as well as mice
homozygous for the disruption of the cyclin dependent kinase inhibitors, p18Ink4C (Franklin
et al., 1998), and p27Kip1 (Kiyokawa et al., 1996). These mice all develop adenomas
specifically of the pituitary gland. Disruption of the Rb pathway is generally associated with
tumour formation in all tissues (Hanahan et al., 2000), and the preferantial development of
pituitary gland tumours in these mouse models is not understood. Studies of human patients
have only found p27KIPI1 downregulated in tumours (Lidhar et al., 1999). The down
regulation of p27KIP1 is observed in most adenomas and appears to be mediated by protein
degradation (Melmed, 2003). Additionally, p16INK4A, another Cdk inhibitor, is very often
found downregulated or missing in pituitary gland tumours (Woloschak et al., 1996). This
downregulation may be caused by promoter methylation (Woloschak et al., 1997).
Although much still remains to be learnt it thus appears that pituitary gland tumourigenesis is
often initiated by deregulation of growth signals that normally regulate pituitary growth such
as hypothalamic releasing hormones, Estrogen or Dopamine and that cell autonomous
mutations to the cAMP pathway and possibly to the Rb pathway contribute to adenoma
formation.
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1.2 Multiple endocrine neoplasia
1.2.1 Multiple endocrine neoplasias
Most endocrine neoplasias are sporadic and not hereditary. All endocrine glands are affected,
however to a varying degree. Apart from the pituitary gland neoplasias, the most frequent
neoplasias are those of the parathyroid glands, which affect approximately 2 percent of
postmenopausal women (Carling, 2001). In contrast, tumours of the pancreatic islets are very
rare.
Most endocrine tumours are not life threatening, but a minority may develop into carcinomas.
Most symptoms experienced by affected individuals are due to hyper secretion of hormones
from the glands affected by the tumours. Indeed most endocrine neoplasias are first
recognised as hormone excess syndromes.
The endocrine glands are a heterogeneous group of organs without a common precursor
during development. Additionally, the glands are positioned in very different places in the
body. Nevertheless, a group of mostly inherited syndromes specifically cause neoplasia and
subsequent adenoma formation in several endocrine glands of the affected individuals.
Although these inherited tumour syndromes are less frequent than sporadic tumours they are
significant as they suggest a common mechanism of growth control in the endocrine system
and they may help to elucidate the underlying mechanism of tumourigenesis.
The name multiple endocrine neoplasias (MEN) refers to the development of tumours in
several different endocrine tissues at the same time. Five hereditary MEN syndromes have
been identified based on their characteristic pattern of neoplasias (Hoff, 2000).
MEN1: Pituitary gland, parathyroid gland, pancreatic islets, adrenal cortex,
cutaneous angiofibromas
MEN2A: medullary thyroid, adrenal medulla, parathyroid gland
MEN2B: medullary thyroid, adrenal medulla, gastrointestinal tract
FMTC: medullary thyroid
Carney complex: pituitary gland, thyroid, testicular, adrenal cortex
Over the last decade, the genes responsible for these syndromes have been cloned.
Interestingly it was found that germline mutations to the RET proto-oncogene was responsible
for MEN2A, MEN2B and FMTC (Mulligan et al., 1993)(Hofstra et al., 1994)(Donis-Keller et
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al., 1993). RET is a receptor tyrosine kinase. For each of the RET associated MEN
syndromes, a distinct set of gain of function mutations have been characterised. RET signals
though the Ras pathway to the MAP Kinases ERK1 and ERK2 and through the RHO family
of GTPases to JNK driving proliferation (Hoff, 2000). The endocrine specific pattern of
tumour formation associated with activating mutations to RET most likely reflects the
expression pattern of RET, rather than an endocrine specific mechanism of tumourigenesis as
RET expression is restricted to the neuronal and the endocrine system (Pachnis et al., 1993).
Loss of function mutations to PRKAR1A, a regulatory subunit of the cAMP dependent protein
kinase PKA, has been shown to be responsible for the Carney complex. People affected by the
Carney complex inherit one disrupted allele of PRKAR1A and subsequent loss of the wildtype
allele promotes tumour formation (Kirschner et al., 2000). These are the classic characteristics
of a tumour suppressor. The concept of tumour suppressors was proposed by Knudson while
studying the eye tumour Retinoblastoma. Knudson observed that his patients fell in two
categories. One group of patients developed retinoblastoma in one eye only, the average age
of onset for these patients was 32 months. The other group of patients developed bilateral
tumours and the average age of onset in these patients was only 15 months. Knudson
proposed that the latter group had inherited one non-functional tumour suppressor allele in the
germline and that the relatively frequent loss of the second allele would initiate the tumour
growth. Thus the characteristics of cancer caused by the inheritance of a disrupted tumour
suppressor is that tumours arise earlier and more frequently than sporadic tumours of the same
organ and that tumours have lost both wildtype tumour suppressor alleles (Knudson, 1971).
In contrast to RET, the expression of PRKAR1A is not limited to the endocrine system
(Barradeau et al., 2000). PKA is the cAMP dependent protein kinase responsible for
mediating most of the proliferative effect of cAMP (Stork et al., 2002) The loss of function
mutation to PRKAR1A leads to increased PKA activity (Kirschner et al., 2000), which
mimics activation of Gαs by ligands binding to G-protein coupled receptors. That activation
of the cAMP pathway can lead to adenoma formation in the testis, adrenal and thyroid gland
as well as the pituitary gland illustrates one of the common themes in regulation of
proliferation in the endocrine system; many cells in the endocrine system normally respond to
growth factors, which signal through G-protein-coupled receptors. That cAMP is a mitotic
signal for many cells of the endocrine system is also supported by the observation that
activating mutations to Gαs are frequently found in sporadic thyroid and pituitary gland
tumours and Leydig cell tumours of the testis (Lania et al., 2001). Moreover, mutations of
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Gαs early in development give rise to the so-called McCune Albright syndrome, which causes
hyper activity of the pituitary gland, thyroid, adrenal cortex and gonads, which can develop
into cancer. Gαs mutations do not pass through the germline suggesting that a general
deregulation of cAMP signalling is not compatible with life (Lania et al., 2001)(Stratakis,
2001).
In many non endocrine tissues cAMP mediates growth arrest. It has been suggested that the
ability of cAMP to activate the MAP Kinase pathway is the primary factor that determines if
cAMP acts as a mitotic signal or as a growth arrest signal (Stork et al., 2002). The stimulatory
effects of cAMP on the MAP kinase pathway appear to be mediated through Rap1 and B-Raf,
whereas Raf-1 activation by Ras is blocked by cAMP. Thus the expression of B-Raf is an
important factor in the proliferative outcome of cAMP signalling (Stork et al., 2002).
Other hereditary tumour syndromes that can cause endocrine as well as other types of
neoplasias have been characterised. These include Peutz-Jeghers syndrome caused by
inactivating mutations of the serine threonine kinase LKB1, Cowdens disease caused by
inactivation of the tumour suppressor PTEN (Stratakis, 2001) and Von Hippel-Lindau disease
caused by loss of function mutations of the VHL  E3 ubiquitin ligase, which leads to
overexpression of TGF-α and VEGF (Alexander, 2001).
1.2.2 Multiple Endocrine Neoplasia type 1 (MEN1)
MEN1 has an estimated prevalence of 0.02-0.2 per 1000 (Verges et al., 2002). Clinical
diagnosis of MEN1 can be made when a patient presents with tumours in at least two of the
following organs: parathyroid gland, pancreatic islets (gastrinomas) or anterior pituitary gland
(prolactinomas) (Schussheim et al., 2001). MEN1 patients also develop other symptoms
namely, adrenocortical tumours, foregut carcinoid tumours of the bronchus, thymus and
stomach as well as fascial angifibromas albeit with lower frequency (Schussheim et al., 2001).
The prevalence of tumours in the individual endocrine organs varies depending on the study.
In one big multi-centre report 95 percent of MEN1 patients had developed parathyroid
tumours, 54 percent tumours of the pancreatic islets (48 percent gastrinomas, 14 percent
insulinomas, 5 percent glucagomas) and 42 percent pituitary gland tumours (62 percent
prolactinomas, 9 percent GH secreting, 4 percent Prolactin and GH secreting, 6 percent
ACTH, 15 percent non-secreting) (Verges et al., 2002). 15 percent of gastrinomas progress to
aggressive malignancy, which is the primary cause of death from MEN1 (Schussheim et al.,
2001).
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The average age of onset was 38 years for pituitary gland tumours, 39 years for parathyroid
tumours and 41 years for pancreatic islet tumours (Verges et al., 2002). For tumours of the
parathyroid gland and pancreatic islets this is at least 10 years before the average onset of
sporadic tumours (Schussheim et al., 2001), but this is not the case for pituitary gland
tumours, where the average age of onset of sporadic and MEN1 tumours is identical (Verges
et al., 2002).
It was also observed that MEN1 pituitary gland tumours were more aggressive than sporadic
tumours, 85 percent being macro-adenomas compared to only 42 percent of sporadic pituitary
gland tumours. Additionally MEN1 tumours respond less well to treatment. Both of these
observations suggest that MEN1 pituitary gland tumours arise through a different mechanism
than sporadic pituitary gland tumours (Verges et al., 2002).
Finally MEN1 pituitary gland tumours showed a gender bias with females being more likely
than males to develop pituitary gland tumours (50 percent compared to 31 percent) (Verges et
al., 2002).
1.2.3 MEN1
The gene responsible for Multiple Endocrine Neoplasias was cloned by linkage analysis of
MEN1 families and by studying loss of heterozygosity in tumours from patients. Unlike the
other multiple endocrine neoplasia genes, this gene had not previously been characterised.
The gene was thus named MEN1. MEN1 maps to chromosome 11q13 (Chandrasekharappa et
al., 1997). Subsequent analysis found that 85 percent of MEN1 patients have germline
mutations of the open reading frame of MEN1 and that tumours from MEN1 patients showed
additional loss of heterozygosity at the MEN1 locus (Verges et al., 2002). As noted these are
the characteristics of a tumour suppressor (Knudson, 1971).
Mutations of MEN1 found in patients are spread over the entire reading frame but there is no
known connection between genotype and phenotype (Verges et al., 2002). Interestingly, while
MEN1 has been found mutated in a significant fraction of sporadic parathyroid and pancreatic
islet tumours (Heppner et al., 1997)(Zhuang et al., 1997), MEN1 inactivation does not appear
to play a major role in sporadic pituitary gland tumours (Prezant et al., 1998)(Farrell et al.,
1999)
The MEN1 gene is encoded by ten exons that give rise to two alternatively spliced mRNA
containing the same open reading frame (Stewart et al., 1998)(Guru et al., 1999). The Men1
transcript can be detected as early as embryonic day 7 in the mouse. At embryonic day 14
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there is high expression in all tissues and at embryonic day 17 there is widespread expression
with the highest signal from the muscles and central nervous system. In the adult mouse, there
is a clear expression in all tissues examined, with the highest expression in the liver, brain and
testis (Stewart et al., 1998)(Guru et al., 1999).
1.2.4 MENIN
The protein encoded by MEN1 has been named MENIN. Human MENIN comprises 610
amino acids and mouse Menin 611 amino acids. The protein is 97 % conserved between the
two species and most of the difference is concentrated in 40 amino acids at the C-terminus of
the protein (Guru et al., 1999)(Stewart et al., 1998). The Drosophila homologue is 46 %
identical to human MENIN (Guru et al., 2001).
Interestingly, Menin has no homology to any other protein and no known functional domains.
The protein does contain 2 nuclear localisation signals (Chandrasekharappa et al., 1997) and it
has been shown to be localised to the nucleus (Guru et al., 1998) and specifically to telomeres
during meiosis (Suphapeetiporn et al., 2002).
As there are no known domains, the structure of the protein does not suggest any function of
Menin. The level of Menin protein has been suggested to vary during the cell cycle in some
reports (Kaji et al., 1999) and to be invariant in others (Guru et al., 1999).
Surprisingly, considering the lack of significant homology to any known protein including
characterised GTPases, Menin binds to GTP and has GTP hydrolysis activity (Yaguchi et al.,
2002). Classical GTPases, which include Ras family proteins, small G-proteins and elongation
factor Tu (EF-Tu), all have a conserved structure that can be recognised from the bacterial
EF-Tu to mammalian Ras (Jurnak, 1985). Although Menin contains very vague GTPase
consensus motifs, the GTPase function of Menin does not appear to require these regions
(Hothorn, personal communication). Menin thus appears to be a novel type of GTPase.
Classical GTPases exist in two different conformations depending on whether they are bound
to GTP or GDP. It is not known if this is the case for Menin.
The GTPase activity of Menin can be increased many folds by the addition of the nucleoside
diphosphate kinase Nm23H1. Thus, Nm23H1 functions as a so-called GAP (GTPase
activating protein) for Menin (Yaguchi et al., 2002). No function has yet been established for
the GTPase activity of Menin.
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1.3 Menin as a regulator of transcription
1.3.1 Menin interacting proteins
The absence of any recognisable domains in Menin has prompted many researchers to look
for Menin interacting proteins in the hope that they would provide some clues to the function
of Menin. Several factors have been identified through yeast two hybrid screening or
immunoprecipitations and sequencing of Menin containing complexes. In agreement with the
nuclear localisation of Menin, all of the Menin interacting proteins except for Vimentin and
GFAP can translocate to the nucleus.
As of April 2004 the unabridged list of interaction partners is:
Gene type Ref.
JunD Transcription factor (Agarwal et al., 1999)
Nm23H1 Multifunction (Ohkura et al., 2001)
NF-κB Transcription factor (Heppner et al., 2001)
Smad3 Transcription factor (Kaji et al., 2001)
Smad1/Smad5 Transcription factor (Sowa et al., 2003)
Pem Transcription factor (Lemmens et al., 2001)
GFAP Structural (Lopez-Egido et al., 2002)
Vimentin Structural (Lopez-Egido et al., 2002)
Replication Protein A DNA replication (Sukhodolets et al., 2003)
FANCD2 DNA repair (Jin et al., 2003)
Myosin II-A Structural (Obungu et al., 2003)
mSin3A Transcriptional Co-repressor (Kim et al., 2003)
Mll2 complex Histone Methylase (Hughes et al., 2004)
Mll complex Histone Methylase (Yokoyama et al., 2004)
From the first Menin interaction partners to be identified (JunD, NF-κB, Smad3 and Pem), a
picture emerged of Menin as a regulator of gene expression. This notion has been
strengthened by the subsequent identification of mSin3a, Mll and Mll2 as Menin interacting
proteins. Menin is not believed to interact with DNA directly, but rather to regulate
transcription by binding to specific transcription factors. I will in the following discuss the
evidence that Menin is involved in transcriptional control by discussing three families of
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transcription factors, that have be shown to interact with Menin. I will also discuss the
transcriptional corepresser mSin3A and the Histone methylases Mll and Mll2, as these
proteins may be involved in mediating the effect of Menin on transcription. Finally I will
discuss the genes whose expression has been published to be modified by Menin.
1.3.2 Menin and JunD
JunD was the first Menin interacting protein to be identified. JunD was initially isolated in a
yeast two hybrid screen with Menin as bait, and the interaction was subsequently confirmed
by immunoprecipitation and pull down experiments using in vitro translated protein (Agarwal
et al., 1999). JunD is a member of the Jun family of proteins. In mammals, two other Jun
proteins exist, c-Jun the founding member (Angel et al., 1988) and JunB. The Jun proteins can
form homodimers or heterodimers with the Fos family of proteins or the ATF proteins (Angel
et al., 1991). These dimers make up the transcription factor AP-1 that binds to the TPA
response element (TRE) TGA(C/G)TCA. AP-1, consisting of c-Jun or JunB, has been shown
to have growth promoting activity in most tissues (Pfarr et al., 1994). This proliferative effect
of c-Jun and JunB is caused both by the direct upregulation of genes required for tissue
proliferation and indirectly by an inhibitory association of the Jun proteins with transcription
factors that stimulate differentiation, such as the Glucocorticoid receptor (Schule et al., 1990),
Estrogen and Vitamin D receptor (Doucas et al., 1991)(Schule et al., 1990). Conversely, JunD
appears to be expressed in differentiated and postmitotic cells (Pfarr et al., 1994) and JunD
has been shown to be able to inhibit Ras mediated transformation of NIH3T3 fibroblasts
whereas c-Jun supports transformation (Pfarr et al., 1994).
The binding of Menin to JunD has been reported to repress the transcriptional activity of
JunD, both in the context of the AP-1 complex and when JunD was fused to the Gal4 DNA
binding domain (Agarwal et al., 1999). Given the anti-proliferative effect of JunD, this
observation makes little sense in the context of the tumour-suppressor activity of Menin. This
apparent paradox was to some extent solved when Agarwal and co-workers subsequently
showed that JunD can promote transformation in Men1 deficient immortalised fibroblasts
whereas JunD expression in Men1 expressing fibroblast had a negative effect on growth
(Agarwal et al., 2003). In this cell line, Menin would thus appear to change JunD from a
growth promoter to a growth suppressor.
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The activity of the Jun family of transcription factors is regulated on a post-transcriptional
level through phosphorylation by the Jnk kinases. Jun phosphorylation may regulate
interaction with transcriptional cofactors such as CBP/p300 (Davis, 2000).
The mechanism by which Menin exerts its effect on JunD is under debate. In one report it was
suggested that Menin prevents JunD and c-Jun phosphorylation by Jnk as well as JunD and
Elk1 phosphorylation by Erk2 (Gallo et al., 2002) whereas another study showed that Menin
can repress Ap-1 transcriptional activity without affecting the phosphorylation state of the
complex (Yumita et al., 2003). Both groups agreed that Menin can repress transcriptional
activation of the c-Fos gene (Yumita et al., 2003)(Gallo et al., 2002).
Menin mediated suppression of JunD driven transcription can be inhibited by trichostatin A, a
Histone deacetylase inhibitor (Gobl et al., 1999), suggesting that Menin may recruit Histone
deacetylases to JunD. Histone acetylation is generally believed to loosen the chromatin
structure and facilitate transcription. Histone acetylation is carried out by 14 mammalian
Histone acetyl transferases (HATs) such as CBP and p300. Conversely, Histone deacetylation
is believed to repress transcription. Nine mammalian Histone deacetylases (HDAC) have been
characterised (Marks et al., 2001). Both HATs and HDACs associate with the chromatin
through transcription factors. The recent finding that Menin binds to the HDAC containing
mSin3A complex and that this complex associates with JunD suggests one mechanism
through which Menin can modify the activity of the transcription factors it binds.
1.3.3 mSin3A and Menin
In vitro translated Menin can immunoprecipitate mSin3A. Furthermore, Menin can
immunoprecipitate mSin3A from Jurkat cells. mSin3A and mSin3B are the mammalian
homologues of the yeast transcriptional co-repressor Sin3p (Ayer et al., 1995)(Schreiber-Agus
et al., 1995). mSin3A is widely expressed and its transcript is found in all tissues examined
(Halleck et al., 1995). mSin3A was originally identified as a transcriptional co-repressor for
the MAD transcriptional repressors. MAD inhibits the function of c-Myc by binding to the
Myc binding partner Max (Ayer et al., 1995)(Schreiber-Agus et al., 1995). mSin3A binds to a
so-called SID (Sin Interaction Domain) domain, which is found in all MAD proteins
(Schreiber-Agus et al., 1995). The binding of mSin3A to transcription factors recruits a multi-
protein repression complex to the promoter. This complex contains HDAC1 (Hassig et al.,
1997) and HDAC2 (Laherty et al., 1997). The Histone deactetylase (HDAC) activity is
necessary for transcriptional repression (Hassig et al., 1997). mSin3A has been shown to be
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involved in transcriptional repression mediated by several transcription factors apart from
MAD, among these are p53 (Murphy et al., 1999) and Pit-1 (Xu et al., 1998).
Menin can also immunoprecipitate deacetylase activity and HDAC1 and HDAC2, which are
part of the mSin3A transcriptional repression complex. The mSin3A interaction domain of
Menin was mapped to amino acids 295-450. This domain contains a putative SID - a 16
amino acid domain, which may form an amphiphatic helix. These 16 amino acids of Menin
can repress transcription when fused to a Gal4-DNA binding domain. Moreover mutation of
two residues in the putative SID, is sufficient to reduce repression of JunD by Menin (Kim et
al., 2003). The interaction of Menin with mSin3A may thus provide a mechanism for Menin
mediated transcriptional repression of JunD. Menin has been shown to function as a
transcriptional repressor for other transcription factors than JunD. These transcription factors
are the NF-κB family of transcription factors.
1.3.4 Menin and NF-κB
Menin can co-immunoprecipitate NF-κB1 (p50), NF-κB2 (p52) and RelA from 293 cell
extracts. Furthermore purified Menin binds recombinant NF-κB1 (p50), NF-κB2 (p52) and
RelA (Heppner et al., 2001).
RelA (p65), NF-κB1 (p50), NF-κB2 (p52) are members of the NF−κB family of proteins that
in mammals consists of five structurally and functionally related proteins. NF-kB binds to
DNA as dimers and the NF-κB family members can combine to form all combinations of
homo and heterodimers. p50, p52 dimers lack a transactivation domain and are believed to
function as transcriptional suppressors. All the family members contain a Rel homology
domain that is responsible for both DNA binding and dimerisation (Ghosh et al., 2002).
Recombinant GST fusions of 40 amino acids of the Rel homology domains from NF-κB1,
NF-κB2 and RelA can pull down purified Menin. Conversely, deletion of this domain from
the NF-kB family members abolished the interaction, suggesting that this domain is
responsible for the interaction between NF-κB and Menin. (Heppner et al., 2001).
In unstimulated cells, NF-κB dimers are cytosolic, being bound to members of the I-κB
family of proteins. Extra-cellular signals, which include TNFα, CD40L, Interleukin-1 and
lipopolysaccharide (LPS) leads to the activation of IKK kinase that phosphorylates I-κB,
which is then ubiquitinated and targeted for degradation by the proteasome. The released NF-
κB translocates to the nucleus to regulate transcription (Ghosh et al., 2002)(Karin et al.,
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2002). NF-κB recognises the so-called κB site GGGRNNYYCC, where N is any base, R is
Purine and Y is Pyrimidine (Kucharczak et al., 2003).
In cell culture experiments Menin overexpression can block RelA mediated transcription of a
reporter plasmid in Cos7 cells, HeLa cells and Ntera-2, a human embryonic carcinoma cell
line. Furthermore, overexpression of Menin can reduce phorbol-12-myristate-13-acetate
(PMA) induced transcription from a κB site driven reporter in HeLa cells (Heppner et al.,
2001).
The inhibition of RelA must be subsequent to RelA translocation to the nucleus since Menin
overexpression did not affect the subcellular localisation of RelA thus suggesting that Menin
affects the interaction of NF-κB with transcriptional cofactors (Heppner et al., 2001).
NF-κB has been shown to regulate many genes involved in control of proliferation and
apoptosis. These genes include CyclinD1 (Hinz et al., 1999), c-Myc (Duyao et al., 1990), IL-2
(Verweij et al., 1991), GM-CSF (Himes et al., 1993). cIAP (Wang et al., 2003), Bfl-1/A1,
BCL-XL (Lee et al., 1999), c-Flip (Micheau et al., 2001). Accordingly, disruption of RelA
leads to early embryonic lethality associated with massive TNF-α induced apoptosis of the
liver (Beg et al., 1995). Considering the nature of these genes it is not surprising that NF-κB
has been implicated in cancer. The product of the oncogene v-Rel is a constitutively active
transcription factor derived from c-Rel (Karin et al., 2002). Other oncoviruses express genes
that constitutively activate the NF-κB pathway such as TAX from the HTLV T-cell leukaemia
virus (Karin et al., 2002). Increased NF-κB expression has been found in leukaemias and
lymphomas which are both caused by uncontrolled growth of blood cells. In these cases,
chromosomal rearrangements of the c-REL  and NF-κB2  loci, which lead to their
overexpression, have been found. NF-κB may also play a role in carcinomas, especially breast
cancer, gastrointestinal cancers and colorectal cancers. Most breast cancers and some
colorectal cancers are associated with high NF-κB activity (Karin et al., 2002).
Many of the NF-κB regulated genes could potentially be involved in control of growth and
 apoptosis in the pituitary gland and other endocrine glands affected by MEN1. Specifically c-
Myc, that when overexpressed induces pancreatic islets tumours in animal models (Pelengaris
et al., 2002), and CYCLIN D1. CYCLIN D1 is also known as PRAD1 (parathyroid adenoma 1)
because it was identified at the breakpoint of a chromosomal rearrangement found in
parathyroid gland adenomas. These rearrangement leads to overexpression of CYCLIN D1 and
the gene has subsequently been found overexpressed in 18 percent of human parathyroid
gland adenomas (Carling, 2001).
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Both the effect of Menin on JunD and NF-κB mediated transcription and the interaction of
Menin with mSin3A would suggest that Menin functions as a transcriptional repressor.
Moreover the similarity between the effect of Menin binding to JunD and RelA suggests a
common mechanism, whereby Menin mediates recruitment of mSin3A to the trancription
factors. There is, however, also evidence that Menin can function as a transcriptional activator
when interacting with other transcription factors. This is the case with the Smad family of
proteins.
1.3.5 Smad transcription factors and Menin
Smad3 but not Smad2 or Smad4 can interact with Menin as demonstrated by the co-
immunoprecipitation of Menin by Smad3 from COS cells ectopically expressing the Smad
transcription factors and Menin (Kaji et al., 2001). Similarly Smad1 and Smad5 can co-
immunoprecipitate with Menin from COS7 cells (Sowa et al., 2003).
Smad transcription factors are the main intercellular mediators of signalling by the TGF-β
superfamily. The TGF-β superfamily consists of TGF-β1, TGF-β2, TGF-β3, the Bone
morphogenic proteins (BMPs), and Activins (Derynck et al., 2003). Upon ligand binding to
the TGF-β superfamily of receptor serine/threonine kinases, the Smads are recruited to the
receptor and activated by phosphorylation. Smad2 and Smad3 are recruited by TGF-β 
receptors, whereas Smad1, Smad5, and Smad8 bind to receptors activated by BMPs and
Activins. Smad4 functions as a common Smad that can interact with the other Smads
(Derynck et al., 2003). Phosphorylated Smads homodimerise and subsequently bind to
Smad4. The resulting trimer then translocates to the nucleus and regulates transcription.
Transfection of an antisense Men1 construct into the rat pituitary gland cell line GH4-C1
inhibits TGF-β mediated growth suppression as well as TGF-β1 induced transcription from
the Pai-1 (Plasminogen activator inhibitor type 1) promoter (Kaji et al., 2001). Furthermore,
depletion of Menin also inhibits TGF-β mediated growth repression in a parathyroid cell line
and TGF-β mediated reduction of Parathyroid Hormone expression (Sowa et al., 2004). Also
TGF-β induced growth arrest in the rat duodenal cell line IEC-17 is blocked by Menin
depletion (Ratineau et al., 2004).
Depletion of Menin by antisense transfection in the mesenchymal stem cell lines 10T1/2, ST2
and PA6 inhibits BMP2 induced differentiation into the osteoblast lineage and BMP mediated
activation of a reporter shown to be Smad 1 and Smad5 dependent (Sowa et al., 2003).
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It would thus appear that Menin not only binds to Smad1, Smad3 and Smad5 but also that the
binding of Menin to these transcription factors is required for their transcriptional activity.
The mechanism by which Menin regulates the transcriptional activity of the Smad
transcription factors has not been firmly established. Smad trimer formation and the
translocation of Smad3 complexes from the cytosol into the nucleus was not affected by the
loss of Menin, however in bandshift assays using cell extracts, Smad3 was unable to bind to
DNA when Menin levels in the extracts had been reduced by antisense Men1 (Kaji et al.,
2001 ). However, the binding of Smad3 to Menin was mediated by the MH2 transactivation
domain of Smad3 and not by the DNA binding domain MH1 (Kaji et al., 2001).
Smad trimers bind to their cognate binding site SBE (CAGAC) with an affinity that is 100
fold lower than that of high affinity transcription factor DNA complexes. Smads are thus
normally recruited to a specific promoter through complex formation with other transcription
factors such as AP-1, Sp1, NF-κB, FAST, OAZ and TFE3 (Derynck et al., 2003)(Massague et
al., 2000). Given that Smad complexes often require association with more specific
transcription factors to bind DNA, it is tempting to speculate that Menin exerts its function by
mediating these interactions rather than directly influencing the interaction of Smad3 with
DNA. In this case the activity of Menin would be dependent on the context of the promoter.
This model would also be in agreement with the binding of Menin to the transactivation
domain of Smad3. There is no evidence that Menin itself can function as a transcriptional
activator and until now no transcriptional coactivator has been shown to interact with Menin.
If Menin is required for Smad transcriptional activity then loss of function of Smad1, Smad3
and Smad5 could possibly mimic MEN1. Homozygous Smad3 null mice are viable but show
reduced growth and fertility. Importantly, Smad3 homozygous null animals develop colorectal
cancers with 100% penetrance by the age of 24 weeks. Unlike most other tumours of the
colon, the Smad3 null tumours were not associated with loss of APC (Zhu et al., 1998).
Smad3 null animals also show accelerated wound healing and an impaired inflammatory
response (Ashcroft et al., 1999). Inactivation of Smad3 by the oncogene Evi-1 has been
implicated in leukaemia (Kurokawa et al., 1998). Smad3 has also been shown to interact with
the products of the oncogenes c-Ski and c-SnoN. The binding of these oncoproteins to the
Smad complex represses transcriptional activation, possibly through recruitment of the
transcriptional repressor N-CoR and mSin3A (Luo et al., 1999)(Stroschein et al., 1999).
Homozygous deletion of Smad1 or Smad5 causes embryonic lethality at embryonic day 9.5
and 11.5 respectively. Mice heterozygous for Smad1 or Smad5 deletion are not prone to
developing cancers and they are thus not functioning as tumour suppressors in the mouse
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(Tremblay et al., 2001)(Lechleider et al., 2001)(Yang et al., 1999)(Chang et al., 1999; Chang
et al., 2000).
1.3.6 TGF-β signalling and growth control
TGF-β can both induce and repress its target genes. Activation is mediated by Smad2 and
Smad3 together with Smad4, through binding to SBE in complex with specific transcription
factors, whereas repression may be mediated by other factors acting through the TGF-β
inhibitory element (TIE), GNNTTGGtGa (Kerr et al., 1990). Recent data suggests that Smad3
can mediate TGF-β repression (Frederick et al., 2004). Depletion of Menin does not only
block TGF-β1 induced transcription from the Pai-1 promoter (Kaji et al., 2001) but also TGF-
β repression of Parathyroid Hormone expression (Sowa et al., 2004) suggesting that Menin
can regulate both TGF-β mediated transcriptional activation and repression.
TGF-β suppresses proliferation in most tissues by blocking cell cycle progression from G1
(Massague et al., 2000)(Blobe et al., 2000). Accordingly, studies of human cancers suggest
that inactivation of TGF-β signalling pathways is an important step in the progression of
many cancer types; 100 % of pancreatic tumours and 83 % of colon cancers show mutations
of one or more components of this pathway (Blobe et al., 2000).
In the pituitary gland, the effects of TGF-β are more complex. TGF-β1 inhibits proliferation
of lactotropes and blocks secretion of Prolactin (Sarkar et al., 1992) and in general TGF-β1
inhibits proliferation of pituitary gland cells possibly through upregulation of p15Ink4B (Frost
et al., 2001). TGF-β1 is mostly expressed in lactotropes (Hentges et al., 2000). In contrast
TGF-β3 is believed to support proliferation of lactotropes in response to Estrogen stimulation
(Hentges et al., 2000).
Several well-characterised TGF-β  targets are relevant for regulation of growth and
tumourigenesis. Most of these are activated by TGF-β and these include p15Ink4B (Hannon et
al., 1994)(Rich et al., 1999), p21Cip1 (Datto et al., 1995), p27Kip1, (Qian et al., 1996), c-Jun
(Wong et al., 1999), Pai1 Dennler et al., 1998),Vegf (Renner et al., 2002). A few genes are
repressed by TGF-β and these include c-Myc, (Frederick et al., 2004), Cdc25 (Iavarone et al.,
1997), and Transin/Stromelysin (Kerr et al., 1990).
To what extent these genes are regulated in vivo by Menin is not known. But genes like
p15Ink4B, p21Cip1 and p27Kip1, which all encode cyclin dependent kinase inhibitors
involved in mediating growth inhibitory signals impinging on the retinoblastoma protein are
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potential gowth regulatory genes in the pituitary gland. As noted previously, mutations to
factors in the Rb pathway have been implicated in pituitary gland tumourigenesis.
Furthermore, as noted previously, c-Myc overexpression induces pancreatic islets tumours in
animal models (Pelengaris et al., 2002).
1.3.7 MLL2 Histone methylation complex and Menin
Menin can co-immunoprecipitate with complexes consisting of MLL2, ASH2, RBBp5,
WDR5 and hDPY-30 from HeLa cells. (Hughes et al., 2004) and MLL, ASH2, RBBp5,
WDR5 and HCF-2 (Yokoyama et al., 2004). These complexes are the mammalian
homologues of the yeast SET1 complex (Roguev et al., 2001). Set1 is the yeast homologue of
the Drosophila trithorax gene. In mammals, three trithorax homologues Mll, Mll2 and Mll3
have been characterised (Djabali et al., 1992)(Huntsman et al., 1999). Both Mll and Mll2 are
ubiquitously expressed (FitzGerald et al., 1999).
The trithorax group of proteins are involved in maintenance of transcriptionally active genes,
enabling expression patterns to exist even after the expression of the transcription factors, that
have established these patterns, has ceased. Although first identified by their involvement in
maintaining the transcriptional state of homeotic genes, they are also involved in the
regulation of other genes. The trithorax group of genes is large and heterogeneous but their
phenotypes in Drosophila are comparable (Francis et al., 2001). The Trithorax family of
proteins functions a Histone methyl transferase that can methylate Histone3 on lysine-4
(Roguev et al., 2001), which is thought to activate transcription (Noma et al., 2001).
The Histone methyl transferase activity associated with the complex immunoprecipitated by
Menin can methylate Histone3 on lysine-4. Like SET1 in yeast, the protein complex can also
interact with RNA polymerase II (Hughes et al., 2004). Point mutants of Menin from human
MEN1 patients, cannot co-precipitate with the MLL2 complex nor any Histone methyl
transferase activity (Hughes et al., 2004).
Both MLL1 and MLL2 have been implicated in cancer. MLL was originally cloned as a gene
at the breakpoint in chromosomal rearrangements in acute leukaemia and the chromosomal
region of MLL2 has been found amplified in pancreatic carcinomas and in glioblastoma cell
lines (Djabali et al., 1992)(Huntsman et al., 1999). Interestingly upregulation of Hoxa7 and
Hoxa9 was implicated in the immortalisation process caused by expression of an oncogenic
Mll-Enl fusion gene in mice (Zeisig et al., 2004).
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Mll heterozygous null mice are growth retarded and show a homeotic transformation and
changed expression pattern of several hox genes including Hoxa7 and Hoxc9. Homozygous
animals are not viable and show no expression of Hoxa7 and Hoxc9 (Yu et al., 1995).
Men1 deficient MEFs showed a significant down-regulation of the hox genes Hoxc6 and
Hoxc8 compared to wildtype MEFs (Hughes et al., 2004). Likewise transfection of Men1
siRNA into HeLa cells reduced the expression of Hoxa9 (Yokoyama et al., 2004).
Hox genes are important regulators of patterning during development. In addition control of
cell proliferation has been suggested to be an important mechanism through which Hox genes
regulate patterning in vertebrates (Deboule, 1995). In adults, the expression of Hox genes is
restricted to stem or progenitor cells of highly proliferating cell populations like those of the
hematopoietic system (Sauvageau et al., 1995) and disruption of Hox gene expression
decreases proliferation of these cell types (Lawrence et al., 1997). Aberrant Hox gene
expression has mostly been associated with cancers of the hematopoietic system.
Furthermore, as Menin appears to be involved in maintaining rather than repressing Hox gene
expression, a direct involvement of Hox genes in MEN1 tumourigenesis seems unlikely.
However the interaction of Menin with the Mll proteins does suggest one mechanism through
which Menin could mediate transcriptional activation.
1.3.8 Menin regulation of telomerase activity
Men1 was isolated in a genetic screen for proteins that when overexpressed in HeLa and
MCF-7 cells, can suppress the expression of the human telomerase protein subunit hTERT
(Lin et al., 2003). Cell lines expressing GFP from the hTERT promoter were infected with a
retrovirus that integrates randomly in the genome and drives overexpression of nearby genes.
Clones were isolated that showed reduced GFP expression. Apart from Men1, genes involved
in the c-Myc and TGF-β pathways were isolated (Lin et al., 2003). Depletion of Men1 from
U2OS cells that normally do not express hTERT resulted in upregulation of hTERT. The
influence of Menin on the expression of hTERT appeared to be mediated by direct binding of
Menin to the hTERT promoter as judged by chromatin immunoprecipitations. The
transcription factors through which Menin bound the hTERT promoter were not identified
(Lin et al., 2003).
In humans, hTERT is not expressed in most somatic tissues. In the absence of telomerase
activity, the number of cell divisions of proliferating cells is limited by the shortening of the
telomers, which eventually induces proliferative senescence. Without telomerase activity, 60
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to 70 cell divisions are possible. In theory, this number should be sufficient for even the
biggest tumour to develop. In practise, however, most advanced tumours have gone through
successive rounds of apoptosis and clonal expansion that may have cost many cell divisions
without any gain in tumour size. 70 cell divisions may thus not be sufficient for most cancers
to develop as the replicative potential of the cancer cells eventually may be exhausted in the
absence of telomerase activity (Hanahan et al., 2000). Upregulation of hTERT is therefore
believed to be an important step in human cancer and it is found in up to 90 percent of
advanced tumours (Hanahan et al., 2000).
1.3.9 Menin regulated transcription and MEN1
There is overwhelming evidence that Menin functions as a transcriptional regulater. Menin
interacts with several transcription factors and can modify their transcriptional activity in cell
culture experiments. Interestingly, Menin appears to function as a transcriptional corepressor
in the case of JunD and the NF-κB family of transcription factors and as a transcriptional
coactivator in the case of the Smad family of proteins. How these different effects of Menin
on transcription is regulated is not known. The transcriptional repression of Menin may in part
be mediated by the interaction of Menin with the transcriptional repressor mSin3A. Likewise
the interaction of Menin with the Mll proteins suggest a mechanism by which Menin can be
involved in maintaining patterns of gene expression.
None of the transcription factors that have been published to bind Menin provide a
satisfactory model for MEN1 tumourigenesis alone. JunD, Smad3 and NF-κB have all been
implicated in growth control or tumourigenesis and many of their direct target genes notably
the CDK inhibitors, c-Myc and Cyclin D1, could potentially be mediators of MEN1
tumourigenesis. However none of these genes would appear to explain the endocrine specific
development of tumours. Futhermore none of these genes have been shown to be regulated by
Menin in vitro or in vivo.
Loss of Smad3 does lead to loss of growth control and cancer but it does not affect any of the
tissues involved in MEN1. Likewise overexpression of NF-kB has primarily been associated
with leukaemeias.
It seems reasonable to assume that the binding of a combination of these transcription factors
or other as yet unidentified Menin interacting proteins, to a set of promoters render these
promoters Menin responsive. Either, this combination of transcription factors occurs on the
critical genes only in the tissues affected by MEN1 or the Menin regulated genes specifically
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regulate growth of the endocrine system. Thus none of the published Menin responsive genes
appear to fit this role.
Alternatively Menin may interact with and regulate other as yet unidentified proteins that are
expressed only in the tissues affected by MEN1, or regulate genes that are relevant only for
growth control in the endocrine system.
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1.4 Aim of Study.
Although the Men1 gene has been the subject of intense research since its identification in
1997, the molecular mechanisms and cause of the tumourigenesis in patients suffering from
MEN1 is still largely unknown. The expression pattern of Men1 does not offer any clues to
the answer since most tissues that express Men1 do not develop tumours. The sequence of the
protein and the distribution of the human mutations also offers little information, since the
protein does not contain any recognisable domains and the mutations are distributed over
most of the open reading frame. Menin, the protein encoded by the Men1 gene, has been
shown to interact with several other proteins but none of them suggest any model that would
explain the potent tumour suppressor activity of Men1, nor the tissue specific development of
tumours in the endocrine system, although they do suggest that Menin functions as a
transcriptional cofactor. Some transcriptional targets of Menin have been published but none
of them appears likely to be the prime cause of tumour formation in the absence of Men1.
The ubiquitous expression of Men1 combined with the tissue specific development of tumours
in MEN1 suggested to us that Men1 could regulate a pathway common to most endocrine
cells. It would therefore be interesting to establish a mouse model that would allows us to
analyse the molecular mechanism and possibly identify genes that may be deregulated in
Men1 deficient cells.
Men1 functions as a classical tumour suppressor as all affected individuals inherit one non-
functional allele and subsequent loss of the second allele induces tumourigenesis. Therefore a
heterozygous mouse model would be a relevant model of MEN1. However, the stochastic
nature of the mechanism that leads to the loss of the wild type tumour suppressor allele meant
that it would be impossible to predict when the second Men1 allele would be lost before the
appearance of macroscopic adenomas. This made a heterozygous model problematic for
certain types of molecular analysis such as gene expression profiling using microarray
analysis, which requires a well defined genetic system.
The published early and widespread expression of Men1 during mouse development
suggested to us that it would be likely that a homozygous deletion of Men1 in the entire
mouse would lead to an early lethal phenotype.
In the light of this, I decided to establish a mouse model of the MEN1 syndrome that would
allow me to investigate the molecular changes associated with homozygous loss of Men1 in a
well defined system and at an age where secondary genetic changes would be unlikely. To
this end I wanted to generate a conditional knockout model that would allow homozygous
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deletion of Men1 in a significant part of the pituitary gland, a tissue relevant for the study of
MEN1
Although the published Menin interacting proteins do link Menin to the regulation of
transcription, none of them suggest a model that could explain the tissue specific development
of tumours in MEN1. To gain further insights into the molecular function of Menin, I also
wanted to undertake a yeast two hybrid screening for novel Menin interacting proteins using a
pituitary cDNA library.
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2 Results
2.1 Generation of Men1 deficient pituitary glands
2.1.1 Construction of the Men1 conditional knockout vector
To investigate the role of Men1 in tumourigenesis, I wanted to generate a mouse model of the
MEN1 disease. As mentioned, the published widespread expression pattern of Men1 (Guru et
al., 1999) in the mouse suggested to us that the biological function of Men1 may not be
restricted to the endocrine tissue. I thus reasoned that Men1  may be required for the
development of the mouse and decided to pursue a conditional knockout strategy that would
enable us to delete Men1 only in specific tissues.
The conditional knock out approach was based on the bacterial Cre recombinase that
recognises a specific 34 bp palindromic sequence called a LoxP site (Hoess et al., 1982). Cre
recombines out any sequence between a direct repeat of LoxP sites and inverts any sequence
between inverted repeats of LoxP. An allele of a gene with inserted LoxP sites is called a
floxed allele.
I screened a chromosomal mouse BAC library with a Men1 exon 2 probe and identified 4
BAC clones that contained the Men1 genomic region. The genomic organisation of Men1 has
been previously published (Guru et al., 1999). Men1 is encoded by 10 exons. The open
reading frame begins in exon 2 and terminates in exon 10. Taking advantage of an HpaI site in
intron 2 and a BstEII site in intron 6, I generated a Men1 conditional knockout vector with
LoxP sites in these two introns as outlined in Figure 2.1.1 A-B which should allow Cre
mediated deletion of exons 3 to 6. The knockout vector contained a positive selection cassette
encoding neomycin resistance flanked by Frt sites, a negative selection marker encoding
diphtheria toxin, to select against random integration events, a 3498 bp 5’ arm and a 2869 bp
3’ arm, to enable homologous recombination. The Frt sites flanking the positive selection
marker should enable subsequent deletion of the cassette leaving only one Frt site and two
LoxP sites, restoring the integrity of the Men1 locus.
Inactivating mutations of Menin have been reported to be distributed over the entire open
reading frame of the protein with no particular hotspots or obvious correlation between
mutation and phenotype (Verges et al., 2002). I therefore reasoned that deletion of exons 3 to
6, which encode amino acids 150 to 304 of Menin would constitute a null allele. Furthermore
possible splicing of exon 2 to exon 7 was predicted to cause a shift in the reading frame.
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2.1.2 Establishment of Men1LoxP-Neo allele
The knockout vector was electroporated into IB10 ES-cells. G418 resistant clones, which had
incorporated the knockout vector, were picked and cultured. To screen the ES-cell clones for
homologous recombination at the Men1 locus, a Southern blot strategy was devised based on
a 3’ external probe as shown in Figure 2.1.1 C and D. A total of 186 ES cell colonies were
screened and 23 were positive for homologous recombination at the Men1 locus.
Homologous recombination to integrate the positive selection marker requires two cross over
events; one in the 3’ arm and one 5’ of the selection cassette. However, since a cross over
event between the two LoxP sites would lead to loss of the 5’ most LoxP site, it was important
to screen the ES-cell clones for the presence of this site. A 96 well plate was thawed and the
positive clones were expanded. DNA was extracted and used for Southern blot analysis to
confirm the identity of the clones (not shown), and for a PCR based screening for the 5’ LoxP
site. Two sets of primers were used as shown in Figure 2.1.1 E; Men1LoxP1 and
Men1LoxP2, which should give rise to a band only in the presence of the 5’ LoxP site; and
Men1LoxP8 and Men1LoxP9 which should give rise to a slow migrating band as well as a
wildtype band if the 5’ LoxP site was present. Two positive clones were identified Figure
2.1.1 F.
The positive clones were injected into blastocysts by the EMBL transgenic facility and
chimeric animals were born with a male to female ratio of 5 to 1 and 12 to 4 for the two
clones respectively, reflecting the male origin of the IB10 ES-cells. Male chimeras that were
highly chimeric for the ES-cell clone, which is reflected by an a high agouti to black coat
colour ratio, were bred to Bl-6 wild type females and their progeny tested for the presence of
the 5’ LoxP site as in Figure 1 E and F. Germline transmission was observed (data not
shown). This Men1 allele was called Men1LoxP-Neo to specify the presence of the positive
selection cassette encoding neo resistance.
When Men1LoxP-Neo/wt mice were inter crossed, no homozygous animals were found (40 animals
tested), suggesting that the presence of the positive selection disrupted the function of Men1,
and that Men1 is essential for development.
2.1.3 FlpE and Cre mediated recombination
The presence of both LoxP sites and Frt sites in the Men1LoxP-Neo allele allows for the
generation of several different Men1 alleles. The names and structures of the different Men1
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Figure 2.1.2 Men1LoxP alleles. Vertical thick black arrows indicate crosses to either Cre of Flp 
expressing mice as indicated. Horizontal thick black arrows indicate crosses between the same genotypes. 
Names in bold are genotypes. On all alleles, primer pairs used for genotyping are indicated. A Genomic 
organisation of the Men1LoxP-Neo allele. B Genomic organisation of the Men1LoxP-Frt allele.C Genomic 
organisation of the Men1LoxP-Null allele.  
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alleles and the breeding strategy used to generate them are shown on Figure 2.1.2. Figure
2.1.2 also shows the PCR strategy that was used to genotype the animals. Men1LoxP-Neo males
were bred to hACTP-FlpE females to excise the positive selection cassette and restore the
function of the floxed allele. hACTP-FlpE mice express the FlpE recombinase throughout the
body and importantly also in the germline cells (Rodriguez et al., 2000). The pups were
genotyped by PCR as above using the primers Men1LoxP8 and Men1LoxP9 (Figure 2.1.2
A). As Figure 2.1.3A Left shows, PCR doublets were observed indicating the presence of the
Men1LoxP-Neo allele.
I next wanted to establish if FlpE could mediate excision of the positive selection cassette.
Figure 2.1.3 D shows the presence of the FlpE allele in the Men1LoxP-Neo positive clones.
Figure 2.1.3 B shows a PCR with the primers Men1Frt1 and Men1Frt2. It is only in the
presence of FlpE that a second, slower migrating PCR band should be seen. This slow
migrating band is the product of a PCR over one LoxP site and one Frt site. The fast migrating
band is the wildtype band present in all mice. In the absence of FlpE, only the wildtype band
can be seen as the 3.500 bp positive selection cassette is too big to be bridged by a standard
PCR reaction. Although it appeared that FlpE mediated recombination efficiently deleted the
positive selection cassette, subsequent breedings showed that only about 30 percent of the
Men1 alleles passed on through the germline from the Men1LoxP-Neo/FlpE animals had indeed
deleted the cassette.
To test the functionality of the LoxP sites, Men1LoxP-Neo mice were crossed with Deleter Cre
animals that express Cre in most somatic cells as well as in the germline (Schwenk et al.,
1995). Figure 2.1.3 A Right shows the presence of the 5’ LoxP site as judged by the primers
Men1LoxP8 and Men1LoxP9. However if the Cre recombination is very efficient, this PCR
should not generate a doublet as the Men1LoxP9 primer anneals to a sequence between the
two LoxP sites. The DNAs that tested negative for the 5’ LoxP site were tested for the
presence of Cre and for the presence of the 3’ Frt site. Figure 2.1.3 E shows the presence of
the Cre allele and Figure 2.1.3 C the presence of the 3’ Frt site using the primers Men1Frt3
and Menseq1. This PCR should indicate the presence of the Men1LoxP-Neo allele and be
unaffected by Cre mediated recombination. Samples 8 and 10 show the presence of Men1LoxP-
Neo and of Cre, but are negative for the presence of the sequence between the LoxP sites (PCR
Men1LoxP8 and Men1LoxP9) suggesting that the LoxP sites are capable of Cre mediated
recombination. Samples 7 and 8 are positive for Cre but negative for the presence of the 3’ Frt
site suggesting that these animals only carry the wildtype allele.
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To verify the PCR results, Southern blot analysis was done with the same DNA digested with
BamHI, using both a 3’ and a 5’ probe. Figure 2.1.3 F shows a Southern blot, which was
probed with the same 3’ probe that was used in the ES-cell screening. Men1LoxP-Neo gives rise to
a 6,3 kb band (lanes 1, 2, 4, 8 and 10), that is almost completely gone in the Men1LoxP-Neo, FlpE
DNA (lanes 3, 5 and 6). The Cre mediated deletion can not be seen with the 3’ probe. Figure
2.1.3 G shows the Southern blot probed with the 5’probe. The Men1LoxP-Neo gives rise to a band
of 14,6 kb compared to the wildtype band of 17,4 (lanes 1, 2 and 4). The Men1LoxP-Neo shifts
down 1577 bp upon Cre mediated recombination (lanes 8 and 10).
In conclusion, both FlpE mediated deletion of the positive selection cassette and Cre mediated
deletion of exons 3-6 is efficient.
2.1.4 Viability of Men1LoxP-Frt/Frt mice and absence of Menin in Men1LoxP-Null/Null
embryos
Men1LoxP-Neo/wt/FlpE animals were bred to wildtype Bl-6 animals and pups that had lost both the
positive selection marker as well as FlpE, were identified. The allele carried by these mice
was called the Men1LoxP-Frt (Figure 2.1.2 B). Men1LoxP-Frt/wt mice were interbred and the
offspring tested for viable mice, homozygous for the floxed Men1 allele. As Figure 2.1.4 A
shows, the homozygous animals (only slow migrating band) were found in the expected
mendelian ratio (1:2:1), and I thus concluded that the insertion of the two LoxP sites in the
Men1 locus did not interfere with the normal function of the gene.
Men1LoxP-Frt/wt were also crossed to Deleter-Cre animals to generate a null allele without the
positive selection cassette. Figure 2.1.4 B+C shows a PCR done using Cre primers and the
primers Men1LoxP8 and Men1Frt2, which should generate a band of 300 bp when both the
positive selection cassette and exons 3-6 have been deleted. The PCR was done on samples
that had been previously selected for the presence of the Men1LoxP-Frt allele using the primers
Men1Frt3 and Menseq1 (as in Figure 2.1.3 C). In all the samples that are positive for Cre, a
300 bp band can been seen on the Men1LoxP8 and Men1Frt2 PCR and in all samples
negative for Cre, a weak 1900 bp non-recombined band is visible. The wildtype allele present
should give rise to this band in all samples but it is out competed by the stronger 300 bp band
when recombination of the floxed allele has occurred.
Men1LoxP-Frt/wt/Deleter-Cre animals were bred to Bl-6 wildtype animals and pups that had lost
both Men1 exons 3-6 and Cre were identified. The allele carried by these animals was called
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Men1LoxP-Null (Figure 2.1.2 C). In contrast to hACTP-FlpE mediated deletion, Deleter-Cre
mediated recombination was very efficiently transmitted through the germline.
To verify that no protein was produced from the null allele, Men1LoxP-Frt/wt animals were
interbred and pups were isolated by caesarean section at embryonic day 11.5. The embryos
were genotyped Figure 2.1.4 D+E, and mouse embryo fibroblasts (MEFs) were established.
Protein was extracted from the MEFs and analysed by western blot with a Menin C-terminal
antibody Figure 2.1.4 F. Cell lines deficient in the wildtype Men1 allele (Figure 2.1.4 D+E
samples 15 and 17), were also deficient in Menin protein Figure 2.1.4 F.
In summary, this demonstrates that the floxed Men1 allele is functionally equivalent to the
wildtype allele and that the floxed Men1 allele allows efficient Cre mediated deletion of exons
3-6, leading to Menin ablation.
2.1.5 Pituitary gland specific cre mouse lines
I have established and characterised several mouse lines expressing a Cre transgene from 14.9
kb of the the Pit-1 promoter, which should drive expression in lactotropes, somatotropes and
thyrotropes (Rhodes et al., 1993). I decided to use the Pit-1-Cre line to generate the tissue
specific deletion of Men1 because this line should ensure a widespread and still relatively late
(E13-E14) deletion of Men1 in the pituitary gland (Rhodes et al., 1993). The late expression
should prevent any possible developmental abnormalities of the pituitary gland due to Men1
deletion. The faithful reproduction of the expression pattern of a gene may often require
cloning a promoter sequence many thousands of bases upstream from the transcription start.
Furthermore, the integration site of the transgene and the copy number may also have a strong
effect on the expression pattern of the gene. Because of this it is necessary to characterise the
expression pattern of any given mouse line expressing a transgene.
I tested the expression pattern of our mouse lines by crossing them to a Cre reporter line
called Z/EG21 (Novak et al., 2000). As depicted in Figure 2.1.5 A, this mouse line carries a
transgene, driven by the pCAGGS promoter, that ensures ubiquitous expression of LacZ. The
LacZ gene is followed by a strong transcriptional termination sequence and by a gene
encoding EGFP. The LacZ gene and the transcriptional termination sites are flanked by LoxP
sites, which allows Cre mediated excision of these elements and expression of EGFP. The
expression pattern of EGFP thus mimics the expression of Cre.
Figure 2.1.5 B shows the pituitary gland of a Z/EG21 mouse and a Z/EG21/Pit-1-Cre mouse
in normal light and 488 nm light. In the absence of Cre, there is no EGFP signal detectable,
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Figure 2.1.5 pit-1-cre  
drives pituitary specific 
cre expression. A 
schematic representation of 
Cre mediated GFP 
expression. B GFP 
expression in mouse 
pituitary glands in the 
absence and presence of 
Pit-1-Cre. C Co-staining for 
EGFP and for pituitary 
hormones as indicated. 
Stainings were done on free 
floating agarose sections as 
described. All antibodies 
except for the anti-GFP 
antibody was used in 1:200 
dilution. GFP antibody was 
used in 1:1000 dilution. 
Antibodies against 
hormones were detected 
with Rodamin coupled anti 
Rabbit antibody and the 
GFP antibody was detected 
with Alexa Fluor coupled 
anti-mouse antibody. 
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but in the presence of Pit-1-Cre, there is strong fluorescence from the pituitary gland
indicating that there is Cre expression in the pituitary gland. Inspection of the mouse revealed
no other fluorescent tissues (data not shown).
To establish the expression pattern of Cre on a cellular level, I stained 50 µm pituitary gland
vibrotome sections with anti GFP antibodies and antibodies against the hormones depicted on
Figure 2.1.5 C. Whereas no expression of GFP in ACTH or TSH expressing cells can be
seen, GFP co-localises with GH and Prolactin. Three independent mouse lines expressing Pit-
1-Cre were characterised and used in Men1 breedings.
2.1.6 Pituitary gland specific deletion of Men1
To ensure an efficient deletion of Men1, I decided to set up the experiment to generate mice
that would carry a floxed allele over a Null allele of Men1 in addition to a Pit-1-Cre
transgene. In these mice, Cre would only have to recombine one allele of Men1 in each cell to
generate a Men1 deficient cell. To generate these mice I mated Men1LoxP-Null/wt mice with three
independent Pit-1-Cre mouse lines. The Men1LoxP-Null/wt/Pit-1-Cre mice were subsequently
mated with Men1LoxP-Frt/Frt mice to generate Men1LoxP-Frt/Null/Pit-1-Cre mice.
The Men1LoxP-Frt/Null/Pit-1-Cre mice were born at the expected mendelian frequency of 25
percent (data not shown). They were phenotypically normal and indistinguishable from their
wildtype and heterozygous littermates. Postnatal growth and development of the Men1LoxP-
Frt/Null/Pit-1-Cre mice was also indistinguishable from that of wildtype mice suggesting that
pituitary gland function was intact. Finally, both males and females were fertile indicating that
Men1LoxP-Frt/Null/ P i t - 1 - C r e  mice had a functional pituitary gland. Furthermore
immunofluorescence revealed the presence of GH, Prolactin and ACTH expressing cells in
the pituitary glands of 8 weeks old Men1LoxP-Frt/Null/Pit-1-Cre mice (data not shown).
2.1.7 Pituitary gland phenotype
To characterise the effect of Men1 deficiency on the pituitary gland, I collected pituitary
glands at different times after birth starting at 7 weeks of age for both males and females.
Figure 2.1.6 A shows examples of pituitary glands from both genders at 7, 10, 13 and 20
weeks of age. Already at 7 weeks the anterior lobe of the Men1 deficient pituitary glands
appeared hyperplastic compared to that of the wildtype pituitary glands. At both 10 and 13
weeks of age the Men1 deficient pituitary glands were significantly larger than wildtype
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Figure 2.1.6 Pituitary phenotype of Men1 deletion. Mice were perfused with PBS and 4 % PFA. The pituitaries 
were removed and photographed. These pituitaries are representative for their gender and genotype. All pictures 
are taken with Leica MZFLIII microscope.A The age, gender and phenotype is indicated. Note that female Men1 
deficient pituitary glands  are bigger than their male counterparts. At 20 weeks of age the female, but not the 
male Men1 deficient gland has changed morphorlogy B Female littermates aged 35 weeks, genotype is indicated. 
Note that the magnification in panel B is different from that in  panel A. At this age, a hemorrhaging outgrowth 
can be seen in the heterozygous pituitary gland. The Men1 deficient pituitary gland is many folds bigger than the 
wildtype pituitary gland and is clearly hemorrhaging blood.
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pituitary glands but were otherwise normal in appearance and morphology. At 20 weeks of
age, the wildtype pituitary glands had regressed somewhat and although the Men1 deficient
pituitary glands had not increased in size compared to earlier stages, 2 out of 3 inspected
pituitary glands from female Men1LoxP-Frt/Null/Pit-1-Cre mice had clearly changed their
morphology. They appeared to have a less smooth surface and to be haemorrhaging blood
from the vessels into the anterior lobe of the pituitary gland, which could not be removed by
perfusion. At 20 weeks of age, this phenotype was never observed with pituitary glands from
male Men1LoxP-Frt/Null/Pit-1-Cre mice (0 out of 5 pituitary glands). Heterozygous pituitary
glands were indistinguishable from wildtype pituitary glands for both genders at these early
stages.
Figure 2.1.6 B shows the pituitary glands from wildtype, heterozygous and Men1LoxP-Frt/Null/Pit-
1-Cre female littermates at 35 weeks of age. The wildtype pituitary gland has reduced
somewhat in size compared to 10 and 13 weeks of age but they are otherwise similar in
appearance. Interestingly, from one side of the Men1 heterozygous pituitary gland, a clonal
outgrowth, which is clearly haemorrhaging blood, can be observed. This was frequently
observed in the pituitary glands from heterozygous animals after 40 weeks of age. This
observation suggests that Men1 heterozygous mice faithfully reproduce MEN1, which is
caused by the inheritance of one disrupted MEN1 allele. By 35 weeks of age, the pituitary
gland from the Men1LoxP-Frt/Null/Pit-1-Cre female is many folds bigger than a normal pituitary
gland, and occupies a significant portion of the brain cavity. Although it retains the overall
shape of a pituitary gland with two recognisable anterior lobes, the morphology of the
pituitary gland is completely different. There is widespread haemorrhaging of blood and the
surface of the tissue is completely different from the wildtype pituitary gland. This can no
longer be characterised as a hyperplastic pituitary gland but rather as a pituitary gland
neoplasm or adenoma.
Although none of the pituitary gland tumours appeared to be invasive, in agreement with the
literature on human pituitary gland tumours, some Men1LoxP-Frt/Null/Pit-1-Cre mice died after 40
weeks of age presumably due to the size of the pituitary gland tumour. To avoid further
pathology from these tumours, mice were sacrificed at 45 weeks of age at the latest.
After 45 weeks, 100 percent (13 out of 13) of female Men1LoxP-Frt/Null/Pit-1-Cre mice had
developed adenomas visible to the naked eye. Interestingly, only 40 percent (6 out of 15) of
male Men1LoxP-Frt/Null/Pit-1-Cre mice had developed adenomas and these were generally smaller
than those of the female mice. In the remaining cases, the pituitary glands retained the
wildtype morphology while still being clearly hyperplastic.
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At 45 weeks, heterozygous females, both Men1LoxP-Frt/Null and Men1LoxP-Frt/wt/Pit-1-Cre mice, had
developed pituitary gland adenomas visible to the naked eye in 3 out of 5 mice. These
adenomas developed from only one side of the pituitary in all of the cases observed. These
adenomas were never found in heterozygous males of 45 weeks of age.
2.1.8 Pituitary gland histology
Pituitary glands from different ages and genders were embedded in paraffin, cut in 7 µm
sections and stained with Hematoxyline and Eosin (H&E) (Figure 2.1.7 A). In these sections
it is apparent that at 7 weeks of age, the entire anterior pituitary gland is significantly
enlarged. Already at this stage there is a clear difference between males and females, with the
female Men1 deficient pituitary glands being significantly larger than their male counterparts,
with a few exceptions. After 10 weeks of age little gain in pituitary gland size is observed.
The posterior and intermediate pituitary gland is clearly compressed by the expanding anterior
pituitary gland of the Men1LoxP-Frt/Null/Pit-1-Cre mice. The overall morphology of the Men1
deficient pituitary glands does not appear to differ much from that of the wildtype pituitary
glands although the anterior gland of the Men1 deficient pituitary glands does appear to
contain larger cavities than wildtype pituitary glands. These cavities are more pronounced in
female pituitary glands and they appear to be most prominent in the distal part of the anterior
pituitary gland starting at 7 weeks of age. At 20 weeks of age the female pituitary gland has
clearly changed morphology and contains large cavities, some of which have been filled with
blood from leaking blood vessels.
At 35 weeks the anterior pituitary gland of the Men1LoxP-Frt/Null/Pit-1-Cre mouse is massively
expanded and it contains multiple blood filled vacuoles (Figure 2.1.7 B). Despite the massive
overgrowth the posterior and intermediate lobe remain intact although they have been
severely compressed, suggesting that the tumour is not invasive.
Figure 2.1.8 A shows higher magnification pictures of the anterior and intermediate lobe of
the female pituitary glands at 7, 10 and 20 weeks of age. At this magnification it is apparent
that the organisation of the cells in the anterior pituitary gland is different in the Men1LoxP-
Frt/Null/Pit-1-Cre mice from the wildtype mice. Most notably the cells appear to be organised
into a sort of epithelium surrounding the vacuoles. The vacuoles appear to grow somewhat in
size from 7 to 10 weeks. At 20 weeks, haemorrhaging from blood vessels has filled some of
the cavities with blood.
AB Men1LoxP-Frt/LoxP-Frt Men1LoxP-Frt/LoxP-Null/Pit-1-CreMen1LoxP-Frt/LoxP-Null
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Figure 2.1.7 Men1 deficient pituitary glands are hyperplastic and develop adenomas by 35 weeks of age. 
Hematoxylene and Eosine stained 7µm paraffin sections. A The age, gender and phenotype is indicated. On the 
pituitary gland from the 7 week wildtype male is indicated the positions of the anterior gland (A), the 
intermediate gland (I) and the posterior gland (P). Note that the female Men1 deficient pituitary glands are more 
hyperplastic than their male counterparts at all ages. In the Men1 deficient pituitary glands, the intermediate and 
posterior lobes are significantly compressed. Female pituitary glands at 20 weeks of age show a change in 
morphology, with hemorrhaging of blood into large cavities some of which can be emptied by perfusion. 
However, there is no major gain in pituitary gland size from 10 to 20 weeks of age. Pictures taken with the Leica 
Axiophot microscope. These sections are representative for their gender and genotype. B Female littermates aged 
35 weeks, genotype is indicated. A massive adenoma has developed from the anterior lobe of the Men1 deficient 
pituitary gland, which is now many folds bigger than the wildtype pituitary gland and is clearly hemorrhaging 
blood into multiple large cavities. The intermediate and posterior lobe of the pituitary gland can still be seen 
although they are severely compressed. Pictures were taken at a Leica MZFLIII microscope. 
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Figure 2.1.8 Men1 deficient pituitaries develop vacuoles. A Higher magnification microscopy of sections from 
females from Figure 2.1.7. Age and genotypes are indicated. The position of the intermediate and anterior gland 
is indicated with I and A respectively. B Higher magnification microscopy of selected areas of the 35 week old 
female Men1 deficient pituitary gland from Figure 2.1.7. Note the intermediate lobe on the left as well as blood 
filled cavities and epithelial like structures in the anterior lobe. Pictures were taken with on a Leica Axiophot 
microscope C Cell density is unaffected by loss of Men1. DAPI stained anterior lobes from female pituitaries. 
Age and genotypes are indicated. Pictures were taken with a Leica DM IRBE microscope. 
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In the 35 week pituitary gland (Figure 2.1.8 B), the cellular organisation is clearly different
from that of that of a wildtype pituitary gland. Apart from the multiple large blood filled
cavities, other structures such as epithelial like structures can be observed.
The hyperplasia of the Men1 deficient pituitary glands, apparent as early as 7 weeks of age,
would suggest an overproliferation phenotype resulting in an increased number of cells
preceding the actual adenoma formation. However, the size of an organ is determined not only
by the number of cells but also by the size of the cells. The hyperplasia phenotype of the
Men1 deficient pituitary glands could therefore be caused by an increase in the size of the
pituitary gland cells rather than an increase in numbers. As the H&E staining does not allow
one to assess the density of the nuclei, which reflects the size of the cells, I stained the 7 µm
paraffin sections with DAPI stain which labels DNA (Figure 2.1.8 C). High magnification
microscopy revealed that the density of nuclei is similar in the wildtype and the Men1
deficient pituitary glands at 7, 10 and 13 weeks of age suggesting that the hyperplasia of the
Men1 deficient pituitary gland is due to hyperproliferation of the pituitary gland cells.
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2.2 Molecular characterisation of Men1 deficient pituitary
glands
2.2.1 Analysis of Menin expression in Men1 deficient pituitary glands
To investigate the extent of Menin depletion in the anterior pituitary gland of Men1LoxP-
Frt/Null/Pit-1-Cre mice compared to wildtype littermates, I performed immunohistochemistry on
pituitary gland paraffin sections and immmunofluorescence on free floating agarose sections
from 12 weeks old mice, using two commercial and three rat polyclonal antibodies against
Menin produced by us. None of these antibodies gave satisfactory results on pituitary gland
sections.
Although western blot analysis does not yield information about the pattern of protein
expression, it does accurately show the amounts of antigen present in the pituitary. Figure
2.2.1 A shows a western blot on pituitary gland protein extracts from 12 weeks old male and 4
and 12 weeks old female Men1LoxP-Frt/Null/Pit-1-Cre mice and wildtype littermates. At all ages
and genders there is a very significant reduction in detectable Menin protein. Moreover, the
amount of Menin is reduced in 12 weeks old Men1LoxP-Frt/Null/Pit-1-Cre mice compared to 4
week old mice, possibly suggesting a proliferative advantage of Men1 deficient cells. Figure
2.2.1 B is a loading control. It shows a probing of the blot with anti Erk1/Erk2 antibodies
indicating that the same amount of protein was loaded on the gel. Above the lower band of the
doublet a weaker slower migrating band can be seen. This band represents phosphorylated and
activated Erk2. No significant difference was seen between wildtype and Men1 deficient
pituitary glands in the amount of activiated Erks. This result was also confirmed with anti
phospho-Erk antibodies (data not shown).
I also performed an in situ hybridisation experiment using a probe against Men1 exons 3-6 on
sections from 7 week old Men1LoxP-Frt/Frt and Men1LoxP-Frt/Null/Pit-1-Cre mice and on sections
from a 41.5 week old Men1LoxP-Frt/Null mouse (Figure 2.2.1 C). At 7 weeks of age, there is clear
expression of Men1 in both the anterior, intermediate and posterior lobe of the pituitary gland
of the Men1LoxP-Frt/Frt mice. In contrast, the Men1 signal is almost absent from the anterior lobe
of the Men1LoxP-Frt/Null/Pit-1-Cre mice, whereas a significant signal is still observed from the
posterior and intermediate lobe, confirming the Cre mediated deletion of Men1 in the Pit-1
lineage. In the 41.5 week old heterozygous pituitary gland, a macroscopic adenoma was
observed in the left side of the pituitary gland. This clonal expansion shows the same
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Figure 2.2.1 Menin is almost absent 
and Men1 mRNA is significantly 
reduced in the pituitary glands of 
Men1LoxP-Frt/Null/Pit-1-Cre mice. 
A+B Western blot on protein extracts 
from pituitary glands from mice with the 
age and gender indicated. Pituitary 
glands were perfused with PBS and 
protein was extracted with RIPA buffer. 
40 µg of total protein were separated by 
SDS-PAGE on a 10 percent gel. Protein 
was blotted to nitrocellulose and probed 
with antibody. A Westernblot was probed 
C19 anti Menin antibody in 1:1000 
dilution in PBS-tween with 1 percent 
milk powder. 2nd HRP coupled rabbit 
anti goat antibody was used in 1:5000 
dilution in the same buffer. Bound 
antibody was detected with ECL reagent. 
B Loading control. Westernblot was 
probed with anti Erk1/Erk2 antibody in 
1:1000 dilution in PBS-tween with 1 
percent milk powder. 2nd HRP coupled 
goat anti rabbit antibody was used in 
1:5000 dilution in the same buffer. 
Bound antibody was detected with ECL 
C In situ hybridisation of 18 µm 
cryosections. Sections of female 
pituitaries from 7 week old 
M e n 1 L o x P - F r t / F r t , 
Men1LoxP-Frt/Null/Pit-1-Cre  mice and 
41.5 week old Men1LoxP-Frt/Null  mice 
were hybridised with a probe against exons 3-6 of Men1. Note that the Men1 signal is almost absent from the 
anterior lobe of the Men1LoxP-Frt/Null/Pit-1-Cre pituitary glands but not from the intermediate lobe. In the 41.5 
week old heterozygous pituitary gland, a clonal outgrowth in the left side was observed. The Men1 signal is 
absent in this outgrowth, suggesting that the wildtype Men1 allele has been lost by chromosomal 
rearrangements. The 35S labeled in situ probe was visualised by 4 weeks of incubation with Kodak NTB2 and 
the tissue counterstained with Bisbenzimide. Photographs were made on the Leica MZFLIII microscope. 
A
B
Men1LoxP-Frt/Frt Men1LoxP-Frt/Null/Pit-1-Cre Men1LoxP-Frt/Null
Men1
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Results
46
Results
47
morphology as the adenomas originating from the Men1LoxP-Frt/Null/Pit-1-Cre mice with large
vacuoles and disrupted cellular organisation. The Men1 signal is absent from the hyperplastic
left side of the anterior lobe, although it can be clearly detected in the rest of the anterior lobe
of the heterozygous pituitary gland. This observation suggests that the wildtype Men1 allele
has been lost by chromosomal rearrangements in the hyperplastic left side of the heterozygous
pituitary gland, and that loss of both alleles of Men1 is required for tumour formation.
2.2.2 Analysis of growth and apoptosis in Men1 deficient pituitary glands
The early hyperplasia phenotype of the Men1 deficient pituitary glands would suggest that
there was increased proliferation in these pituitary glands. To investigate the role of Menin in
regulating the proliferation rate of the pituitary gland cells, I performed
immunohistochemistry on wildtype and Men1 deficient pituitary gland sections from 12 week
female mice using antibodies against two different proliferation markers. Figure 2.2.2 A
shows a staining with an antibody against KI-67. KI-67 is a nuclear proliferation marker, that
is expressed in cells in S-phase, G2-phase and M-phase (Gerdes et al., 1984). It is evident that
while few nuclei stain in the wildtype pituitary gland, there is widespread staining in the Men1
deficient pituitary gland, suggesting that a significant fraction of the cells in the Men1
deficient pituitary gland are cycling at 12 weeks of age. Figure 2.2.2 B shows staining with
an antibody against Histone H3 phosphorylated on Serine 10. Phospho-Histone 3 is a nuclear
marker for mitosis (Ajiro et al., 1996). In the wildtype pituitary gland very few nuclei stain,
and those that do do not display a mitotic appearance. In the Men1 deficient pituitary gland
there is widespread staining, and the stained nuclei have a mitotic appearance, suggesting
chromosomal segregation was in progress. A much lower number of cells stain positive for
phospho-Histone H3 than do for KI-67. This reflects that mitosis is very short compared to the
rest of the cell-cycle.
Increased proliferation caused by aberrant growth signals often leads to apoptosis (Hanahan et
al., 2000). To test if this was true for the hyper proliferation induced by the loss of Men1, I
probed the pituitary gland sections with an antibody against an apoptotic marker, a cleavage
product of Caspase3, which is cleaved and activated in apoptosis (Nicholson et al., 1995). As
Figure 2.2.2.C show, no staining could be detected regardless of the antigen retrieval method
used (data not shown).
It thus appears that Men1 loss leads to hyperplasia caused by hyperproliferation and that this
proliferation is not associated with apoptosis.
AB
Figure 2.2.2 Increase of proliferation 
makers in Men1 deficient pituitaries.  
Immunohistochemistry on 
Men1LoxP-Frt/LoxP-Frt and 
Men1LoxP-Frt/LoxP-Null/Pit-1-Cre mice. 
12 week old female mice were 
perfused with 2 percent PFA and  
pituitaries were fixed overnight in 2 
percent PFA.  The pituitaries shown 
are representative of their age and 
genotype. A Anti KI67 
immunohistochemistry. 7 µm paraffin 
sections were probed with the KI67 
antibody from Novocastra in a 1:750 
dilution. Antigen was recovered using 
the microwave method. Bound 
antibody was detected with HRP 
coupled 2nd antibody and DAB 
substrate with nickel. The tissue was 
counter stained with Methyl Green  B 
Anti phospho-Histone H3 
immunohistochemistry. 7 µm paraffin 
sections were probed with the pHistone 
H3 antibody from Upstate Biotech in a 
1:300 dilution. Note the characteristic 
staining of the dividing nuclei 
indicated with red arrowheads in the 
high magnification pictures. Antigen 
was recovered using the plain  method. 
Bound antibody was detected with 
HRP coupled 2nd antibody and DAB 
substrate with nickel. The tissue was 
counter stained with Methyl Green. C 
Anti Cleaved Caspase 3 
immunohistochemistry. 7 µm paraffin 
sections were probed with the cleaved 
Caspase 3 antibody from Cell signaling 
technology in a 1:300 dilution. Antigen 
was recovered using the plain  method. 
Bound antibody was detected with 
HRP coupled 2nd antibody and DAB 
substrate with nickel. The tissue was 
counter stained with Methyl Green. All 
pictures were done on the Leica 
Axiophot microscope. 
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2.2.3 Microarray analysis of expression pattern in Men1 deficient pituitary
glands
In order to identify genes that may mediate the hyperplastic phenotype of the Men1 deficient
pituitary glands, I decided to analyse the gene expression profile of Men1 deficient and
wildtype pituitary glands. I decided that microarray analysis would be feasible for two
reasons. Firstly, even though the Men1 deficient pituitary glands were hyperplastic, they still
retained normal pituitary gland morphology, and the pituitary glands appeared to be
functional. Secondly, the Pit-1 lineage constitutes more than 60 percent of the pituitary gland
and it would therefore be reasonable to assume that any changes in gene expression caused by
Men1 deficiency would be detectable over the background of Men1 expressing cells.
As MEN1  tumourigenesis leads to chromosomal instability with loss and gain of
chromosomes, which would make the interpretation of the microarray experiment impossible,
I decided to analyse relatively young pituitary glands. Furthermore I decided to analyse RNA
from each pituitary gland on separate chips, which would allow me to detect if any gain or
loss of chromosomes would have occurred that would lead to a major change in expression
profile.
RNA from the pituitary glands of three heterozygous and three Men1LoxP-Frt/Null/Pit-1-Cre 12
weeks old males was isolated (four of these animals were littermates). The RNA was used for
expression profiling using the Amersham Codelink 20K mouse chip.
For each microarray, the Codelink software calculates a normalised threshold. Genes with
intensities below the threshold of the microarray are considered not to be expressed. For all of
the microarrays, the thresholds were between 0.275 and 0.338. I defined that only if a gene
would be above the threshold in all three of the biological replicates for the heterozygous
pituitary glands or all three of the biological replicates for the Men1 deficient pituitary glands,
it would be considered expressed in the pituitary gland. By this definition 10370 genes out of
the 20000 genes on the microarray were expressed in the heterozygous pituitary glands, 10018
in the Men1 deficient pituitary glands and 10962 were expressed in the pituitary glands of
either of the two genotypes.
The microarray data was subsequently analysed using Genespring 6.2 (Silicon Genetics). The
raw intensity values were normalised to the 50th percentile of the array intensity. Figure 2.2.3
A shows a scatterplot of the normalised intensities of the 10370 genes expressed in the
heterozygous pituitary glands from the microarray results from two different heterozygous
pituitary glands. Most genes align along the diagonal indicating identical expression and 99.1
AB
Figure 2.2.3 Gene expression profiling 
of Men1 deficient and heterozygous 
pituitay glands. Scatterplot of 
biological replicates. More than 98 
percent of the genes expressed in the 
pituitary glands fall within the lines 
indicating two fold difference. Gene 
expression profiling was performed on 
RNA from individual pituitary glands 
using the Codelink 20K microarrays that 
contains probes for 20000 individual 
mouse genes. Three biological replicates 
were done for both genotypes.  The data 
from the microarrays were imported  
from the Codelink software into 
Genespring and normalised to the 50th 
percentile of all spots on each array (per 
chip normalisation or scaling) A 
Scatterplot of two heterozygouse 
biological replicates. 10370 out of 20000 
genes were expressed at levels above the 
threshold value for each microarray in 
all three biological replicates of the 
heterozygous pituitary glands. For these 
genes, the normalised intensity values 
from the microarray analysis of the 
pituitary glands of two heterozygous 
littermates are plotted against each other. 
Most data points are close to the 
diagonal indicating identity and 99.1 
percent of all datapoints fall within the 
lines indicating two fold difference.  
Note that the axis are logarithmic.  B  
Scatterplot of two Men1 deficient 
biological replicates. As above with the 
results from two pituitary glands from 
MenLoxPFrt/Null/Pit-1-Cre mice. 10018 
genes are expressed at levels above the 
threshold value in all three biological 
replicates of the Men1 deficient pituitary 
glands. 98.4 percent of all datapoints fall 
within the two lines indicating two fold 
difference.     
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percent of all the genes expressed in the heterozygous pituitary glands fall within the two lines
indicating a two fold difference. Figure 2.2.3 B shows the same representation of two
Men1LoxP-Frt/Null/Pit-1-Cre littermates. As with the heterozygous samples, most genes align
along the diagonal and 98.4 percent of the 10018 genes expressed in the Men1 deficient
pituitary glands fall within the two lines indicating a two fold difference. These data suggests
that the reproducibility of the experiment is very high and that the pituitary glands are well
suited for microarray experiments, but the few datapoints falling well outside the diagonal
also emphasises the importance of doing several biological replicates.
Figure 2.2.4 A shows a condition tree of the three heterozygous biological replicates and the
three Men1  deficient biological replicates. The condition tree shows that the three
heterozygous and the three Men1LoxP-Frt/Null/Pit-1-Cre samples cluster together suggesting that
the overall differences are biggest between the heterozygous and Men1 deficient pituitary
glands, independently of whether the mice were siblings. These data suggests that the
predominant gene expression changes are due to Men1 deficiency in the Men1LoxP-Frt/Null/Pit-1-
Cre mice. Figure 2.2.4 B shows that over all genes, the biological replicates are between 97.7
and 98.1 percent identical. For samples of different genotype the identity is between 96.7 and
97.5 percent.
The 20K mouse chip contains probes for all of the published Menin interacting proteins
except for Mll2 and Fancd2, thus one can evaluate the expression of these genes in the
pituitary gland using the microarray data. All of the Menin interacting NF-κB subunits are
expressed in the pituitary gland, with NF-κB1 showing the highest expression. In addition,
according to the microarray data Smad1, Smad2 and Smad4 are expressed in the pituitary
gland but not Smad3 or Smad5. Of the other interaction partners present on the chip, only
PEM shows no expression.
Many of the genes that have been implicated in growth control and tumour formation in the
pituitary gland are present on the microarray. In addition, the genes that have been published
to be Menin targets are represented on the microarray as well as many of the TGF-β/Smad3
and NF-κB regulated genes that could be relevant for growth control and tumourigenesis of
the endocrine system. Figure 2.2.5 shows the intensity of these genes in all of the biological
replicates. All of these genes are either expressed in the pituitary gland, but not significantly
changed in the knockout compared to the heterozygous, or not expressed in the pituitary gland
in both the heterozygous and knockout pituitary glands. Among the genes that have
previously been implicated in pituitary gland tumourigenesis, genes like PTTG1, bFGF, NGF,
AFigure 2.2.4 Gene expression profiling 
of Men1 deficient and heterozygous 
pituitary glands. Biological replicates 
cluster together, suggesting that loss of 
Men1 is the primary cause of change 
in the gene expression profile. A 
Condition tree. Three biological 
replicates were done using RNA from 
three different pituitary glands from 
mice of both genotypes. Four of the six 
animals were littermates (two 
heterozygous and two Men1 deficient). 
The microarray results were analysed in 
Genespring. All 20000 genes were 
normalised to the 50th percentile of all 
spots on each array (per chip 
normalisation or scaling). The samples 
were clustered in a condition tree using 
spearman correlation. Each gene is 
represented with a bar. The colour of the 
bar indicates the normalised intensity of 
the gene on each microarray. Red 
represents the highest intensity and blue 
the lowest. The three heterozygous and 
the three Men1 deficient samples cluster 
together, which means that the overall 
differences are biggest between 
heterozygous and homozygous animals 
whether or not they are littermates. This 
suggests that the main cause of change 
in gene expression profile is due to loss 
of Men1. B Correlation cofficiencies 
between all six microarrays. All 20000 
genes were normalised to the 50th 
percentile of all spots on each array. The 
standard correlation between all pairs of 
microarrays were calculated in 
Genespring. All biological replicates  are 
between 97.8 and 98.1 percent identical 
for the heterozygous samples and 
between 97.7 and 97.8 percent identical 
for the Men1 deficient samples. The 
correlation between all pairs of 
heterozygous- Men1 deficient samples is 
between 96.7 and 97.5 percent. 
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FGF4, TGF-α, TRH, GHRH, Dopamine D2 receptor, Rb, p16Ink4a, p18Ink4c and Gαs are
present on the microarray but not differentially expressed in the Men1 deficient pituitary
glands. The telomerase gene, which has been reported to be a Menin target, is neither
expressed in the heterozygous nor in the knockout pituitary gland. The same is true for
Hoxa9, whereas Hoxc6 is expressed in both cases at the same level. Both of these genes have
been published to be Menin targets. Among the well characterised TGF-β/Smad3 and NF-κB
regulated genes present on the microarray are p21Cip1, Cyclin D1, c-Myc, c-Jun, Cdc25,
cIAP, Pai-1, Transin/Stromelysin, GM-CSF, BCL-XL and c-Flip. None of these genes show
any changes in expression levels in the Men1 deficient pituitary glands compared to the
heterozygous pituitary glands.
These data suggest that the tumour suppressor activity of Men1 is not mediated by repression
or activation of the normal TGF-β or NF-κB targets and that MEN1 tumourigenesis does not
involve differential expression of genes that are associated with sporadic tumourigenesis of
the pituitary gland. Furthermore, the microarray data suggest that the published Menin
responsive genes are not affected by loss of Men1 in the pituitary gland.
Interestingly, even though the Men1 probe on the microarray does not hybridise to exons 3 to
6 but rather to exon 10 of the Men1 mRNA, there is still a 60 percent reduction in the Men1
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signal in the Men1LoxP-Frt/Null/Pit-1-Cre pituitary glands compared to the heterozygous pituitary
glands. This is most likely the effect of nonsense mediated RNA decay of the Men1 message
due to the disruption of the open reading frame by the Cre mediated recombination.
2.2.4 Genes deregulated in Men1 deficient pituitary glands
Figure 2.2.6 shows the average expression of the three biological replicates for each
individual gene in the heterozygous pituitary glands vs. the knockout pituitary glands for the
10962 genes expressed in the pituitary glands of either of the two genotypes. Along the
diagonal, the two lines indicate two fold above and two fold below identity. It is apparent that
most genes fall between these two lines. I have defined the 2 fold above or below identity as
the cut-off values for deregulated genes. Of the genes that fall outside these lines, most are
higher expressed in the heterozygous pituitary glands and these genes are thus normally
directly or indirectly activated by Menin. A smaller part of the genes outside the two fold
lines are more highly expressed in the knockout pituitary glands than in the wildtype. These
genes would normally have been repressed by Menin.
To identify genes that were differentially expressed in the knockout pituitary glands compared
to the heterozygous pituitary glands, I generated two sets of genes. One set contained genes
whose average expression in the knockout pituitary glands was 2 fold higher than that of the
heterozygous pituitary glands, and the other set contained genes whose expression was 2 fold
higher in the heterozygous samples. 500 genes were downregulated in the Men1 deficient
pituitary glands compared to the heterozygous pituitary glands and 135 genes were
upregulated. To eliminate genes, where a single outlying data point led to an unrepresentative
average, a students T-test was performed on the three biological replicates and only genes
with a p-value less than 0.05 were considered. This analysis produced two sets of genes that
were either more than 2 fold up or 2 fold downregulated in the knockout pituitary glands
compared to the heterozygous pituitary glands. The datapoint representing these genes are
coloured yellow in Figure 2.2.6. In total 199 genes were downregulated and 67 genes were
upregulated in the knock out.
Figure 2.2.7 A shows a genetree of the biological replicates for these 266 genes. The intensity
of each gene was normalised to median of the intensity of the gene on all the microarrays. The
values for the intensities are therefore not comparable to those of Figure 2.2.6. It is apparent
that the expression of these genes is similar in all of the heterozygous samples and knockout
samples respectively. Figure 2.2.7 B shows a Venn diagram of the 10370 genes that were
BHet
KO
Figure 2.2.6 266 genes are differentially expressed in Men1 deficient compared to heterozygous pituitary 
glands. Scatter plot of heterozygous vs. Men1 deficient pituitary glands.  All genes were normalised to the 
50th percentile of all spots on each array. Genes that were expressed in either all the heterozygous or in all the 
Men1 deficient samples were selected (10962 in total). The average intensity of the gene in the heterozygous 
pituitary glands is plotted against the average intensity of the gene in the knockout pituitary glands. The middle 
line along the diagonal indicates identity. The outer lines indicate 2 fold difference. Two sets of genes were 
generated that showed at least two fold difference in average expression between Men1 deficient and 
heterozygous pituitary glands. 500 genes were were downregulated and 135 upregulated in the Men1 deficient 
pituitary glands. To eliminate genes, where a single outlying datapoint would lead to an unrepresentative 
average, a students T-test was performed on the three biological replicates and only genes with a p-value less 
than 0.05 were considered. By these criteria, 199 genes were downregulated and 67 genes were upregulated more 
than 2 fold in Men1 deficient pituitary glands. These genes are indicated with yellow colour on the scatterplot. 
The white lines indicate a cutoff of 0.5 in normalised intensity, which is common practice to identify meaningful 
datapoints. 127 downregulated genes and 49 downregulated were above this intensity. The axes are logarithmic. 
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Figure 2.2.7 Expression analysis of deregulated genes. A For 
the 266 deregulated genes, all biological replicates are similar. 
Genetree of 266 deregulated genes in Men1 deficient pituitary 
glands. Genes that were expressed in either all the heterozygous 
or in all the Men1 deficient samples were selected (10962 in 
total). These genes were normalised to the 50th percentile of all 
spots on each array. Two sets of genes were generated that 
showed at least two fold difference in average expression between 
Men1 deficient and heterozygous pituitary glands. A students 
T-test was performed on the three biological replicates and only 
genes with a p-value less than 0.05 were considered. 199 genes 
are downregulated and 67 genes are upregulated more than 2 fold 
in Men1 deficient pituitary glands. The intensity of each gene on 
all microarrays was subsequently normalised to the median of the 
intensity of each gene across all samples. Note that therefore the 
values for the intensities are not comparable to those from Figure 
2.2.6. B Venn diagram of distribution of 266 genes 
deregulated in Men1 deficient pituitary glands. Venn diagram 
of 266 deregulated genes, the 10370 genes expressed at levels 
above the threshold value for each microarray in all three 
biological replicates of the heterozygous pituitary glands and the 10018 genes are expressed at levels above the 
threshold value in all three biological replicates of the Men1 deficient pituitary glands. 70 of the 199 
downregulated genes are not expressed at a detectable level in the Men1 deficient pituitary glands. 22 of the 67  
upregulated genes are not expressed at a detectable level in the heterozygous pituitary glands. 
Above threshold in 
all heterozygous 
biological replicates
Above threshold in 
all Men1 deficient 
biological replicates
More than two fold differentially expressed on 
average between the two different genotypes 
and p-value less than 0.05 in students T-test 
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expressed in the heterozygous pituitary glands, the 10018 that were expressed in the Men1
deficient pituitary glands and and the 266 deregulated genes. Of the downregulated genes, 70
cannot be detected in the Men1 deficient pituitary glands. Conversely, 22 of the upregulated
are not expressed in the heterozygous pituitary glands.
Table 2.1 and 2.2 shows the name and description of these genes as well as the fold up or
down regulation in the knockout compared to the wildtype.
2.2.7 VIP, Cdc2/cyclin B and IGF1
The analysis of the Men1 deficient pituitary glands had revealed an early hyperplasia
phenotype, that was associated wih hyperproliferation in the pituitary glands of 12 week old
Men1 deficient pituitary glands. To elucidate the cause of this hyperproliferation, I inspected
the gene lists for genes that had previously been associated with regulation of proliferation. I
identified four genes that were clearly upregulated on the microarrays on the Men1 deficient
pituitary glands. These genes included those encoding Vasoactive Intestinal Peptide (VIP) 7.4
fold, Insulin like Growth Factor 1 (IGF1) 4.6 fold, Cdc2A 3.0 fold and CyclinB2 3.7 fold.
VIP is a 28 amino acid peptide originally isolated as a glucagon related vasoactive peptide
(Said et al., 1972). It has subsequently been shown to regulate many other physiological
activities including embryonic growth, activity of the immune system and neuronal growth
and survival (Gozes et al., 1999). In general, VIP causes vasodilation, bronchodilation,
immunosuppression, smooth muscle relaxation and increased gastric motility (Gozes et al.,
1999). Importantly VIP increases hormonal secretion including Prolactin and GH from the
pituitary gland (Gozes et al., 1999) and Insulin from the pancreatic islets (Kato et al., 1994).
VIP is a member of a large peptide family whose members include Glucagon, GH Releasing
Hormone (GHRH), Secretin and Pituitary gland cyclase activating hormone (PACAP).
PACAP and VIP activate the same receptor (Gozes et al., 1999). VIP is expressed from a
mRNA that encodes a protein of 170 amino acids. This protein contains two very related
peptide hormones VIP and PHI-27. Subsequent cleavage and processing releases the two
hormones. Most of the biological activity of the transcript is attributed to VIP (Itoh et al.,
1983).VIP is mostly released through nerve terminals (Gozes et al., 1999). VIP binds to two
G-protein coupled receptors VPAC1 and VPAC2, that activates adenylate cyclase (Laburthe
et al., 1996). The resulting increase in cAMP activates PKA and leads to phosphorylation of
NM_026358 11.1
Crabp1 cellular retinoic acid binding protein 6.4
Cabp2 calcium binding protein 2 6.1
Prostein prostein protein 5.6
Mab21l2 mab-21-like 2 4.7
Cpne7 copine VII 4.6
Clpx caseinolytic protease X 4.6
Trpv2 transient receptor cation channel 4.1
NM_146028 4.0
Pygm muscle glycogen phosphorylase 3.8
BB439385 3.7
Fxyd3 FXYD domain ion transport regulator 3.6
BE690945 3.6
Tm4sf7 transmembrane 4 superfamily 3.5
NM_030069 3.5
Slc7a1 solute carrier family 7 3.5
Rbp4 retinol binding protein 4 3.5
AK003491 3.5
Edr erythroid differentiation regulator 3.3
Col13a1 procollagen, type XIII, 3.2
Nkx2-4 NK2 transcription factor 3.2
BC017634 3.2
AK005465 3.2
AK006636 3.2
Rax retina and anterior neural homeobox 3.2
AK020483 3.2
Dhcr7 7-dehydrocholesterol reductase 3.1
Olfr157 olfactory receptor 157 3.1
Adh6a alcohol dehydrogenase 6A 3.1
NM_025685 3.0
Krt2-6a keratin complex 2-6a 3.0
olfactory receptor MOR171-7 3.0
AK014167 3.0
MOR3-1 olfactory receptor MOR3-1 3.0
Masp1 mannan-binding lectin serine protease 3.0
AK018700 2.9
AI158842 2.9
AK009469 2.9
AK010542 2.9
NM_023546 2.9
atrophin-1 tatorubral pallidoluysian atrophy 2.9
Cst11 cystatin 11 2.8
Mmp14 matrix metalloproteinase 14 2.8
AK004614 2.8
Ehd3 EH-domain containing 3 2.8
Hoxb7 homeo box B7 2.8
Plcd4 phospholipase C, delta 4 2.8
Jph2 junctophilin 2 2.7
Synpo2 synaptopodin 2 2.7
Slc6a3 solute carrier family 6 (dopamine) 2.7
Slitl2 Slit-like 2 2.7
olfactory receptor MOR267-4 2.7
AW492503 2.7
Cpxm2 carboxypeptidase X 2 2.7
BC016427 2.7
NM_028785 2.7
Cthrc1 collagen triple helix repeat 2.7
AK015259 2.6
C1sb complement component C1SB 2.6
Aldh1b1 aldehyde dehydrogenase 1 family 2.6
BC010552 2.6
NM_153158 2.6
Protectin CD59a antigen 2.6
Apbb1ip amyloid beta interacting protein 2.6
Xdh xanthine dehydrogenase 2.6
Slc9a3r1 solute carrier family 9 regulator 1 2.6
AV151664 2.6
Ccnt2 cyclin T2 2.5
AK007819 2.5
BE950979 2.5
Tnk1 tyrosine kinase, non-receptor, 1 2.5
AV328325 2.5
AK008737 2.5
Slc12a4 solute carrier family 12, member 4 2.5
NM_026083 2.5
NM_025749 2.5
AK007198 2.5
BM210487 2.5
BQ032470 2.5
AK009760 2.5
Mlc1 megalencephalic leukoencephalopathy 2.4
BE691581 2.4
AW456706 2.4
Gdf10 growth differentiation factor 10 2.4
Top3a topoisomerase (DNA) III alpha 2.4
Men1 multiple endocrine neoplasia 1 2.4
BB089777 2.4
Pla2g7 phospholipase A2 2.4
Klk6 kallikrein 6 2.4
ARH2 LDL receptor adaptor protein 2.4
IL-17RE Interleukin 17 receptor E 2.4
BB089777 2.4
NM_013737 2.4
NM_026606 2.4
Guca1b guanylate cyclase activator 1B 2.4
Scnn1a sodium channel, nonvoltage-gated 2.4
Ntn3 netrin 3 2.4
Mid1 midline 1 2.4
hypothetical protein 5230400M03 2.4
Traf1 Tnf receptor-associated factor 1 2.4
AK008235 2.4
Pacsin3 PKC and Casein kinase substrate 2.4
Clasp1 CLIP associating protein 1 2.4
Elovl4 elongation of very long chain fatty acids 2.4
Prelp proline arginine-rich, leucine-rich repeat 2.3
BB098221 2.3
NM_145366 2.3
Cklfsf7 chemokine-like factor super family 7 2.3
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Kcnc1 potassium voltage gated channel 2.3
Tpit T-box 19 2.3
Mrpl19 mitochondrial ribosomal protein L19 2.3
Rorb RAR-related orphan receptor beta 2.3
Slc38a2;  solute carrier family 38, member 2.3
NM_029415 2.3
Kremen kringle containing transmembrane 2.3
NM_133751 2.3
Fbp2 fructose bisphosphatase 2 2.3
AK006490 2.3
olfactory receptor MOR266-1 2.3
taip-2 2.3
NM_146115 2.3
olfactory receptor MOR267-5 2.3
AV290652 2.3
AW048447 2.3
Adh8 alcohol dehydrogenase 8 2.3
AK013762 2.3
Cldn7 claudin 7 2.3
NM_025748 2.3
NM_138654 2.3
P38gamma mitogen-activated protein kinase 2.3
Stk10 serine/threonine kinase 10 2.3
Itpr5 inositol 1,4,5-triphosphate receptor 5 2.3
NM_019631 2.3
Temt thioether S-methyltransferase 2.3
BQ174653 2.3
ORF18 open reading frame 18 2.2
Sh3d4 SH3 domain protein 4 2.2
Ndr2 N-myc downstream regulated 2 2.2
Anxa11 annexin A11 2.2
Sardh sarcosine dehydrogenase 2.2
BM240122 2.2
Lor Mus musculus loricrin 2.2
BB211203 2.2
CD-RAP melanoma inhibitory activity 2.2
BG068423 2.2
NM_023256 2.2
Spp1 secreted phosphoprotein 1 2.2
Mark1 microtubule affinity-regulating kinase 2.2
Fshb follicle stimulating hormone beta 2.2
BC013092 2.2
PRECE-2 kallikrein 26 2.2
NM_028770 2.2
AK005003 2.2
BM198106 2.2
NM_145545 2.2
MLN51 MLN51 protein 2.2
Activin inhibin beta-A 2.2
BB342841 2.2
Ephb3 Eph receptor B3 2.2
AK014475 2.1
APO3L tumour necrosis factor ligand superfam. 2.1
Cited4 Cbp/p300-interacting transactivator 2.1
Tnip1 TNFAIP3 interacting protein 1 2.1
BF019837 2.1
Slc15a2 solute carrier family 15 2.1
Adh1 alcohol dehydrogenase 1 2.1
Stard13 serologically def.colon cancer antigen 2.1
hypothetical protein LOC227699 2.1
AK017526 2.1
Leutropin luteinizing hormone beta 2.1
TWIK-1 potassium channel, subfamily K 2.1
hypothetical protein D330010C22 2.1
AI586049 2.1
Mus musculus otoraplin (Otor), mRNA. 2.1
hesr3 hairy/enhancer-of-split related 2.1
Pet-1 Fev protein 2.1
AK002411 2.1
BC018252 2.1
AK003154 2.1
Bak1 BCL2-antagonist/killer 1 2.1
Gtl2 imprinted maternally expressed mRNA 2.1
AK017115 2.1
Sept9 septin 9 2.1
NM_028139 2.1
Kdt1 kidney cell transcript 1 2.1
Eph1 epoxide hydrolase 1 2.1
Gldc glycine decarboxylase 2.1
PHAS-I eIF4E binding protein 1 2.0
AW556148 2.0
Scya19 chemokine ligand 19 2.0
FBP1 folate receptor 1 2.0
Pcolce procollagen C-proteinase enhan. protein 2.0
AW556148 2.0
Scyb14 chemokine ligand 14 2.0
Gna14 guanine nucleotide binding protein14 2.0
E2f3 E2F transcription factor 3 2.0
Srebf1 sterol regulatory element binding factor 2.0
NM_145470 2.0
NM_172660 2.0
Gene/description Gene/descriptionFold Down
KO vs Het
Fold Down
KO vs Het
Tabel 2.1 199 genes were downregulated in Men1 
deficient pituitary glands. Genes that were 
expressed in either all the heterozygous or in all the 
Men1 deficient samples were selected (10962 in 
total). These genes were normalised to the 50th 
percentile of all spots on each array. Genes were 
chosen whose average expression in the biological 
replicates were at least two fold lower in the Men1 
deficient than in the heterozygous pituitary glands . A 
students T-test was performed on the three biological 
replicates and only genes with a p-value less than 
0.05 were considered. Gene name/description is 
shown as well as the fold downregulation. Red 
writing indicate genes that fall below the 0.5 
expression threshold indicated in Figure 2.2.6.
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Tabel 2.2 Gene/description Gene/descriptionFold Up
KO vs Het
Fold Up
KO vs Het
Plac1 placental specific protein 1 10.6
Scya8 chemokine (C-C motif) ligand 8 8.9
Vip vasoactive intestinal polypeptide 7.4
ribonuclease P 25kDa subunit 6.7
Penk1 preproenkephalin 1 5.2
Hist3h2ba histone 3, H2ba 5.1
Necl1 nectin-lke 1 5.1
AK013779 4.6
Igf1 insulin-like growth factor 1 4.4
Gng3 G protein, gamma 3 subunit 4.2
AK013855 4.0
Pnmt phenylethanolamine-N-methyltransferase 3.9
AK010426 3.7
Stmn2 stathmin-like 2 3.7
CycB2 cyclin B2 3.7
Calca-1 calcitonin/calcitonin-related polypeptide3.5
C77158 3.4
Ube2c ubiquitin-conjugating enzyme E2C 3.4
Cnil cornichon-like (Drosophila) 3.4
Topk T-LAK cell-originated protein kinase 3.2
NM_026481 3.2
Crtl1 cartilage link protein 1 3.2
AK013867 3.1
NM_172515 3.1
Adcy8 adenylate cyclase 8 3.1
Ryr1 ryanodine receptor 1, skeletal muscle 3.1
Cdc2a cell division cycle 2 homolog A 3.0
Calb1 calbindin-28K 3.0
Atp1a3 ATPase, Na+/K+ transporting, alpha 3 3.0
NM_145967 3.0
AK005765 2.9
Vsnl1 visinin-like 1 2.9
Survivin baculoviral IAP repeat-containing 5 2.9
NM_029703 2.8
Nnmt nicotinamide N-methyltransferase 2.8
Cilp cartilage, nucleotide pyrophosphohydrolase 2.7
AK004470 2.7
AK008943 2.7
Fabp5 fatty acid binding protein 5, epidermal 2.7
Matador Bcl-2-related ovarian killer protein 2.6
AK008577 2.6
AK005178 2.5
Cyca cyclin A2 2.5
Nkd1 naked cuticle 1 homolog 2.5
Myoc myocilin 2.5
Lck lymphocyte protein tyrosine kinase 2.5
Prc1 protein regulator of cytokinesis 1 2.4
AK011241 2.4
NM_020591 2.3
Bmp2 bone morphogenetic protein 2 2.3
NM_172920 2.3
Mill2 MHC I - like leukocyte 2 2.3
Galnt3 N-acetylgalactosaminyltransferase 3 2.3
Padi1 peptidyl arginine deiminase, type I 2.3
NM_023396 2.3
NM_025572 2.3
Cycb-4 cyclin B1 2.2
Zbp1 Z-DNA binding protein 1 2.2
Ubce8 ubiquitin-conjugating enzyme 8 2.2
Cxcl13 chemokine (C-X-C motif) ligand 13 2.1
Fxyd2 FXYD domain ion transport regulator 2 2.1
Bcl11a B-cell CLL/lymphoma 11A 2.1
NM_133851 2.1
Pnma1 paraneoplastic antigen MA1 2.1
AK011311 2.1
Faim2 Fas apoptotic inhibitory molecule 2 2.0
Bscl2 Bernardinelli-Seip congenital lipodystroph 2.0
Tabel 2.1 67 genes were upregulated in Men1 
deficient pituitary glands. Genes that were 
expressed in either all the heterozygous or in all 
the Men1 deficient samples were selected (10962 
in total). These genes were normalised to the 50th 
percentile of all spots on each array. Genes were 
chosen whose average expression in the 
biological replicates were at least two fold higher 
in the Men1 deficient than in the heterozygous 
pituitary glands . A students T-test was performed 
on the three biological replicates and only genes 
with a p-value less than 0.05 were considered. 
Gene name/description is shown as well as the 
fold downregulation. Red writing indicate genes 
that fall below the 0.5 expression threshold 
indicated in Figure 2.2.6.
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CREB. cAMP also activates the mitogen activated protein kinase (MAP kinase) pathway
through the GTPase Rap1 (Romano et al., 2003). As mentioned in the introduction, cAMP is
a mitotic signal in cells of the endocrine system, which is also reflected by the frequent
mutations to Gαs and PRKAR1α in endocrine cancers (Lania et al., 2001)(Kirschner et al.,
2000).
Cdc2 also known as Cdk1, is thought to be the key initiator of mitosis in vertebrate cells
(Takizawa et al., 2000). Activated Cdc2/Cdk1 mediates cytosolic events such as centrosome
segregation and nuclear events such as nuclear envelope breakdown (Takizawa et al., 2000).
Cdc2/Cdk1 is a cyclin dependent kinase that is dependent on binding to Cyclin B1 or Cyclin
B2 for its activity. In addition to the availability of Cyclin B, the activity of the Cdc2/Cdk1
kinase is controlled by many independent mechanisms including inhibitory phosphorylation
of Cdc2/Cdk1 by the Wee kinase and activating dephosphorylation through Cdc25. The
activity of the Cdc2/Cdk1-Cyclin B complex is also regulated by phosphorylation of Cyclin B
and the subcellular localisation of the complex (Takizawa et al., 2000).
IGF1 is a 7 kDa polypeptide highly related to insulin that functions as a growth and survival
factor. The main function of IGF1, and the related IGF-2 is thought to be mediating the
anabolic and mitogenic effects of GH (Laron, 2001). GH increases systemic IGF1 by
stimulating endocrine IGF1 production from the liver. GH also stimulates paracrine
production of IGF1 in many other tissues (Laron, 2001). IGF1 stimulates prenatal and
postnatal growth and IGF1 deficient mice are 30 percent smaller than their wildtype
littermates and show severe postnatal growth retardation (Liu et al., 1993).
IGF1 and the related IGF2 signal through the IGF1R. This receptor tyrosine kinase exists a
tetramer composed of two α and two β subunits both encoded by the same gene (Sachdev et
al., 2001). Upon IGF binding the receptor autophosphorylates and binds to target proteins that
are then phosphorylated. Among these IGF receptor binding proteins are proteins of the IRS
family. These proteins function as adaptor proteins that recruit several signal transduction
molecules (Sachdev et al., 2001). The most important downstream mediators of IGF
signalling are the PI3K, the STAT and the Ras pathways (Sachdev et al., 2001)(Surmacz et
al., 2003). Through these effectors the IGF receptor can activate pathways that control
proliferation as well as apoptosis. The Ras pathway is one of the most well characterised
proliferation promoting signals. Ras activates several kinase cascades that lead to the
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activation of several MAP kinases. The PI3K pathway is well characterised as an anti-
apoptotic pathway. PI3K phosphorylates inositol phosphates that subsequently activate
PKB/AKT. PKB/AKT promotes survival by phosphorylating and inhibiting the proapoptotic
protein Bad (del Peso et al., 1997).
2.2.8 Analysis by in situ hybridisation of deregulated genes
To verify the microarray results and to investigate the expression pattern of the potential
mediators of the hyperplasia and hyperproliferation associated with Men1 loss, I cloned in situ
hybridisation probes from a pituitary gland cDNA library or from chromosomal DNA for the
genes encoding VIP, IGF1, Cdc2A and Cyclin B2. Figure 2.2.8 shows the expression of VIP,
IGF1 and Cdc2a in sections from both male and female mice, either wildtype, heterozygous
or homozygous for Men1 in the Pit-1 lineage. In the 41.5 week old heterozygous pituitary
gland, a macroscopic adenoma was observed in the left side of the pituitary gland (not
shown), which showed no hybridisation signal with the Men1 exon 3-6 probe (see Figure
2.2.1 C for the Men1 in situ hybridisation of sections from the same heterozygous pituitary
gland).
As the microarray data suggested, VIP is clearly overexpressed in 13 week old male pituitary
glands. Moreover the overexpression appears to be concentrated in patchy structures scattered
over the posterior lobe. Interestingly however, VIP is expressed many folds higher in female
Men1 deficient pituitary glands at both 7 and 13 weeks of age. Although the level of VIP
expression in the female pituitary glands is many fold higher than in male, VIP still appears to
be expressed in patchy structures and in some sections VIP expression appears to be
concentrated along the upper edge of the anterior lobe. Importantly, VIP is also many fold
overexpressed in the Men1 deficient outgrowth of the 41.5 week old heterozygous pituitary
gland, suggesting that VIP overexpression is also associated with the clonal expansion of
Men1 deficient cells occurring during MEN1 tumourigenesis.
The expression of Cdc2 is similar to that of VIP. Again, expression is much higher in Men1
deficient female pituitary glands than in male pituitary glands. The Cdc2  signal is
concentrated in small punctate structures. Like VIP, Cdc2 is also clearly overexpressed in the
Men1 deficient clonal outgrowth of the heterozygous pituitary gland.
The overexpression of IGF1 in the male Men1 deficient pituitary gland is not as apparent as
the microarray would suggest. However, in the female Men1 deficient pituitary gland at 13
weeks, there is a very clear overexpression of IGF1. Unlike VIP and Cdc2, IGF1 is
Figure 2.2.8 VIP, Cdc2 and IGF1 are overexpressed in Men1 deficient pituitaries. In situ hybridisation of 
18 µm cryosections. Sections of male and female pituitaries from Men1LoxP-Frt/Frt (Wt), 
Men1LoxP-Frt/Null/Pit-1-Cre (Null) and Men1LoxP-Frt/Null (Het) mice with the indicated ages were hybridised 
with the indicated probes. The VIP staining shows a patchy expression pattern and is strongest along the upper 
periphery of the anterior lobe. Cdc2 signal is concentrated in punctate structures spread over the anterior lobe 
of the Men1 deficient pituitary glands. The IGF1 signal is more homogeneously spread over the anterior lobe. 
In the heterozygous pituitary glands VIP, Cdc2 and IGF1 are overexpressed in the clonal outgrowth, which 
has lost Men1 expression (see Figure 2.2.1). The 35S labeled in situ probe was visualised by 4 weeks of 
incubation with Kodak NTB2 and the tissue counterstained with Bisbenzimide. Photographs were done on the 
Leica MZFLIII microscope. 
7 week13 week 13 week 41.5 week
Wt
Null
Wt
Null
Wt
Null
Het
Het
Het
VIP
Cdc2
IGF1
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Figure 2.2.9 VIP, Cdc2 and IGF1 are overexpressed in Men1 deficient pituitaries but not in Men1 deficient 
embryos.  In situ hybridisation of 18 µm cryosections. The S35 labelled in situ probe was visualised by 4 weeks 
of incubation with Kodak NTB2 and the tissue counterstained with Bisbenzimide A 13 week female pituitaries 
from Men1LoxP-Frt/LoxP-Frt (Wt) and Men1LoxP-Frt/LoxP-Null/Pit-1-Cre (Null) mice were cryosectioned and 
hybridised with the probes indicated.  Photographes were done on the Leica DC500 Axiophot with a 20 times 
objective. B 11.5 day old Men1wt/wt and Men1LoxP-Null/LoxP-Null embryos were cryosectioned and and 
hybridised with the indicated probes. Photographes were done on the Leica MZFLIII microscope .
Wt
VIP
Wt
Null
Null
IGF1Cdc2
A
B
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homogenously expressed in the anterior and this may also make the overexpression more
difficult to detect in the in situ hybridisation experiment. IGF1 is also overexpressed in the
Men1 deficient part of the heterozygous pituitary gland, although not as clearly as VIP and
Cdc2.
CyclinB expression was not observed in any of the pituitary gland sections (data not shown).
This discrepancy between the microarray data and the in situ results could be the result of
alternative splicing of an exon hybridising to the 30 bp microarray probe .
Figure 2.2.9 A shows higher magnification microscopy of the in situ hybridisation of the 13
week female pituitary glands. In this magnification, the patchy expression of VIP and Cdc2
and the more homogenous expression of IGF1 is clearly visible. As the conditional knockout
approach only allowed us to assess the effect on gene expression of Men1 deletion in the
pituitary gland, I also performed in situ hybridisation on E11,5 wildtype and Men1LoxP-Null/Null
embryonic sections. As Figure 2.2.9 B shows, Men1 deficient embryos are clearly smaller
than their wildtype counterparts at this stage, however there is no major difference in the
expression levels of VIP, Cdc2 and IGF1 in the embryos.
2.2.9 Analysis of VIP expression by immunohistochemistry
To verify that the overexpression of VIP mRNA also results in an overexpression of VIP
peptide, I probed pituitary gland sections with an antibody against VIP. Figure 2.2.10 A
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shows that Men1 deficient pituitary glands clearly overexpress the VIP protein. The pattern of
staining overlaps with that of the mRNA signal. The strongest VIP signal can be seen along
the upper edges of the anterior lobe close to the intermediate lobe, but VIP expressing cells
can also be found scattered over the entire anterior lobe.
Results
67
2.3 Screening for novel Menin interaction partners
2.3.1 Yeast two hybrid screening for novel Menin interactors
To identify new interaction partners of Menin, I undertook a yeast two hybrid screening using
Menin as a bait. In a first attempt, I used the Cytotrap system from Stratagene with little
success. The Cytotrap system is a yeast two hybrid system based on cytosolic interactions. In
a second attempt, I used the Matchmaker Gal4 two hybrid system from Clontech. Menin was
fused to the Gal4 DNA binding domain (Gal4-DB) and cotransformed into the yeast strain
AH109 together with a self-made randomly primed pituitary gland library fused to the
activation domain (Gal4-AD) of Gal4. The AH109 strain carries two independent selectable
markers encoding the Ade2 and His3 genes that are dependent on interaction between bait and
target for expression. Approximately 3x106 transformants were assayed for adenine and
histidine independent growth and 109 colonies were isolated that grew on medium selecting
for both genetic markers. DNA was isolated from the yeast and electroporated into E.coli.
Bacterial DNA was then isolated and analysed by restriction digestion to identify the library
plasmid.
Isolated plasmids were retransformed into AH109 together with Menin-Gal4-DB or with
Gal4-DB. 22 plasmids were identified that promoted growth when cotransformed with Menin-
Gal4-DB but not with Gal4-DB alone (Figure 2.3.1). These plasmids were sequenced. 9
different genes were identified. Table 2.3 shows the name, the number of yeast clones and the
approximate fragment size and position for each gene.
Among the isolated genes are two genes encoding previously published Menin interacting
proteins, JunD and Vimentin, confirming the validity of the system. Trip11/GMAP210 was
found most frequently with 10 out of 22 positive clones. All of these clones were identical
judged by restriction digest and 5’ sequencing. The second most frequent insert encoded a
predicted novel gene, referred to as GAD5. This insert was found in 4 positive plasmids. All
of these inserts were also identical. JunD was identified with two different fragments each
encoding almost the entire reading frame of the protein. All other clones were unique. The
growth rate of the yeast on selective plates reflects the strength of the interaction between bait
and target protein, as well as the expression level and availability of the target-Gal4 fusion.
Judged by growth rate the interaction of Menin with Trip11 was the strongest and the
interaction of Menin with Spectrin and Gad27 the weakest. All other interactions were of
intermediate strength.
Trip11/GMAP210 10 aa 732 - 957
Gad27 1 app. 900 aa
Gad67 1 415 aa
Gad69 1 app. 400 aa
Spectrin 1 aa 350 - app.780
Gad5 4 app. 630 aa
Vimentin 1 aa 1 - app.430
Ldb1a 1 aa 1 - app 340
JunD 2 aa 23 - 341aa 1 - 319
Gene Number of clones Size of encodedprotein fragment
Table 2.3
Vimentin
Trip11/GMAP210
JunD
Gad5
Gad27
Spectrin
Gad5
Ldb1a
Gad67
Gad69
pGBT-
Menin
pGBT pGBTpGBT-
Menin
Figure 2.3.1 Yeast two hybrid screening for novel 
Menin interactors. Clones isolated from the library 
screening were retransformed into AH109 together with 
pGBT-Menin or with pGBT alone. Transformants were 
streaked onto SD-Ade, His, Leu, Trp and incubated for 
4-5 days at 30 ºC to test for Menin dependent growth.
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Of the seven novel Menin interaction partners, three have already been cloned and
characterised in mammals.
2.3.2 Previously characterised genes as novel Menin interactors
Trip11/GMAP210/Trip230
Trip11/GMAP210 was originally characterised as a Thyroid Hormone Receptor (TR)
interacting protein (Lee et al., 1995 ). The protein encoded by the gene is 1979 amino acids in
length. Trip11/GMAP210 has been shown to act as a transcriptional coactivator for TR in a
Thyroid Hormone dependent manner (Chang et al., 1997). Furthermore, Trip11/GMAP210
binds to RB and this binding prevents Trip11/GMAP210 from acting as a transcriptional
coactivator for TR (Chang et al., 1997).
Surprisingly, Trip11/GMAP210 has also been shown to be a Golgi apparatus associated
Protein that binds to the minus end of microtubules (Infante et al., 1999). Furthermore,
overexpression of Trip11/GMAP-210 blocks transport between the endoplasmic reticulum
and the Golgi apparatus (Pernet-Gallay et al., 2002).
This apparent paradox may be explained by the observation that upon Thyroid Hormone
addition Trip11/GMAP210 becomes phosphorylated and then translocates from the Golgi
apparatus to the nucleus (Chen et al., 1999).
Spectrin β2/ELF
Spectrin is a tetrameric actin cross-linking complex consisting of two α and two β subunits. In
mammals there are five genes encoding β Spectrin (Tang et al., 2002). Spectrin β2 gives rise
to at least 3 different isoforms, all encoding proteins of roughly 2000 amino acids. They all
share the region encoded by the insert from the yeast two hybrid clone .
Interestingly, the knockout of Spectrin β2 in the mouse gives a phenotype similar to that of
double heterozygous Smad2/Smad3 animals (Tang et al., 2003).
Furthermore, Spectrin β2 interacts with Smad3 and Smad4 but not Smad2, and Spectrin β2
translocates to the nucleus upon TGF-β stimulation. Finally TGF-β signalling is disrupted in
Spectrin β2 null mouse embryonic fibroblasts (Tang et al., 2003).
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Ldb1a
Ldb1a is a transcriptional cofactor that was first characterised as a cofactor for the Lim
homeodomain family of transcription factors (Agulnick et al., 1996). In Drosophila it has
been shown to interact with several other transcription factors including Bcd, Ftz and SuHw
(Matthews et al., 2003). Knockout studies in the mouse have shown that Ldb1a is required for
normal anterior posterior patterning as well as heart development (Mukhopadhyay M, 2003).
2.3.3 Novel proteins interacting with Menin
Four of the novel Menin interacting proteins had not previously been characterised in
mammals. These were referred to Gad5, Gad27, Gad67 and Gad69 from the name of the
vector and the number of their respective yeast clone.
The sequences of these yeast two hybrid inserts were blasted against the NCBI nucleotide
database. For each of the novel genes, a prediction based on the genomic sequence and/or
ESTs was available.
Gad5 is predicted be part of a gene that encodes a protein of 730 amino acids that contains
domains homologous to GTPase accelerating proteins for Rab-like GTPases. The accession
number of the predicted gene is XM_283964
Gad27 is predicted to be part of a transcript encoding a protein of 1330 amino acids that has
homology to Guanine nucleotide exchange factors for Rho like GTPases. The accession
number of the predicted gene is XM_147847
Gad67 is predicted to be part of a gene that encodes a Bromodomain containing protein
Gad69 is part of a gene predicted to encode a protein of 542 amino acids with no recognised
domains or significant homology to any characterised protein. The accession number of the
predicted gene is BC034212
The inserts from the yeast two hybrid library clones were cloned into the Bluescript vector
and used as probes in in situ hybridisation on embryonic and adult mouse sections.
Gad5, Gad27 and Gad69 did not show any distinct expression at E11.5, E13.5, E17.5 heads or
E18,5 heads as well as adult pituitary gland, kidney and adrenal glands (data not shown).
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2.3.4 Expression pattern of Gad67 and cloning of cDNA
The in situ analysis with the Gad67 probe revealed that the gene showed an expression pattern
that suggests an almost ubiquitous expression of Gad67 (Figure 2.3.2). At E11,5, the
strongest expression was in Rathke’s pouch, the precursor to the pituitary gland, and the roof
of the midbrain. At E13,5, the strongest expression was in the developing pituitary gland, roof
of the neopallial cortex, the gastroduodenal junction, kidney and cartilage of vertebrate.
Gad67 expression was distinctly absent from the liver. In E17,5 heads, the strongest signal
was from the subventricular zone, olfactory epithelium and pituitary gland. At E18.5 the
choroid plexus showed a very specific and strong signal.
To further characterise Gad67, I decided to clone the complete cDNA of the gene.
To this end, I probed a pituitary gland cDNA phage library with the yeast two hybrid library
insert. One positive clone was isolated that contained a 3525 bp fragment overlapping 92 bp
with the probe. Sequencing revealed that this fragment contained the 5’ end of an open
reading frame that stretched through the yeast two hybrid clone. ESTs suggested that the open
reading frame continued for approximately 1000 bp downstream of the yeast two hybrid
clone. To clone this 3’ fragment, I performed PCR on a pituitary gland cDNA library with a
primer within the yeast two hybrid clone and a primer downstream of the predicted
termination codon of the open reading frame. A 1000 bp fragment was cloned and sequenced.
The full length cDNA is 5542 bp. Alignment with the mouse genome revealed that the gene is
positioned on the X chromosome where it is encoded by 40 exons. The open reading frame of
Gad67 begins in exon1 and stretches 5244 bp. The encoded protein is 1747 amino acids in
length. Figure 2.3.2 B-C shows the amino acid sequence and predicted structural domains of
the protein. Gad67 has two predicted domains. In the N-terminus there is a WD40 repeat
region of 322 amino acids and in the C-terminus a double Bromodomain. The yeast two
hybrid clone overlaps precisely with the Bromodomain as indicated in Figure 2.3.2 B,
suggesting that Menin binds to the Bromodomain of Gad67. In mammals two homologous
proteins have been identified, WDR9 and WDR11. Orthologues have been predicted but not
characterised in Danio Rerio, Gallus Gallus and Drosophila.
WD40 repeat domains, also called WD or transducin repeats, consist of an approximately 40
amino acid core domain that is repeated 4 to 16 times (Li et al., 2001). Gad67 contains seven
WD40 repeats. The WD40 repeat domain forms a stable β-propeller structure (Wall et al.,
1995), which is believed to function as a rigid platform for protein complex assembly (Li D,
2001). The mouse genome contains 190 predicted WD40 domain containing proteins. WD40
MAAAPTQIEAELYYLIARFLQSGPCNKSAQVLVQELEEHQLIPRRLDWEGKEHRRSFEDLVAANAHIPPDYLLKICERIGPL
LDKEIPQSVPGVQTLLGVGRQSLLRDAKDCKSTLWNGSAFAALHRGRPPELPVNYVKPPNVVNITSARQLTGCSRFSHV
FPSSAYQHIKMHKRILGHLSSVYCVAFDRSGRRIFTGSDDCLVKIWATDDGRLLATLRGHSAEISDMAVNYENTLIAAGSC
DKVVRVWCLRTCAPVAVLQGHSASITSIQFCPSTKGTTRYLTSTGADGTICFWQWHVKTMKFRDRPVKFTERSRPGVQI
SCSSFSSGGMFITTGSTDHVIRIYYLGSEIPEKIAELESHTDKVVAVQFCNNGDSLRFVSGSRDGTARIWQYQQQEWKSIV
LDMATKMSGNNLTSAEDKVTKLKVTMVAWDRYDTTVITAVNNFLLKVWNSVTGQLLHTLSGHDDEVFVLEAHPFDQRIILS
AGHDGNIFIWDLDRGTKIRNYFNMIEGQGHGAVFDCKFSPDGNHFACTDSHGHLLLFGFGCSKYYEKIPDQMFFHTDYR
PLIRDANNYVLDEQTQQAPHLMPPPFLVDVDGNPHPTKFQRLVPGRENCKDEQLIPQLGYVANGDGEVVEQVIGQQTND
QEESILDGIIRELQREQDLRLINEGDVPHFPINRSYSVNGALSSPNMDIPSSPNIGLRRSGQIEGVRQMHNNAPRSQMATE
RDLMAWSRRVVVNELNSGVSRVQEECRNAKGDLEVSLYTVEKKKKPSYPIQRNDYQPSCGRSLRRTQRKRQHTYLTRS
NIEHNSQASSQTSGVQEDSDSSSEEDETVGTSDASVEDPVVEWQSESSSSDSSSEYSDWIADAGINLQPPKRQTRQAT
QKIYSSSEDENLKLEDRQKKPKQTKKKKGGLVSMAGEPNEEWLAPQWILDTIPRRSPFVPQMGDELIYFRQGHEAYVRA
VRKSKIYSVNLQKQPWNKMDLREQEFVKIVGIKYEIGPPTLCCLKLAFLDPISGKMTGESFSIKYHDMPDVIDFLVLHQFYN
EAKERNWQIGDRFRSIIDDAWWFGTVESQQPFQPEYPDSSFQCYSVHWDNNEREKMSPWDMEPIPDGTAFPDEVGAG
IPVSQEELTALLYKPQEGEWGAHSRDEECERVIQGINNLLSLDFASPFAVPVDLSAYPLYCTVVAYPTDLNTIKQRLENRFY
RRISALMWEVRYIEHNARTFNEPDSPIVKAAKIVTDVLLRFIGDQSCADILDTLQLKSKPEDPDSSDLEEDSEMVDLDSDG
PGTSSGRRAKCRGRRQSLKCNPDAWKKQCEELLSLIYEREDSEPFRQPADPQSYPVQQQQEGESSQSVPPDRQDPSL
SEDYQDGIDTPMDFSTVKETLESGNYDSPLEFYKDVRQIFSNSKAYTSNKKSRIYSMTLRLSALFENHIKNIISDYKSAIQS
QKRRRPRYRKRLRSSSSSLSSSRAPSPKGKQKQMKLQPKNDQNTSVAYARTSSPFSSPDHSLDGPLTNVDGREPRTGA
KRKLLSASEEDESMGGEEKEMKETKEQVHLSSSESGELGSSLSSESTSGSDSDSESTSRTDQDYVDGDHDYSKFIQTR
PKRKLRKQHTNGKRNWKTRGTGGRGRWGRWGRWSRGGRGRGGRGRGGRGRGGGGGRGRGRGRGGRGASRGS
SRAKRARVADDEFDTMFSGRFSRLPRIKTRNQGRRTVLYNDDSDNDNFVSTEDPLNLGTSRSGRVRKMTEKARVSHLM
GWNY
A
B
Bromo Bromo
Yeast two hybrid clone
WD40C
E11.5 E13.5 E17.5 E18.5
E11.5 E13.5 E17.5 E18.5 Adult
Figure 2.3.2 Cloning and characterisation of Gad67. A Gad67 is expressed in the pituitary gland and many 
other tissues. In situ hybridisation of embryonic and adult cryosections with a 1200 bp Gad67 probe 
corresponding to the yeast two hybrid clone. The 35S labeled in situ probe was visualised by 4 weeks of 
incubation with Kodak NTB2 and the tissue counterstained with Bisbenzimide. Photographs were done on the 
Leica MZFLIII microscope Top sagital sections of embryos at E11,5 and E13,5 and sagital head sections of 
embryos at E17,5 and E18,5 Bottom close up of pituitaries from same sections. B Complete amino acid 
sequence of Gad67. The full length cDNA of Gad67 was cloned by screening of a pituitary gland λ-phage 
library and by PCR from a pituitary gland cDNA library. The part of the protein encoded by the yeast two hybrid 
clone is highlighted in blue. C Predicted domain structure of protein encoded by the full length cDNA. The 
protein was predicted to contain a WD40 domain and a double Bromodomain by the Conserved Domain 
Database at NCBI. The yeast two hybrid clone overlaps precisely with the predicted double Bromodomain.
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repeat proteins have been shown to be involved in biological processes such as signal
transduction (G-protein β-subunit, RACK1 and Stratin), RNA synthesis (most TFIID
associated factors – TAFs), chromatin assembly (CAF-1, HIR1 and HIR2), cell cycle
regulation (CDC20, Mad2), programmed cell death (Apaf1) (Li et al., 2001) and
transcriptional repression (Groucho/TLE1) (Pickles et al., 2002).
The Bromodomain was originally characterised in the Drosophila protein Brahma (Tamkun
et al., 1992). Bromodomains specifically recognise acetylated Histones (Dhalluin et al.,
1999). Activation of transcription often involves Histone acetylation on specific lysines
followed by the remodelling of nucleosomes by ATP dependent chromatin remodelling
complexes (Agalioti et al., 2002). Many chromatin associated proteins and nearly all Histone
acetyl transferases contain Bromodomains (Jeanmougin et al., 1997). Additionally, all known
SWI/SNF like ATP dependent chromatin remodelling complexes contain a Bromodomain
protein (Marmorstein et al., 2001). Thus most Bromodomain containing proteins are involved
in chromatin remodelling processes.
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3 Discussion
3.1 loss of Men1 leads to pituitary gland hyperplasia and adenoma formation.
To elucidate the role of Men1 in tumourigenesis of the endocrine system and specifically of
the pituitary gland, I established a conditional mouse model of the MEN1 syndrome. Using
homologous recombination I replaced the Men1 coding region with a targeting vector
containing two LoxP sites and a positive selection marker flanked by two Frt sites. When
intercrossing mice heterozygous for the targeted allele I obtained no homozygous animals,
showing that the positive selection cassette disrupted the expression of Menin, and that Menin
is required for the embryonic development of the mouse. This has also been reported by two
other groups, who found that Men1-/- embryos die around embryonic day 11.5 with multiple
defects (Crabtree et al., 2001)(Bertolino et al., 2003a).
By crossing to FlpE expressing mice, the Frt site flanked positive selection cassette was
successfully excised. The resulting floxed allele was functional and animals homozygous for
the floxed Men1 allele appeared at the expected mendelian ratio. Importantly, the LoxP sites
allowed efficient Cre mediated excision of exons 3 to 7 of the Men1 allele leading to absence
of Menin expression.
By crossing the floxed Men1 allele into Pit-1-Cre expressing mice, I specifically deleted
Men1 only in the Pit-1 lineage of the pituitary gland of the mouse. Homozygous deletion of
Men1 in the pituitary gland led to pituitary gland hyperplasia followed in most cases by
massive pituitary gland adenoma formation as early as 35 weeks of age. The pituitary glands
from heterozygous animals were indistinguishable from those of wildtype animals at early
ages but they also developed tumours later showing that the deletion of Men1 in the mouse is
a relevant model for studying MEN1. This is also in agreement with parallel studies using
conventional knockout strategies (Crabtree et al., 2001)(Bertolino et al., 2003b).
Development of pituitary gland adenomas was much more frequent and more rapid in mice
with a homozygous Men1 deletion in the pituitary gland than it was in heterozygous
littermates in agreement with the results from recent conditional knockout models in the
pancreatic islets and parathyroid gland (Bertolino et al., 2003c)(Crabtree et al., 2003)(Biondi
et al., 2004). All adenomas originated from the anterior pituitary gland. Although many of
these tumours grew aggressively, invasion of surrounding tissue like the posterior pituitary
gland was never observed.
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There was a clear gender difference with respect to the propensity to develop pituitary gland
adenomas. By 45 weeks of age, 100 percent of the female mice with a homozygous deletion
of Men1 had developed adenomas visible to the naked eye whereas the corresponding number
for males was only 40 percent. This gender difference was also observed in the heterozygous
mice, where 3 out of 5 female mice had developed macroadenomas by the age of 45 weeks
whereas no males were observed with adenomas visible to the naked eye. In human MEN1
patients there is also a clear gender difference with respect to the frequency of pituitary gland
tumours. In one study 50 percent of female MEN1 had been diagnosed with a pituitaty gland
tumour compared to 31 percent of Male patients (Verges et al. 2002). Interestingly, this
gender difference has not been described for other endocrine tumours in MEN1 (Verges et al.
2002).
Pituitary gland adenoma formation was preceded by significant pituitary gland hyperplasia in
all mice tested as early as 7 weeks of age. At 10 weeks of age, the anterior lobes of pituitary
glands from Men1LoxP-Frt/Null/Pit-1-Cre mice were more than twice as big as those from
wildtype or heterozygous littermates. The extent of hyperplasia formation also showed a
gender difference. At all ages, most Men1 deficient pituitary glands were bigger in females
than in males.
At 12 weeks of age a significant fraction of the cells in the Men1 deficient pituitary gland
stained positive for the G1/S/M phase marker KI-67. This staining was not observed in the
wildtype pituitary glands of the same age. The presence of KI-67 suggests that in the absence
of Men1 many cells are still actively progressing through the cell cycle. A significant fraction
of cells in the Men1 deficient pituitary gland but not in the wildtype pituitary gland also stain
positive for the mitotic marker phospho-Histone3, suggesting that cell division is still taking
place in pituitary glands from 12 week old female Men1LoxP-Frt/Null/Pit-1-Cre mice but not in
those from their wildtype littermates. The lack of staining for the apoptotic marker cleaved
Caspase3 in any of the pituitary gland sections suggests that this hyperproliferation is not
associated with significant apoptosis. Hyperproliferation caused by the expression of
oncogenes is often associated with increased apoptosis, induced by the deregulation of growth
promoting pathways (Hanahan et al., 2000). The absence of apoptosis in connection with the
hyperproliferation induced by loss of Men1 may reflect that the loss of Men1 not only leads to
an increase in growth signal but also to a suppression of apoptosis.
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The growth of the wildtype and Men1 deficient pituitary glands at early ages and the
subsequent development of adenomas in the Men1 deficient pituitary glands offer some
insight into the mechanism of MEN1 tumourigenesis.
At 7 weeks of age, the wildtype pituitary glands have stopped gaining in size whereas the
Men1 deficient pituitary glands expand significantly until 10 weeks of age. After 10 weeks,
the expansion of the Men1 deficient pituitary glands slows down dramatically and even for
female Men1 deficient pituitary glands there is little gain in size from 10 weeks onwards until
adenoma formation sometime after 20 weeks of age. Although there is still some proliferation
occurring at 12 weeks of age, which must lead to gain in cell numbers. This suggests that loss
of Men1 leads to significant hyperproliferation after the normal growth of the pituitary gland
has started to decrease. Furthermore, after a certain size of the pituitary gland or a certain age
has been reached, even Men1 deficient pituitary glands show a very significant reduction in
growth.
The size of the pituitary adenomas present as early 35 weeks of age suggest that in these
pituitary glands, rapid proliferations has resumed at some point causing them to gain many
folds in size. When this resumption of growth happens and what initiates it remains to be
established. Although massive adenomas develop with 100 percent penetrance in the female
Men1 deficient pituitary glands by 45 weeks of age, these adenomas vary significantly in size.
In addition, only 40 percent of male Men1 deficient pituitary glands have developed
adenomas by 45 weeks of age. These observations suggest that although loss of Men1 induces
hyperproliferation, it is not sufficient for adenoma formation. This conclusion is also
supported by the observation that adenomas in heterozygous Men1 mouse models show loss
and gain of chromosomes, with gain of mouse chromosome 15 being the most frequent
(Crabtree et al., 2003). These chromosomal rearrangements may lead to genetic lesions that
initiate resumption of rapid growth and adenoma formation. The complete loss of Men1 signal
in the heterozygous adenoma, suggests that it is only Men1 deficient cells that contributes to
adenoma formation. This suggests that the secondary genetic lesions are cell autonomous
lesions (not secreted growth factors) that leads to a clonal expansion of Men1 deficient cells.
This is also in agreement with the theory that all pituitary adenomas are of clonal origins
(Melmed, 2003).
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3.2 Gene expression profiling suggests a novel mechanism for MEN1
tumourigenesis
Although little is known about the function of Menin, most data suggest that the protein
functions as a transcriptional regulator. As cancer invariably involves changes in gene
expression pattern (Hanahan et al., 2000), I reasoned that the tumourigenesis caused by loss
of Men1 would most likely be associated with changes in the gene expression profile of the
pituitary gland cells.
To investigate the molecular mechanism of the tumour suppressor activity of Men1, I
analysed the expression profile of the Men1  deficient pituitary glands compared to
heterozygous littermates by microarray analysis. Relatively young males (13 weeks) were
chosen to minimise the risk of major chromosomal rearrangements or the gain of secondary
mutations.
Many of the genes implicated in sporadic pituitary gland tumourigenesis were among the
11500 genes expressed in the pituitary glands. These genes included PTTG1, bFGF, NGF,
FGF4, TGF-α, TRH, GHRH, Dopamine D2 receptor, Rb, p16Ink4a, p18Ink4c and Gαs. None
of these genes showed any significant change in expression levels. Furthermore, western blot
analysis with anti p27Kip1 antibodies showed no difference between wildtype and Men1
deficient pituitary glands at 13 weeks of age (data not shown). Down regulation of p27Kip1
on a posttranslational level is associated with pituitary gland tumourigenesis (Melmed, 2003).
The clear gender bias in adenoma formation and the enhanced hyperplasia in early female
pituitary glands would suggest a hormonal influence. Systemic administration of Estrogen, the
female sex hormone, has been shown to cause pituitary gland hyperplasia and subsequently
adenoma formation in rats (Heaney et al., 1999). This hyperplasia is associated with increased
expression of PTTG1 and bFGF (Heaney et al., 1999). As neither PTTG1 nor bFGF were
overexpressed in the Men1 deficient pituitary glands it appears that a general deregulation of
Estrogen signalling is not present in MEN1 tumourigenesis.
The microarray data thus suggests that the mechanism of tumourigenesis associated with loss
of Men1 differs from those previously described for sporadic pituitary gland tumourigenesis.
This conclusion is also in agreement with the observation that inactivation of MEN1 does not
appear to play a major role in sporadic pituitary gland tumours (Prezant et al., 1998)(Farrell et
al., 1999)
 The finding that Menin may regulate transcriptional pathways involving NF-kB and Smads
and thus interfere with TGF-β signalling suggests a possible mechanism for tumourigenesis.
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Although it does not explain the very tissue specific development of tumours. Many TGF-β
and NF-κB target genes have been implicated in growth control, apoptosis and metastasis and
they would therefore be potential mediators of MEN1 tumourigenesis. These genes include
p15Ink4B , p21Cip1, c-Myc, cyclin D1, c-Jun, Cdc25, cIAP, Pai-1, Transin/Stromelysin, GM-
CSF, BCL-XL and c-flip. Interestingly however, none of these genes showed any change in
their expression pattern in Men1 deficient pituitary glands suggesting that they are not
involved in MEN1 tumourigenesis.
3.3 VIP, IGF1 and Cdc2 are upregulated in Men1 deficient pituitary glands
The adenoma formation in Men1 deficient pituitary glands was invariably preceded by
hyperplasias and hyperproliferation. It is thus reasonable to conclude that loss of Men1 leads
to deregulation of genes that can provide self-sufficiency in growth signals or alternatively,
change the expression level of genes that normally mediate growth inhibitory signals. The
absence of apoptosis associated with the hyperproliferation may also reflect changes to genes
affecting apoptosis and survival.
Analysis of the microarray experiment yielded two lists of genes that were reproducibly either
more than two fold overexpressed or two fold underexpressed in the Men1 deficient pituitary
glands compared to the heterozygous pituitary glands.
Although the majority of the genes that showed differential expression in the Men1 deficient
pituitary glands were downregulated in the absence of Men1, I did not identify any genes in
this group that were obvious candidates for growth control genes. However, on inspection of
the upregulated genes, a number of genes were identified that, according to the literature,
could be involved in regulation of growth or apoptosis. These included genes encoding
secreted growth factors as well as genes involved in cell cycle control and apoptosis. Of the
genes overexpressed in the Men1 deficient pituitary glands, I decided to further analyse four
genes. These were the genes encoding two secreted growth factors, Insulin like Growth Factor
1 (IGF1), 4,6 fold upregulated and Vasoactive Intestinal Peptide (VIP), 7,4 fold upregulated
and the genes encoding the cyclin dependent kinase Cdc2/Cdk1 and its ligand Cyclin B2,
which were 3,0 and 3,7 fold upregulated respectively. However, it should be noted that there
are other genes among the genes upregulated in the Men1 deficient pituitary glands, which
could play a role in MEN1 tumourigenesis. These include BMP2, which as noted previously
plays a role in the development of the pituitary and the specification of the pituitary gland cell
types (Treier et al., 1996)(Dasen et al., 1999), and most notably Survivin. Survivin is a
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member of the IAP family of apoptosis inihibitory proteins that are believed to suppress
apoptosis by blocking activation of caspases. A role for Survivin in regulating chromosome
segregation has also been suggested (Reed et al., 2000). BMP2 and Survivin were upregulated
2.3 and 2.9 fold respectively in the microarray experiment. The overexpression of these two
factors have not yet been verified by in situ hybridisation, but the overexpression of Survivin
could potentially play a role in the suppression of any apoptosis that may be associated with
progression to pituitary adenoma.
In situ hybridisation analysis of male and female pituitary glands at different ages confirmed
VIP, IGF1 and Cdc2 but not CyclinB2 as being differentially expressed in Men1 deficient
pituitary glands compared to wildtype. VIP, Cdc2 and IGF1 were all clearly overexpressed in
the anterior lobe of the Men1 deficient female pituitary glands compared to the wildtype
pituitary glands at 13 weeks of age. Moreover, all genes showed a clear gender difference in
expression levels. At 13 weeks, female Men1 deficient pituitary glands expressed VIP, Cdc2
and IGF1 at a level many folds higher than the male pituitary glands. Interestingly, the
difference in expression levels between wildtype and the Men1 deficient pituitary glands
increased with the age of the female for all three genes. CyclinB2 showed no expression at any
of the ages and genotypes tested. For both VIP and Cdc2 the expression of the genes was
concentrated to patchy structures scattered over the anterior pituitary gland, whereas the
expression of IGF1 was evenly distributed over the entire anterior lobe.
Overexpression of growth factors like VIP and IGF1 are likely to lead to increased signalling
through their cognate receptors. However, for a cyclin dependent kinase like Cdc2/Cdk1, the
level of Cyclin B as well as the activity of the inhibitory Wee kinase and the activating Cdc25
phosphatase has more influence on the activity of the kinase than the concentration of
Cdc2/Cdk1 itself. As I could not confirm the overexpression of cyclinB by in situ
hybridisation under any of the tested conditions, there is no evidence at present to suggest that
Men1 deficient cells have increased Cdc2/Cdk1 activity. I will therefore only discuss the
implications of the VIP and IGF1 overexpression for MEN1 here.
The overexpression of VIP in the female Men1 deficient pituitary glands was especially
striking. The in situ hybridisation does not yield any quantitative data, but if the upregulation
in the male pituitary gland was 7 fold as the microarray suggested, then that of the female
pituitary glands must be many times higher. Importantly, there was very strong VIP
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expression in the Men1 deficient neoplasia present on the 41 week old heterozygous pituitary
gland, suggesting that the data obtained from the young pituitary glands are valid for the older
heterozygous pituitary glands that resemble the MEN1 syndrome most closely.
In some of the female sections, VIP expression was highest along the periphery of the anterior
pituitary gland. This is the same region of the Men1 deficient pituitary glands that develops
the most prominent vacuoles at 7 weeks of age. To what extent the formation of vacuoles and
the subsequent haemorrhaging of blood into them is caused by VIP is not known, but VIP has
been shown to be a vasodilating peptide (Gozes et al., 1999).
According to the microarray data, IGF1 was clearly overexpressed in 13 week old male
pituitary glands. Although the in situ experiment presented clearly validates the microarray
experiment and demonstrated overexpression of IGF1 in the female 13 week old pituitary
gland, the overexpression in the 13 week old male in this experiment was less clear. However,
other in situ experiments did clearly demonstrate overexpression in the male pituitary glands
supporting the microarray data. In the heterozygous pituitary gland, IGF1 did show
overexpression in the Men1 deficient outgrowth, albeit to a lesser extent than VIP or Cdc2.
VIP protein was also significantly upregulated in Men1 deficient pituitary glands. VIP
expressing cells were scattered over the entire anterior pituitary gland, although VIP
expressing cells appeared to be more concentrated in certain areas such as the edge of the
anterior lobe facing the intermediate lobe. As we do not yet have a reliable antibody that
detects Menin in pituitary gland sections, I have not yet been able to investigate if VIP is
exclusively expressed in Men1 deficient cells.
The Pit-1-Cre transgene should ensure expression of Cre in the lactotrope, somatotrope and
thyrotrope lineages (Rhodes et al., 1993), although I could only detect Cre mediated EGFP
expression in the lactotrope and somatotrope lineages. The in situ hybridisation experiment
with the Men1 probe and the western blot with the anti Menin antibody showed that the
deletion of Men1 was efficient, suggesting that Men1 has been deleted in the lactotrope and
somatotrope lineages, which constitutes more than half of the pituitary cells. It remains to be
established which of these two cell lines express the deregulated genes in the Men1 deficient
pituitary glands. There is no evidence that both cell lineages deregulate the same genes in
response to the deletion of Men1. It may thus be that each of the two lineages only are
responsible for a subset of the genes found deregulated in the Men1LoxP-Frt/Null/Pit-1-Cre
pituitary glands. Intriguingly, for secreted growth factors there even is a possibility that one
cell type secretes the growth factor that stimulates the growth of the other. These issues could
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be resolved by selectively deleting Men1 in the somatotrope or lactotrope lineages using the
GH or Prolactin promoter to drive Cre expression.
3.4 VIP and pituitary gland proliferation
VIP is a small peptide of the glucagon family, closely related to the GH Releasing Hormone
that signals though a G protein coupled receptor. Receptor activation by these peptides leads
to increased intracellular cAMP as well as activation of Phospholipase C and intracellular
Ca2+ release. Among the physiological effects of VIP is the increased secretion of many
hormones from the endocrine system. These include Prolactin and GH from the pituitary
gland (Gozes et al., 1999) and Insulin from the pancreatic islets (Kato et al., 1994). Indeed,
VIP has been proposed to be a physiological Prolactin releasing factor (Abe et al., 1985) and
VIP stimulates Prolactin release in vivo in response to TRH (Balsa et al.,), IGF1 (Lara et al.,
1994) and Serotonin (Balsa et al., 1998) or low Thyroid Hormone or Dopamine levels (Balsa
et al., 1996). In the endocrine system, factors that induce hormone secretion often additionally
stimulate proliferation of the secreting cells. Thus, overproduction of releasing hormones
from the hypothalamus leads to pituitary gland hyperplasia that may progress to adenomas
(Melmed, 2003). The vast majority of hormone secreting adenomas in human MEN1 patients
secrete Prolactin and a smaller fraction secrete GH or ACTH (Verges et al., 2002), whereas
only Prolactin and GH secreting tumours were observed in mouse models (Crabtree et al.,
2001)(Bertolino et al., 2003), suggesting that Men1 controls growth of lactotropes and
somatotropes.
VIP is a mitogen for lactotropes. It stimulates proliferation of lactotropes in vitro (Prysor-
Jones et al., 1989)(Fernandez et al., 2003). The VIP induced proliferation of lactotropes is
abolished by addition of a PKA inhibitor (Fernandez et al., 2003) indicating that the mitotic
signal is mediated by cAMP. Interestingly, the stimulation of lactotrope proliferation by VIP
can also be partly blocked by MAP kinase inhibitors (Fernandez et al., 2003) suggesting that
VIP can activate the MAP kinase pathway. Indeed it has been shown that in addition to PKA
activation, VIP stimulation of Prolactin secretion also involves activation of the small GTPase
Rap1, through cAMP responsive exchange factors, and subsequent activation of MAP kinases
(Romano et al., 2003). This is in agreement with the observation that cAMP mediated
stimulation of lactotrope proliferation requires activation of both PKA and the MAP kinase
pathway (Suzuki et al., 1999).
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VIP has also been implicated in lactotrope stimulation in vivo. Estrogen induced hyperplasia
is associated with increased VIP expression, with a correlation between pituitary gland size
and the concentration of VIP (Prysor-Jones et al., 1988). Additionally, VIP antagonists have
been shown to block Estrogen induced hyperplasia (Gomez et al., 2003)
Prolonged overstimulation with Estrogen can lead to prolactinoma formation (Heaney et al.,
1999)(Piroli et al., 2004). Moreover, Estrogen induced pituitary gland prolactinomas show a
gender bias both with respect to adenoma size and VIP expression suggesting that VIP could
be a mediator of Estrogen induced prolactinoma formation (Piroli et al., 2004).
Intriguingly, overexpression of the VIP related GHRH induces somatotrope hyperplasia and
subsequent adenoma formation with exactly the same kinetics as loss of Men1 does (Kineman
et al., 2001). As noted previously, VIP induces hormone secretion in both lactotropes and
somatotropes and both cell types recognise cAMP as a mitotic signal. The reason why VIP
may preferentially induce prolactinomas is that the VIP receptor is enriched in lactotropes
(Wanke et al., 1990).
3.5 IGF and pituitary gland proliferation
IGF1 is a 7 kDa polypeptide related to insulin. IGF1 and the highly related IGF2, signal
through IGF1R, a receptor tyrosine kinase. IGF signalling leads to activation of the PI3K
pathway, the STAT pathway and the RAS pathway (Sachdev et al., 2001)(Surmacz, 2003).
Through these effectors the IGF receptor can activate pathways that control proliferation as
well as apoptosis.
IGF1 is normally expressed by cells within the pituitary gland and IGF1 can induce
proliferation of pituitary gland lactotropes and corticotropes in vitro, but has no effect on the
other pituitary gland cell lines (Oomizu et al., 1998)(Fernandez et al., 2003). It may in some
cases even attenuate proliferation of somatotropes (Fernandez et al., 2003). The IGF1 induced
lactotrope proliferation can be blocked by MAP kinase inhibitors, suggesting that IGF1
stimulates proliferation through activation of Ras and its downstream MAP kinase.
Interestingly, the mitogenic effect of IGF1 on cultured lactotropes could also be partially
blocked by PKA inhibitors or VIP antagonists, suggesting that part of the mitogenic signal of
IGF1 is through an autocrine loop involving VIP (Fernandez et al., 2003). Likewise, VIP has
been implicated in IGF1 induction of Prolactin secretion from lactotropes (Lara et al., 1994).
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3.6 VIP and IGF1 in Cancer
Both VIP, IGF1 and the related IGF2 have been implicated in cancer. VIP is found
overexpressed in some cancers, especially cancers of the pancreatic islets. These tumours of
the pancreatic islets are called VIPomas and the disease is also known as Verner-Morrison
syndrome. The Verner-Morrison syndrome is extremely rare with only 1 out of 10 million
being affected. To what extent VIP expression contributes to the process of tumourigenesis is
not known. In rodent models, VIP receptor antagonists have been shown to inhibit mammary
gland carcinogenesis (Moody et al., 2004), ovarian cancer (Chatzistamou et al., 2001),
prostate cancer (Plonowski et al., 2002) and non-small cell lung cancer (Moody et al., 1993),
whereas VIP itself inhibits growth of small cell lung cancer (Maruno et al., 1998). In vitro,
VIP has also been shown to stimulate proliferation of HT29 colon adenocarcinoma cells by
activating the ERK pathway through Rap1 (Alleaume et al., 2003) and VIP receptor
antagonists have been shown to inhibit growth of neuroblastoma cell lines (Lilling et al.,
1994-95).
High levels of circulating IGF, within the normal range, leads to an increased risk of breast
and prostate cancer, two cancers that are normally considered to be strongly affected by sex
hormones. To what extent IGF directly contributes to the tumourigenesis is not known
(Renehan et al., 2004).
In an interesting mouse model for pancreatic islet cancer, Christofori et al. overexpressed the
SV40 large T antigen, which binds to, and inactivates RB and p53, in the pancreatic islets. Its
overexpression led to hyperplasia in 50 percent of the islets followed by adenoma formation
in a smaller fraction. The adenoma formation was in all cases associated with a clear
overexpression of IGF2. Overexpression of SV40 large T antigen in igf2-/- mice led to
suppression of tumour growth associated with increased apoptosis (Christofori et al., 1994).
The association of proliferation with apoptosis was also illustrated by another mouse model
where the overexpression of c-Myc in the pancreatic islet led to widespread apoptosis.
However, when the c-Myc expression was combined with expression of the anti apoptotic
gene BclXL, the suppression of apoptosis led to rapid adenoma formation (Pelengaris et al.,
2002).
3.7 Regulation of VIP and IGF expression
The expression of VIP is regulated by many hormones and growth factors. Thus VIP
expression is stimulated by TRH (Balsa et al., 1996a), IGF1 (Lara et al., 1994), Serotonin
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(Balsa et al., 1998), Estrogen (Degerman et al., 2002), TGF-β1, ciliary neutropkic factor (Pitts
et al., 2001) and Activin (Symes et al., 2000) and repressed by Thyroid Hormone (Degerman
et al., 2002) and Dopamine (Balsa et al., 1996b). VIP expression is normally restricted to
specific areas of the brain, the peripheral nervous system and to the anterior pituitary gland.
The VIP promoter is regulated by many transcription factors. Of special interest for Menin is
the binding of Smad3 and Smad4 in response to TGF-β. Binding of AP-1 and STAT can also
activate the VIP promoter (Pitts et al., 2001). AP-1 and STAT probably mediate the effect of
IGF1 on the VIP promoter (Pitts et al., 2001) as IGF can activate these transcription factors
through IRS and through Ras activation. The Activin stimulation of VIP is likely to be
mediated by Smad1 and Smad5, two other Menin interacting proteins.
Sequence analysis of the mouse and human VIP promoter reveals that they contain a Thyroid
Hormone Response Element (TCACCCTGACCC in the mouse) within 3000 bp of the
transcriptional start as well as AP-1 sites (TGA(C/G)TCA). Moreover, both the mouse and the
human promoter contain perfect TGF-β inhibitory elements (TIE). In the mouse there are 3
TIE sites just upstream of the transcriptional start point and in the human 1 TIE site 800 bp
downstream of the transcriptional start. Also in both mouse and human consensus NF-κB
binding sites can be found 5000 bp upstream of the transcriptional start for the mouse
promoter and 1500 bp downstream of the transcriptional start for the human promoter.
The expression of IGF1 is primarily regulated by GH and many of the effects of GH are
thought to be mediated by IGF1 (Laron, 2001). Additionally, IGF1 expression can be
stimulated by Thyroid Hormone (Fagin et al., 1989) and possibly Estrogen (Umayahara et al.,
1994). The regulation of IGF1 expression is complex as it involves 4 different transcriptional
start sites giving rise to several alternatively spliced forms (Jansen E, 1991). The IGF1
promoter contains binding sites for AP-1 (Umayahara et al., 1994), Sp-1 (Zhu et al., 2000)
and GATA transcription factors (Wang et al., 2000).
3.8 Menin interacting proteins
Using a yeast two hybrid system, I screened a pituitary gland cDNA library for novel Menin
interacting proteins. After screening approximately 3 million transformants, which
corresponds to roughly a third of the estimated complexity of the library, I identified 22
plasmids that enabled Menin dependent growth. These plasmids contained fragments from 9
different genes. Of these, JunD and Vimentin had previously been published as Menin
interacting proteins, confirming our yeast two hybrid approach. 3 plasmids contained
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fragments from known genes that had not previously been published as encoding Menin
interacting proteins. These were GMAP210/TRIP11, Ldb1a and Spectrin. Finally 4 plasmids
contained fragments from novel genes. In situ hybridisation failed to reveal any expression of
3 of these genes, but the fourth, Gad67, showed expression in most tissues except for the liver.
I subsequently cloned the full-length cDNA from a phage library. Sequencing revealed that
the protein contained two predicted domains. A WD40 repeat domain in the N-terminus and a
double Bromodomain in the C-terminal half. The yeast clone overlapped precisely with the
Bromodomain.
The isolation of JunD once again confirmed this protein as a Menin interacting protein.
Likewise, the identification of Spectrin as a potential Menin interacting protein further
strengthened the association between Menin and TGF-β signalling (Tang et al., 2003).
Moreover, the finding that Menin can interact with Spectrin in a yeast two hybrid system
suggests a mechanism for the regulation of Smad3 by Menin and also provides a mechanism
whereby Menin could regulate TGF-β signalling in the absence of Smad3. The binding
between Menin and Spectrin remains to be confirmed by an independent method. It also
remains to be investigated if Menin, Spectrin and Smad3 all bind to each other directly or
indirectly.
It is interesting to note that the proposed functions of Spectrin and GMAP210/Trip11 are
similar. Both are structural proteins in the cytosol that may translocate to the nucleus to
function as transcriptional cofactors upon stimulation with either TGF-β or Thyroid Hormone
(Chen et al., 1999)(Tang et al., 2003). It is also noteworthy that Spectrin, GMAP210/Trip11
and Ldb1a have all been characterised as transcriptional coactivators. Although Menin has
previously been shown to interact with transcriptional corepressors, this is the first time that
transcriptional coactivators have been suggested to interact with Menin.
The function of Gad67 is unknown. The presence of a WD40 domain suggests that Gad67 can
function as an assembly platform for protein complexes (Li et al., 2001). More importantly,
the double Bromodomain of Gad67 suggests that the protein is involved in chromatin
remodelling. The Bromodomain binds to acetylated lysines, most often in the context of
Histone tails (Dhalluin et al., 1999). Furthermore, Bromodomain containing proteins are an
integral part of Histone modification and chromatin complexes (Jeanmougin et al.,
1997)(Marmorstein et al., 2001). To what extent Gad67 is involved in MEN1 tumourigenesis
is yet to be elucidated. It should however be noted that the Bromodomain is one of 11 protein
domains that was found significantly overrepresented among 291 characterised cancer genes
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compared to their frequency among all genes, in a recent survey of the literature. According to
this survey, 10 percent of all bromodomain proteins have been found mutated in human
cancers (Futreal et al., 2004).
3.9 VIP and IGF1 as mediators of MEN1 tumourigenesis
There is no evidence that Menin binds DNA directly. Rather it appears to regulate
transcription by binding to transcription factors or to transcriptional cofactors. It follows from
this that the influence of Menin on a promoter in a given cell is dependent on the transcription
factors and cofactors expressed in that cell. Thus, the loss of Menin is likely to effect different
genes in different tissues. For the same reasons it seems unlikely that the interaction of Menin
with a single transcription factor or cofactor will provide a satisfactory explanation for the
endocrine tumourigenesis caused by the loss of Menin. It seems more likely that a complex
interplay between several Menin binding factors on a set of promoters will render these
promoters Menin responsive.
Menin has been reported to function as a coactivator for some transcription factors and as a
corepressor for others. The microarray analysis of Men1 deficient pituitary glands did not
provide any definitive answers regarding the effect of Menin on transcription. While the
expression of most genes was unaffected by the deletion of Men1, a subset of the genes were
either upregulated or downregulated in the Men1 deficient pituitary glands. To what extent
these genes are direct targets of Menin or if the change of expression is an indirect effect, is
not known as microarray or in situ hybridisation analysis does not distinguish between direct
or indirect effects on transcription.
In the microarray experiment VIP was one of the genes with the highest fold of deregulation.
Moreover, the in situ hybridisation analysis of VIP, Cdc2 and IGF1 demonstrated that the
overexpression of VIP in the Men1 deficient pituitary glands was much more pronounced that
that of Cdc2 or IGF1. VIP would therefore be an obvious choice for promoter analysis to
establish the mechanism of Menin regulation. As noted previously, the VIP promoter contains
several elements that would allow Menin interaction. The binding of Menin to the VIP
promoter should be verified experimentally by chromatin immunoprecipitation or bandshift
analysis. To elucidate a possible mechanism for Menin dependent regulation, promoter
analysis of the VIP promoter in a suitable system should yield information about the
transcription factors Menin may bind to regulate expression of VIP.
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The loss of Men1 in the pituitary gland changes the expression level of a small subset of the
genes expressed in the pituitary gland. If the tumour suppressor activity of Menin is related to
its role as a transcriptional regulator, it is likely that the mediators of MEN1 tumourigenesis
are among these genes. Thus, VIP and IGF1 are the best candidate genes for causing the
pituitary gland hyperplasia and hyperproliferation associated with MEN1 tumourigenesis.
Both VIP and IGF1 are potent mitogens for lactotropes and possibly also for somatotropes
and corticotropes. The combination of VIP and IGF1 should in theory be sufficient to supply
growth signals and to suppress possible apoptosis associated with hyperproliferation.
According to the theory of Robert Weinberg, these are two of the 6 characteristics acquired by
malignant tumours. To what extent VIP and IGF1 are sufficient to induce pituitary gland
hyperplasia or even adenoma formation in vivo remains to be tested by transgenic
overexpression experiments.
The MEN1 syndrome also involves tumour formation in other endocrine organs than the
pituitary gland. Though it is not certain, it seems likely that the mechanism of tumourigenesis
is similar in all of these organs. It would therefore be interesting to investigate if VIP and
IGF1 are overexpressed in Men1 deficient parathyroid or adrenal glands or in the pancreatic
islets. This could be tested by deleting Men1 specifically in these organs by crossing the
floxed Men1 allele into mice expressing Cre in beta cells using the Insulin promoter or in the
parathyroid gland using the Parathyroid Hormone promoter.
Little is known about the effects of VIP and IGF1 on the parathyroid gland. VIP can stimulate
Parathyroid Hormone release through stimulation of cAMP production (Joborn et al., 1991)
suggesting that the Chief cells of the parathyroid gland are VIP responsive. Likewise, IGF1
has been shown to be able to bind to and stimulate growth of human parathyroid adenoma
cells in vitro (Tanaka et al., 1994).
Overexpression of VIP alone in the pancreatic islets does not lead to adenoma formation in
mouse models although it does increase insulin secretion. Whether the overexpression was
associated with hyperplasia was not reported (Kato et al., 1994). The absence of adenoma
formation could reflect that cells of the pancreatic islets may not be as responsive to cAMP as
a mitotic signal as cells of other endocrine organs. Pancreatic islet tumours are not very
frequent in neither the Carney syndrome caused by deregulated PKA signalling, nor the
McCune Albright syndrome, caused by an activating mutation to Gαs. Alternatively, the
expression of VIP, like that of c-Myc and SV40 largeT antigen is not tumourigenic in the
absence of a survival signal such as BCL-XL or IGF1 or 2. To verify that VIP and IGF1 can
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indeed mediate the MEN1 tumourigenesis, transgenic experiments with the two growth
factors should be performed.
In addition, the role of VIP as mediator of MEN1 tumourigenesis can also be investigated by
blocking the action of VIP by administering VIP antagonists to Men1LoxP-Frt/Null/Pit-1-Cre mice.
This experiment would establish if VIP overexpression is required for the hyperplasia and
subsequent adenoma formation in Men1 deficient pituitary glands.
In conclusion, I have established a mouse model that faithfully reproduces the MEN1
syndrome in the pituitary gland. Using this mouse model I have begun to elucidate the
mechanism of MEN1 tumourigenesis, and identified a number of genes that are deregulated in
Men1 deficient pituitary glands. This work has laid the foundations for the understanding of
how Menin regulates proliferation in the pituitary gland. The identification of several growth
factors that are overexpressed in Men1  deficient pituitary glands may explain their
hyperproliferation phenotype and subsequent progression to aggressive pituitary adenoma.
Transgenic overexpression studies of these growth facors in the pituitary will doubtlessly help
to further understand the role of M e n 1  in pituitary tumourigenesis.
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List of Abbreviations
ACTH Adrenocorticotropin
BAC Bacterial Artificial Chromosome
BMP Bone Morphogenic Protein
cAMP cyclic Adenosine Mono Phosphate
CREB cAMP Response Element Binding protein
CRH Corticotropin Releasing Hormone
EGFP Enhanced Green Fluorescent Protein
ERK Extracellula signal Regulated Kinase
FGF Fibroblast Growth Factor
FMTC
FSH Follicle-Stimulating Hormone
g gram
GH Growth Hormone
GHRH Growth hormone releasing hormone
GnRH Gonadotropin Releasing Hormone
HDAC Histone Deacetylase
IGF Insulin Like Growth Factor
L Litre
MAP kinase Mitogen Activated kinase
ml milli litre
µl micro litre
LH Luteinising Hormone
M Molar
MEN1 Multiple Endocrine Neoplasias type 1 (disease)
MEN1 Multiple Endocrine Neoplasias type 1 (human gene)
Men1 Multiple Endocrine Neoplasias type 1 (mouse gene)
mM milli Molar
µM micro Molar
MSH Melanocyte Stimulating Hormone
NGF Nerve Growth Factor
PKA Protein kinase A
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TGF Transforming Growth Factor
TR Thyroid Hormone Receptor
TRH Thyrotropin Releasing Hormone
TSH Thyroid Stimulating Hormone
VEGF
VIP Vasoactive Intestinal Peptide
wt wild type
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4 Materials and Methods
4.1 Materials
4.1.1 Chemicals
Acrylamide Biorad
L-Adenine Sigma
Agar, Bacto Becton-Dickinson
Agarose Invitrogen
Ampicillin Sigma
Amino acids (for yeast) all Sigma
Except L-Phenyl-Alanin Merck
Ammonium Chloride Merck
Ammonium-Persulfate (APS) Biorad
Bovine Serum Albumin, Fraction V (BSA) Sigma
Bromophenol blue Sigma
Calcium Chloride Merck
Carrier DNA (Herring testis) Clontech
Chloramphenicol Sigma
Dextran Sulfate Amersham Pharmacia
Dextrose Merck
Dithiothreitol (DTT) Biomol, Germany
DMSO (Dimethylsulfoxide) Sigma
DPX Agar Scientific
EDTA Merck
Ethanol Merck
Ethidium Bromide Sigma
Fetal Calf Serum Invitrogen
N,N-Dimethylformamide Sigma
Formalin Electron Microscopy Sciences
Geneticin-Sulfate Sigma
L-Glutamine Invitrogen
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Glycine Merck
HEPES Invitrogen
Isopropanol Merck
Kanamycin Sigma
Lithium Acetate Sigma
Lithium Chloride Merck
Magnesium Chloride Merck
MEM Non-essential amino acids Invitrogen
β-Mercaptoethanol Sigma
Methanol Merck
P32-dCTP Amersham
Paraformaldehyde (PFA) Sigma
Penicillin/Streptomycin Invitrogen
Peptone Difco
PEG4000 Sigma
Potassium Chloride Merck
Protease Inhibitors Complete Roche
35S-UTP Amersham
Sodium Acetate Merck
Sodium Hydroxide Merck
Sodium Pyruvate Invitrogen
TEMED Biorad
Triethanolamine Sigma
Triton X-100 Sigma
Trypsin Invitrogen
Tween20 Gerbu
L-Uracil Sigma
Xylene Sigma
Yeast extract Difco
Yeast Nitrogen Base without amino acids Difco
4.1.2 Equipment, plastic ware and other materials
Acid washed beads (0,5 mm) Sigma
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Agilent Bioanalyser Agilent
Aquamount‚ Aqueous Mountant LERNER Laboratories
Bacterial Petri dishes Greiner Bio-One
High-Density mouse BAC membranes Research Genetics
Cell counter chamber (Neubauer improved) BRAND
Cell culture dishes NalgeNUNC International
Cell incubator Hera cell KendroLaboratoryProducts
Centricon YM-10 Amicon
Centrifuge 5417C Eppendorf
Centrifuge RC5C Sorvall‚ Instruments
Centrifuge RC-3B Sorvall‚ Instruments
Cryotome CM 3050S Leica Microsystems
Codelink 20K mouse Bioarray Amersham
Coverslips (24x60 mm) Superior Marienfeld
Electrophoresis chambers PeqLab
Electroporation system Gene Pulser II BIO RAD
Electro-SeparationSystem S&S BIOTRAP Schleicher & Schuell Bioscience
Filtration bottles STERICUP MILLIPORE
Fine forceps and scissors ROBOZ
Gene Pulser ‚ Electroporation cuvettes BIO RAD
Hybridiser incubator Techne HB-1D TECHNE
Hybridisation bottles TECHNE
Hybridisation Transfer Membrane NEN Life Science Products
Microlance hypodermic needles Becton Dickinson
Microscope Slides Super Frost ‚Plus 25x75mm ROTH
Microscope Axiovert 25 Zeiss
Mini Protean 3 system Bio-Rad
Mini Trans-Blot Cell Bio-Rad
Nitrocellulose Membranes PROTRAN Schleicher & Schuell
Nylon Membranes Biotrans ICN Biomedicals Inc.
OCT Coumpound Embedding Medium Tissue-Tek‚
Optical Microscope Zeiss
Paraffin Microtome RM2165 Leica Microsystems
PCR thermal cycler PTC-200 Biozym
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PCR thermal reaction tubes ABgene
Plastic tubes (50 ml and 15 ml) FALCON
Power supply Power Pac 300 BioRad
Reaction tubes (1.5 ml) ROTH
Serological Pipets (25 ml; 10 ml; 5 ml; 2 ml) FALCON
Spectrophotometer Ultraspec 3000 Pharmacia Biotech
Vibrotome VI 1000S Leica Microsystems
Ultracentrifuge L8-M BECKMAN
4.1.3 Enzymes
Proteinase K MERCK
Hot Star Taq DNA Polymerase QIAGEN
Restriction endonucleases New England BIOLABS; Roche,
SIBenzyme
Pwo DNA polymerase Roche
Expand High Fidelity system Roche
Klenow New England Biolabs
4.1.4 Molecular weight markers
1kb DNA ladder Invitrogen
Broad Range protein ladder Biorad
4.1.5 Oligonucleotides
Targeting vector synthesis
The targeting vector linker was put together by four oligoes:
MenKO1S:
5’ cgcgatcgcgatatcataacttcgtataatgtatgctatacgaagttatgttaacg 3’
MenKO1AS:
5’ gtaccgttaacataacttcgtatagcatacattatacgaagttatgatatcgcgatcgcgagct 3’
MenKO2S:
5’ aacataacttcgtataatgtatgctatacgaagttatggcgcgccggtcaccactagtgcgatcgcg 3’
MenKO2AS:
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5’ gtaccgcgatcgcactagtggtgaccggcgcgccataacttcgtatagcatacattatacgaagttatgtt 3’
Cloning of pGad67
Gad67SacI1: 5’ agcagagctcccagtccaaaaggc 3’
Gad67PstI: 5’ aaattccctgcagtagaaggccagtg 3’
Gad67BamHI: 5’ tacgctatgctgcttgaaacttgcca 3’
Gad67AseI: 5’ tgttcaatatagcgtacctcccac 3’
Gad67NotIXhoI: 5’ ggtggcggccgcctcgagatggcggcggcacc 3’
Gad67SacIDn: 5’ ggctgccaccagatcc 3’
Mouse genotyping:
Men1LoxP1: 5’ gttatcataacttcgtataatgtatgc 3’
Men1Loxp3: 5’ agccacaccggcattgac 3’
Men1LoxP8: 5’ gcaagcatctgaggcctcttgtgagc 3’
Men1LoxP9: 5’ caggtccacccagccagaaactgcc 3’
Men1Frt1: 5’ gttagcttgctcattgtggtaggaggc 3’
Men1Frt2: 5’ tactccctcccacctccattccaggc 3’
Men1Frt3: 5’ cggcgcgccggtcaccactcctac 3’
Menseq1: 5’ ctccctgtctctaatactgc 3’
Cre1: 5’ gcctgcattaccggtcgatgcaacga 3’
Cre2: 5’ gtggcagatggcgcggcaacaccatt 3’
FlpE1: 5’ ctaatgttgtgggaaattggagc 3’
FlpE2: 5’ ctcgaggataacttgtttattgc 3’
In situ probes
Men1-Up: 5’ ccagaattcgcaccaaactggacagctcg 3’
Men1-Dn: 5’ ccaaagcttcttgtgataaagggtgagtgg 3’
VIP-Up: 5’ ccagaattcatggaagccagaagcaagc 3’
VIP-Dn: 5’ ccaaagcttccagctcttcaagaaagtctgc 3’
IGF-Up: 5’ ccagaattcatgtcgtcttcacacctc 3’
IGF-Dn: 5’ ccaaagcttgaccacttttgcaaggtgc 3’
Cdc2-Up: 5’ ccagcggccgcgttcatggattcttcactcgcc 3’
Cdc2-Dn: 5’ ccaaagcttcttcagggccattttgccag 3’
CyclinB-Up: 5’ ccagcggccgcgctgtcaagaacaagtatgcc 3’
CyclinB-Dn: 5’ ccaaagctttaagtagatcaatagctttattttc 3’
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4.1.6 Antibodies
Primary antibodies:
αGFP Mouse Chemicon
αProlactin Rabbit Chemicon
αGrowth Hormone Rabbit Chemicon
αTSH Rabbit Parlow
αACTH Rabbit Parlow
αKI-67 Rabbit Novacastra
αMenin C19 Goat Santa Cruz
αphospho-CREB Rabbit Cell Signalling Technologies
αphospho-Histone H3 Rabbit Upstate Biotech
αVasoactive intestinal peptide Rabbit Chemicon
αCaspase Rabbit Cell Signalling Technologies
αErk1/2 Rabbit Cell Signalling Technologies
αphospho-Erk1/2 Mouse Cell Signalling Technologies
αp27Kip Mouse Santa Cruz
Secondary antibodies:
HRP-coupled αRabbit (western) Goat Chemicon
HRP-coupled αMouse (western) Goat Chemicon
HRP-coupled αGoat (western) Rabbit DAKO
Rhodamine Red-X-Conjugated αRabbit Jackson ImmunoReaserch
Fluoroscein-Conjugated αMouse Jackson ImmunoReaserch
4.1.7 Plasmid vectors
Bacterial vectors:
pBluescript SK Stratagene
pSP73 Promega
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pET-41-a-c Novagen
Yeast vectors:
pGAD, pGBT Clontech
Mammalian vectors:
FLPe cassette Stewart, A.F.
pKS-DTA Tajbakhsh, S.
Mouse BAC genomic clones Research Genetics
4.1.8 Commercial kits
ABC kit Vectastain
Codelink Expression Assay Reagent Amersham
DAB Peroxidase Substrate System Vector
Geneclean Spin kit Q-BIO gene
Lambda mini kit Qiagen
Large Construct kit Qiagen
QIAquick Gel Extraction kit Qiagen
Maxiprep Qiagen
Prolong Antifade Kit Molecular Probes
Riboprobe® Combination System-SP6/T7 Promega
RNeasy Qiagen
4.1.9 Generally used solutions
BAC Church: 7 % SDS, 25 mM Na2HPO4 pH 7.2, 1 % BSA, 1 mM EDTA
BAC Wash: 1 % SDS, 20mM Na2HPO4, 1mM EDTA
Gel-loading Buffer: 0.25 % bromophenol blue, 15 % Ficoll, in water
PBS: 137 mM NaCl, 2.7 mM KCl, 6.5 mM Na2HPO4, 1.5 mM
KH2PO4
20xSSC: 3M NaCl, 0.3M Na3citrate•2H2O (pH to 7.0 with 1M HCl)
50xTAE: 0.04 M Tris-Acetate, 0.001 M EDTA
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Tail Buffer: 0.1 M EDTA, 0.1 M NaCl, 1 % SDS, 0.05 M Tris-HCl, pH 7.6,
ProteinaseK, 0.5 mg/ml
5xTBE: 45 mM Tris-borate, 1 mM EDTA
TBF1: 30 mM Potassium acetate, 100 mM RbCl, 10 mM CaCl2,
50 mM MnCl2, Glycerol to 15 % (v/v), pH 5.8 with acetic acid
TBF2: 10 mM MOPS, 75 mM CaCl2, 10 mM RbCl, Glycerol 15 %
(v/v), pH 6.5 with KOH
TBS: 100 mM Tris-HCl pH 7.5, 150 mM NaCl
TE 10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0)
4.1.10 Generally used media for bacteria and yeast
LB: 1 % Bacto-tryptone, 0.5 % Bacto-yeast extract, 0.5 % NaCl
YPD: 2 % Peptone, 1 % Yeast extract, 2 % Dextrose, 2 % Agar (for plates only)
SD: 0.67 % Yeast nitrogen base, 2 % dextrose, 1xDropout solution, 2% Agar (for plates
only)
10xDropout solutions:L-Adenine 200 mg/L, L-Arginine-HCl 200 mg/L, L-Histidine
200 mg/L, L-Isoleucine 300 mg/L, L-Leucine 1000 mg/L, L-
Lysine-HCL 300 mg/L, L-Methionine 200 mg/L, L-
Phenylalanine 500 mg/L, L-Threonine 2000 mg/L, L-
Tryptophan 200 mg/L, L-Tyrosine 300 mg/L, L-Uracil 200 mg/L,
L-Valine 1500 mg/L.
4.1.11 Cells
Bacterial strains
E.coli XL-10 strain: Tetr, D(mcrA)183, D(mcrCB-hsdSMR-mrr)173,
endA1, supE44, thi-1, recA1, gyrA96, relA1, lac Hte (F’ proAB, lacIqZ
DM15 Tn10 (Tetr) Amy Camr)a
E.coli Y1090 strain: F-, D (lacU)169, lon-100, araD139, rpsL, supF, mcrA,
trpC22::Tn10/pMC9
BL21 DE3
Yeast strains
AH109: MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4D,
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gal80D, LYS2::GAL1UAS-Gal1TATA-HIS3, GAL2UAS-Gal2TATA-ADE2,
UAR3:: MEL1UAS-MEL1TATA-lacZ
ES cells
ES cells used for gene targeting were from the IB10 line. The IB10 is a mycoplasma-free
ES cell line rederived at the EMBL Transgenic Service from the E14,1 ES cell
line, therefore containing a 129/OLA genetic background.
4.2 Methods
4.2.1 DNA - Plasmids
Preparation of plasmid DNA from bacteria
Mini preparation of plasmid DNA was performed according the following procedure: 1.5 ml
of an overnight (O/N) bacterial culture was centrifuged in an eppendorf tube for 1 minute at
14000 rpm and room temperature (RT), the pellet was resuspended in 300 µl of resuspension
buffer (50 mM Tris-Cl, pH 8.0, 10 mM EDTA, 100 mg/ml RNAse A), 300 µl of lysis buffer
(200 mM NaOH, 1 % SDS) were added, mixed by inversion and incubated at RT for 1
minute, the lysate was mixed with 300 µl of cold neutralization buffer (3.0 M Potassium
Acetate, pH 5.5), incubated on ice for 10 minutes and centrifuged for 10 minutes at 14000
rpm and RT, 800 µl of the supernatant were transferred to a new tube and the DNA was
precipitated with 500 µl isopropanol, centrifuged for 5 minutes at 14000 rpm and washed with
1 ml of 70% ethanol. The DNA was air dried and resuspended in 50 µl TE. For large scale
preparation of plasmid DNA, the QIAGEN Plasmid Maxi Kit was used according to the
manufacturer’s instructions.
Purification of supercoiled DNA by CsCl gradient centrifugation
For purification of supercoiled plasmids, 4 g Caesium Chloride were dissolved in 3.8 ml of
TE containing the DNA to be purified. 0.2 ml of Ethidium Bromide solution (10 mg/ml in
water) were added and the mixture was transferred to a 4 ml centrifuge tube (Beckman) for
centrifugation in a Beckman vertical Vti65 rotor. After sealing, the tubes were spun O/N at
60000 rpm and 25°C. One visible band at the center of the gradient was collected into a glass
tube using a hypodermic needle. Ethidium Bromide was extracted from the DNA by a series
of equal volumes of 1-Butanol extractions until no pink colour was detected. The DNA was
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centrifuged in a centricon filter device at 4000 rpm (SS34 - Sorvall) and 25°C and washed 3
times with TE to remove CsCl.
Plasmid extraction from yeast
5 ml of SD-Leu were inoculated with one yeast colony and grown for 2 days at 30°C. The
yeast culture was spun down 1500 rpm (RC-3B – Sorvall) for 5 minutes, washed once in
water and resuspended in 300 µl yeast lysis buffer (2.5 M LiCl, 50 mM Tris-HCl pH 8.0, 4 %
triton X-100, 62.5 mM EDTA). 300 µL Phenol/Chloroform (50/50) was added and the
suspension was vortexed vigorously for 1 minute with 50 µl acid washed beads. The mixture
was spun at 14000 rpm (Eppendorf) for 5 minutes and the top aqueous phase was collected
into a new tube. The DNA was precipitated with 600 µl of ice-cold ethanol for 15 minutes at -
80°C, spun at 14000 rpm for 10 minutes at 4°C. The pellet was washed in 70 % ethanol and
dried. The pellet was resuspended with 40 µl water and precipitated with 4.8 µl Sodium
Acetate and 100 µl Ethanol at 14000 rpm for 10 minutes. The pellet was washed in 70 %
ethanol, dried and resuspended in 20 µl water. Purified yeast plasmid was transformed into
E.coli XL-10 by electroporation.
Spectrophotometric determination of DNA and RNA concentration
Spectrophotometric measurements of DNA solutions were done at wavelengths of 260 nm.
An OD=1 at 260 nm corresponds to a concentration of 50 µg/ml for double-stranded DNA
and 33 µg/ml for single-stranded oligonucleotides and 40 µg/ml for RNA.
DNA restriction and Klenow treatment
To a solution of DNA the appropriate 10xbuffer and restriction enzyme were added according
to the manufacturer’s recommendations, mixed in a reaction tube and typically incubated O/N
at the appropriate temperature. Klenow treatment was done in accordance with the NEB
protocol.
Electrophoresis of DNA
Analysis and preparation of DNA were performed using agarose gels containing 0.5 µg/ml
Ethidium Bromide. 1xTAE-buffer was used as gel and electrophoresis buffer. DNA samples
were loaded into the gels in 1xDNA loading buffer and run at 5 V/cm of gel. The DNA
samples were generally run in parallel to a DNA molecular weight marker (1kb ladder).
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Isolation and purification of DNA from preparative agarose gels
DNA was isolated from agarose using two different commercial kits according to the
fragment size. For fragments up to 6 kb, the QIAquick® Gel extraction Kit (Qiagen) was used
according to the manufacturers instructions. For fragments bigger than 6 kb, the Gene Clean
Spin Kit was used according to the manufacturers instructions. For purification of large
amounts of DNA from agarose gels, the S&S BIOTRAP Electro-Separation-System for
elution and purification of charged molecules was used according to the manufacturer’s
instructions.
DNA ligation
For ligation of purified DNA fragments into linealised plasmid vectors, an appropriate amount
of each DNA species was incubated O/N in a total volume of 10 µl with 1 µl of 10xbuffer and
1U DNA ligase. Ligation reactions were incubated O/N at 16°C.
Preparation of chemocompetent Escherichia coli XL-10 cells
5 ml of LB medium (+tetracycline) were inoculated with a single colony of E.coli XL-10 and
incubated with shaking (300 rpm) O/N at 37°C. 250 ml of LB medium were inoculated with
3-4 ml of the overnight culture and incubated with shaking at 37°C until an OD600 of 0.5 to
0.6. The cell suspension was incubated on ice for 5 minutes, poured into 50 ml Falcon tubes
and centrifuged at 3000 rpm (GSA - Sorvall) and 4°C for 10 minutes. The supernatant was
discarded and the bacterial pellet was resuspended in 20 ml of TBF1 buffer (2/5 volume) and
incubated on ice for 5 minutes. The cell suspension was centrifuged at 3000 rpm (RC-3B) and
4°C for 5 minutes, the supernatant was discarded and the bacterial pellet was resuspended in 2
ml TBF2 buffer (1/25 initial volume). After 15 minutes of incubation on ice 200 µl aliquots
were frozen in liquid nitrogen and stored at -80°C.
Transformation of chemocompetent Escherichia coli XL-10 cells
100µl of competent E.coli XL-10 cells were added to DNA in an eppendorf tube and
incubated on ice for 30 minutes, the mixture was then heat shocked for 90 seconds at 42°C,
followed by a 3 minutes incubation on ice. 1 ml of LB medium was added and the cell
suspension was incubated for 30 minutes at 37°C. The transformation was then plated on the
appropriate selective media and incubated at 37°C overnight.
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Preparation and transformation of electrocompetent E.coli XL-10 cells
5 ml of LB medium was inoculated with one colony of XL-10 and grown O/N at 37°C. 500
ml of LB was inoculated from the overnight culture and grown to an OD600 of 0.6. The
bacteria were chilled on ice for 10 minutes and spun down at 4000 rpm (GSA) at 4°C for 20
minutes. The supernatant was aspired and the pellet resuspended in 500 ml of ice-cold water
and spun as above. This procedure was repeated. After two washes, the bacteria were
resuspended in one volume of ice cold water. Up to 0.5 µg plasmid DNA in 1 µl water was
mixed with 100-300 µl of competent bacteria and placed in a pre-chilled cuvette. The
electroporation apparatus was set at 2.5 kV, 25 mF and 200 ohms and the transformation was
subjected to one pulse. The transformation was transferred to 1ml of LB and incubated on a
wheel for 30 minutes at 37°C. Finally the bacteria was plated on the appropriate selective
plates (LB-ampicilin in the case of pGAD vector recovery)
Transformation of yeast
50 ml YPD was inoculated with one or more yeast colonies and grown 16-18 hours at 30°C
(OD600>1.5). The overnight culture was diluted in 300 ml to an OD600 of 0.2 in fresh YPD
and the culture was grown until an OD600 of 0.6. The yeast was spun spun down at 1.000
rmp (RC-3B) for 5 minutes at room temperature, the pellet was resuspended and washed in 50
ml of water, spun again and finally resuspended in 1.5 ml of freshly prepared TE-LiAc (10
mM Tris-HCl PH 7.5, 1 mM EDTA, 100 mM LiAc).
For small scale transformations 0.1 µg of plasmid and 100 µg of herring testis carrier DNA
were added to an eppendorf tube and 100 µl of competent yeast suspension were added and
mixed by vortexing. 600 µl of PEG/LiAc solution (40 % PEG4000, 10 mM Tris-HCl PH 7.5,
1 mM EDTA, 100 mM LiAc) were added and the mixture vortexed again. The transformation
was incubated for 30 minutes at 30°C, 70 µl of DMSO were added and the mixture was then
heat shocked for 15 minutes at 42°C. After cooling on ice, the yeast was spun down at 14000
rpm, and the supernatant was removed. The pellet was resuspended in 300 µl sterile TE and
plated on appropriate selective medium.
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4.2.2 DNA - λ phage
Culture and preparation of bacteria for infection with λ-phage
For the preparation of bacteria for infection, a 500 ml Y1090 culture (LB medium
supplemented with 0.2 % Maltose and 10 mM MgCl2) was inoculated and incubated O/N at
37°C with agitation. The following day 500 ml of fresh medium were inoculated with the O/N
culture and grown until an OD600 of 1.5. The cells were then centrifuged for 15 minutes at
4000 rpm (GSA) and 4°C. The cell pellet was resuspended and washed in the same volume of
a 10 mM MgSO4 solution. The cells were again centrifuged at 4000 rpm for 15 minutes,
resuspended in 1/4 volume of 10 mM MgSO4 and stored at 4°C up to 4 weeks.
Infection with and plating of λ-phage
To plate λ phage infected bacteria, tenfold serial dilutions of λ-phage stocks were prepared in
suspension medium (0.1 M NaCl, 0.01 M MgSO4, 0.05 M Tris-HCl, pH 7.5). For infection,
180 µl of E. coli in MgSO4were added to 10 ml tubes and 10 µl of λ-phage dilution were
added and mixed. The mixture was incubated at 37°C for 20 minutes to allow adsorption of
the phage particles to the bacteria. 4 ml of molten 0.7 % agarose were added to each tube,
mixed with the bacteria and poured onto a pre-warmed (37°C) LB plate. The plates were left
standing at room temperature until the top agarose was solidified and then incubated at 37°C
for 8 hours until the phage plaques were visible.
Detection of specific λ-phage plaques by southern blot
Detection and localisation of phage plaques containing a desired cDNA was performed by
hybridisation of a specific radioactively labeled DNA probe to a nitrocellulose membrane
containing a replica of the phage plaques on the growth plates. To transfer phages onto the
nitrocellulose membrane, a membrane was placed on the surface of an infected plate so that
the entire membrane would be in contact with the plate. The plate and membrane were
marked for subsequent orientation. Transfer of the plaques was done for 5 minutes at room
temperature. For isolation of viral DNA, the membranes were placed facing up in 0.5 N
NaOH/1.5 M NaCl for 2 minutes at room temperature. After a neutralization step using 0.5 M
Tris-HCl pH 8.0/1.5 M NaCl for 2 minutes, the membranes were air-dried for a few minutes.
Phage DNA was immobilized by incubating the nitrocellulose membranes for 2 hours at
80°C. Detection and localization of specific phage plaques was performed using the Southern
blot technique as described.
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Picking λ-phage plaques
To isolate phage plaques, the tip of a Pasteur pipette was used to stab and separate an agarose
piece containing the chosen plaque. The agarose piece was placed in an eppendorf tube
containing 500 µl of suspension medium plus 10 µl chloroform. The tube was incubated O/N
at 4°C to allow diffusion of the phage particles to the medium.
Extraction of λ-phage DNA
For preparation of DNA from individual clones of λ-phage, a suspension containing a phage
clone was used to infect plating bacteria as described. To propagate a phage clone in soft
agarose, the most appropriate dilution of a series of tenfold dilutions was chosen to give a
confluent phage plaques plate. This dilution was used to generate four confluent plates. To
harvest the phages, 5 ml of suspension medium were added to the plates and incubated O/N at
4°C with gentle shaking. All suspension medium containing a single phage clone was
transferred into a polypropylene tube. DNA extraction from the suspension medium
containing the propagated phage clone was performed using the Lambda mini kit (Qiagen)
according to the manufacturer’s instructions.
4.2.3 DNA - Genomic
Preparation of genomic DNA
For genomic DNA preparation from mouse tails, each tail was incubated O/N in 800 µl of tail
buffer at 56°C. The following day, 300 µl of 6M NaCl was added, mixed by shaking and
centrifuged for 10 minutes at 14000 rpm (Eppendorf) at RT to pellet the tail debris. 800 µl of
the supernatant were transferred into a new reaction tube, mixed with 500 µl isopropanol and
centrifuged at 14000 rpm for 5 minutes to pellet the genomic DNA. Supernatant was aspirated
and the recovered DNA was washed in 70 % ethanol and dissolved in 100 µl TE.
For preparation of genomic DNA from ES-cells, a confluent well from a 24 well plate was
washed twice in PBS, incubated O/N at 37°C with 600 µl ES-cell lysis buffer (10 mM Tris-
HCl pH 8.0, 5 mM EDTA, 100 mM NaCl, 1 % SDS and 0.5 mg/ml Proteinase K). The next
day DNA was precipitated in an eppendorf tube by addition of 500 µl isopropanol followed
by mixing by shaking. The precipitated DNA was transferred to a new tube with a tip and
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washed O/N with 70% ethanol. After spinning down the DNA was resuspended in 100 µl TE
O/N at 37°C
Polymerase Chain Reaction (PCR)
For mouse genotyping, the standard genomic PCR reaction was performed with a hot start
protocol that employs the HotStarTaq DNA polymerase. One reaction contained:
17 µl H2 O
2 µl 10xPCR buffer (QIAGEN)
0.5 µl dNTP solution (10 mM each dATP, dCTP, dGTP, dTTP)
0.2 µl each primer 50 mmol)
0.5-1U HotStarTaq DNA polymerase
5 ng DNA
The PCR reaction was initially denatured for 15 minutes at 94°C to activate the HotStarTaq
DNA polymerase. PCR was typically performed with 36 cycles, each cycle consisting of 40
seconds denaturation at 95°C; 40 seconds annealing at the appropriate temperature for the
oligonucleotides; 45 seconds of elongation at 72°C. The amplification products were assayed
by gel electrophoresis.
For cloning purposes either the Pwo polymerase or the High Fidelity Expand was used,
essentially as described above with the omission of the 15 minutes hot start.
Southern blot analysis
Detection and localisation of specific sequences within genomic or plasmid DNA was
performed using the Southern blot technique. Typically the DNA (20mg of mouse genomic
DNA or 1mg of plasmid DNA) was treated with one or more restriction enzymes. The
resulting fragments were separated according to size by agarose gel electrophoresis (0.6 % gel
cast in 0.5xTBE containing 0.5 µg/ml Ethidium Bromide was used for genomic DNA
samples). After electrophoresis was completed, the gel was photographed with a fluorescent
ruler for subsequent assessment of band sizes. The DNA was denatured by incubating the gel
in 0.5 N NaOH, 1.5 M NaCl for 30 minutes with agitation. The gel was then briefly rinsed in
deionized water before the DNA was transferred to a nylon membrane by capillarity under
neutral conditions (20XSSC). The membrane was incubated for two hours at 80°C to
immobilise the attached DNA, followed by a pre-hybridisation (2 hours minimum) in Church
hybridisation solution at 65°C. The membrane was then probed O/N at 65°C with a radio-
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labeled probe in 30 ml of Church buffer. After hybridisation, the membranes were washed in
the following series of increasingly a stringent washing buffers: 2xSSC, 1 % SDS; 0.5xSSC, 1
%S DS; 0.1xSSC, 1 % SDS for 30 minutes each. Autoradiography was used to locate the
positions of the bands complementary to the probe.
Radiolabelling of DNA probes for southern blot analysis
Labelling of DNA probes for southern blot analysis was performed PCR. Using a previously
amplified sequence (in general with a size of 300 bp) as a template in the following reaction,
radioactive dCTP-P32 was incorporated of into the probe:
8 µl H2O
2 µl 10xPCR buffer
3 µl dNTP solution (0.5 mM each dATP, dGTP, dTTP)
5 µl P32-dCTP (50 µCi)
0.5 µl each primer
2.5 U HotStarTaq DNA polymerase (QIAGEN)
5 ng Template DNA
The PCR reaction was initially denatured for 15 minutes at 94°C to activate the HotStarTaq
DNA polymerase. PCR was usually performed with 30 cycles, each cycle consisting of 20
seconds denaturation at 95°C, 30 seconds annealing at 50°C, and 30 seconds of extension at
72°C. A final cycle of 5 minutes at 95°C was performed to denature the labelled probe. The
probe was incubated on ice for 4-5 minutes and then added into the hybridisation solution.
4.2.4 RNA
Microarray analysis of pituitary gland expression pattern
13 week male mice were perfused with PBS, and the pituitary gland immediately removed.
The pituitary glands were dissected with scissors in 600 µl RLT buffer (Qiagen), sheared with
a p1000 pipette and with a Gauge21 syringe and snap frozen in liquid nitrogen. RNA was
prepared using the Qiagen RNeasy kit in accordance with the protocol. The quantity of RNA
was measured by spectrophotometry and the quality of the RNA was analysed by denaturing
gel electophoresis (Gel: 1 % Agarose, 20 mM MOPS, 0.75 % formaldehyde, 0.5 µg/ml
Ethidium Bromide. Running buffer: 20 mM MOPS.) on 2 µg of RNA. 1.8 µg of total RNA
from each pituitary gland was labelled with biotin using the Codelink Expression Assay
Reagent kit according to the protocol. The labelled mRNA was assayed by use of the Agilent
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Bioanalyser and quantified by spectrophotometry. 10 µg of labelled mRNA were fragmented
and loaded on the 20K mouse Bioarray as describe in the protocol and hybridised O/N at
37°C. The Bioarrays were then washed and bound biotin labelled probe detected with Cy5-
streptavidin. The arrays were scanned in a GenePix Array scanner at 635 nm as described and
analysed by Codelink Expression Analysis software. Microarray results were analysed using
the software Genespring from Silicon Genetics.
4.2.5 DNA constructs
Construction of the Men1 targeting vector
A 129 Mouse BAC library was screened with a probe corresponding to exon2 of mouse
Men1. 4 positive BAC clones wereidentified: 7B24, 7D21, 7D23 and 7 F23 and the presence
of Men1 exon 2 was confirmed by PCR. Southern blot on BAC 7B24 and 7D21 revealed the
presence of an approximately 8 kb EcoRV fragment that already published sequence (Guru et
al., 1999) suggested would contain the entire Men1 gene. The EcoRV fragment was cloned in
the Bluescript vector. Unique HpaI and BstEII sites in intron 2 and 6 respectively (se Fig
2.1.1) was used to insert LoxP sites and a positive selection cassette in as described below.
A poly-linker was constructed from 4 oligos with the following sites:
SacI SgfI EcoRV LoxP HpaI LoxP AscI BstEII SpeI SgfI Asp718
First, a 3498 bp EcorV, HpaI 5´arm was inserted into the EcoRV site of the poly-linker. Next,
a 1577 bp HpaI, BstEII Klenow blunted fragment was inserted into the HpaI site.
Independently, a 2869 bp BstEII, EcoRV 3’arm fragment was fused to a PmeI, Spe1 fragment
containing a negative selection Diphteria toxin A (DTA) cassette (Tajbakhsh, S.). This
approximately 3900 bp fragment was inserted into the BstEII and SpeI sites of the construct.
Finally the construct was partially digested with AscI (to avoid cutting an AscI site in the
DTA cassette) and a 3500 bp FRT flanked positive selection neomycin resistance cassette was
inserted as an AscI fragment.
Cloning of full length Gad67
A 1247 bp clone was isolated in a yeast two hybrid screening with Menin as a bait.
Retransformation of the clone into AH109 showed that the clone supported growth in the
presence of Menin-Gal4DNA binding domain but not in the presence of a vector encoding
Gal4DNA binding domain alone.
The clone was used to screen a λ phage pituitary gland library as described. One clone
containing a 3525 bp insert encoding the predicted 5’ end of the gene was isolated. This
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cloned overlapped the original yeast clone with only 92 bp. To clone the predicted 3’ end of
the gene, ESTs were studied and a PCR based approach based on a primer upstream of a SacI
site in the 3’ end of the yeast clone - Gad67SacI1, and a primer downstream of the predicted
translation termination - Gad67PstI was chosen. A 924 bp fragment containing the predicted
sequence was cloned.
To fuse the yeast clone with the λ phage fragment, a 591 bp BamHI, AseI fragment was
cloned by PCR from the yeast two hybrid library using the primers Gad67BamHI and
Gad67AseI. Finally, to clone the open reading frame, the 5’ 108 bp of the open reading frame
was cloned from the phage clone using the primers Gad67NotIXhoI and Gad67SacIDn. The
cDNA was assembled from the 108 bp NotI, SacI fragment + 2921 SacI, BamHI fragment +
591 bp BamHI, AseI + 779 bp AseI, SacI fragment and 924 bp SacI, PstI fragment
Generation of Pit-1-Cre transgene
14.9 kb of Pit-1 promoter containing sequences from –14.8 to +13 of the mouse Pit-1
promoter was cloned as a NotI, XhoI fragment (Rhodes et al., 1993) in front of an expression
cassette consisiting of Cre  recombinase flanked by a rabbit β-globin intron and
polyadenylation signal in the BSSK- vector. This promoter fragment should be sufficient to
ensure tissue specific expression of the transgene (Rhodes et al., 1993).
The plasmid was linealised with NotI and purified from the agarose gel using the BIOTRAP
system. The DNA was dialysed against TE prepared from distilled tissue culture tested water
(GibcoBRL) and diluted to 2 ng/µl in the same buffer.
DNA was injected into the pronuclei of fertilised Oocytes derived from BL-6, CD1 crosses by
the EMBL transgenic facility. The injected Oocytes were implanted in pseudopregnant CD-1
foster-mothers.
DNA constructs for in situ probes
All probes were generated by cloning a DNA fragment containing either the complete cDNA
or relevant parts of the cDNA of the gene to be probed into the BSSK vector. For all probe
except cyclin B and the yeast two hybrid clones, the fragment were generated by PCR from a
pituitary gland cDNA library. The probe for cyclin B was generated by PCR from
chromosomal DNA and the probes from the yeast two hybrid clones were cloned from the
yeast plasmids.
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4.2.6 Cell culture methods
Culture conditions
Mouse embryonic stem (ES) cells were cultured in ES medium: glucose-rich (4500 mg/liter)
DMEM medium supplemented with 15 % Fetal Calf Serum (FCS), 1 % MEM nonessential
amino acids, 1 % Penicillin-Streptomycin, 1 % Glutamine, 1 % Sodium Pyruvat and
Leukaemia Inhibitory Factor (LIF). The ES cells were grown on a layer of mouse embryo
fibroblasts (MEFs) at 37°C with 5 % CO2. Selection of ES cell clones that had integrated the
replacement vectors was done by adding the antibiotic G418 (250 mg/ml) to the medium.
Ongoing cultures of MEFs and ES cells were typically grown in 10-cm tissue culture dishes
with 10 ml of medium. All ES-cell medium was changed daily.
Trypsinisation of cells
ES cells and fibroblasts at sub-confluent density were passed into new tissue culture dishes at
lower density. The medium was aspirated and the cells were washed once with PBS. The cells
were subsequently covered with 0.5 % (w/v) trypsin and incubated at room temperature until
they were visibly detached from the dish. The trypsinisation reaction was stopped by addition
of FCS containing medium. Cells were collected in a 50 ml tube, centrifuged (1500 rpm, 3
minutes) and the pellet was resuspended in new medium. The cells were counted using a
Neubauer chamber and plated at appropriate numbers on new tissue culture dishes.
Mitomycin C treatment of Mouse Embryo Fibroblasts
To mitotically inactivate feeder cells, confluent layers of MEFs in tissue culture dishes were
treated with medium containing 10 mg/ml of Mitomycin C for 3 hours at 37°C with 5 % CO2.
The dishes were washed three time with PBS and the cells collected by trypsinisation. After
centrifugation, the cells were resuspended in feeder medium (glucose-rich (4500mg/liter)
DMEM medium supplemented with 15 FCS, 1 % MEM nonessential amino acids, 1%
penicillin-streptomycin, 1% glutamine), counted and the appropriate number was transferred
to tissues culture dishes to ensure the production of a uniform confluent mono layer of cells.
Freezing and thawing cells
Cells were trypsinised, counted and centrifuged for 3 minutes at 1500 rpm. The supernatant
was discarded and the pellet was resuspended in new medium at a density of 2.5x106 cells/ml.
Aliquots of 1x106 cells were transferred into individual cryo vials and an equal volume of
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medium containing 20% DMSO was added to each vial (10% DMSO final concentration).
The cell suspension was frozen, by storing the vials at -80°C. For long-term storage, vials
were transferred into liquid nitrogen. For thawing, cells the vials were rapidly warmed at 37°C
and the cell suspension was transferred into a centrifuge tube containing medium. The cells
were centrifuged at 1500 rpm for 3minutes, resuspended in new medium and transferred to
tissue culture dishes. ES cells were transferred to tissue culture dishes containing a confluent
layer of mitotically inactive MEFs.
Electroporation of ES cells
An exponentially growing culture of ES cells at passage #4 was prepared for electroporation
by changing medium approximately 3 hours before harvesting the cells. The cells were
trypsinised and medium added to stop the trypsinisation reaction. Cells were centrifuged for 4
minutes at 3000 rpm and RT, washed once and resuspended in PBS as a single cell
suspension. The ES cell suspension was counted, and the cell suspension was centrifuged
once more, washed and resuspended at a density of 1.5x107 cells/ml in Ca2+ /Mg2+ free PBS.
For each electroporation, 0.8 ml (1.5x107 cells) of cell suspension was placed in a sterile
cuvette and 25 µg of linearised DNA were added and mixed well. This mixture was left at
room temperature for 5 minutes and a single pulse of 240 V, 500 mF was applied to the
cuvette. After electroporation, the cells were incubated on ice for 5 minutes and plated onto
10-cm tissue culture dishes of neo-resistant MEF feeder cells. Each 0.8 ml sample from the
electroporation was divided and equally distributed on eight tissue culture dishes. The cells
were allowed to recover for 48 hours in non-selective medium. The G418 selection of ES
clones that had integrated the replacement vectors started 48 hours after electroporation.
Isolation of individual ES cell colonies
Selected individual ES cell colonies were isolated 9-10 days after electroporation. Sets of 96-
well tissue culture dishes containing confluent mono-layers of MEFs in fresh medium were
prepared in advance. Culture medium was replaced by PBS. The tip of a 10 µl micropippete
was used to dissociate individual colonies to small aggregates of only a few cells. The
dissociated colonies were transferred into the 96-well dishes and incubated at 37°C with 5 %
CO2. 48 hours after isolation, the individual clones were trypsinised and further cultured in the
same well to give rise to an exponentially growing set of evenly distributed ES cell colonies.
The growth of all ES cell clones was monitored daily and when considered appropriate (~50%
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confluency for the highest number of clones) all clones in one dish were trypsinised and
divided in the following way: Half of the ES cells of each clone were transferred to a new 96-
well dish containing mitomycin C treated MEFs and these cells were subsequently frozen; the
remaining cells from each clone were transferred to gelatin coated 24-well dishes for later
preparation of genomic DNA. Homologous recombination was verified by southern blot.
ES cell injection into blastocysts and chimera production
Blastocyst injection was performed at the EMBL Transgenic Service. IB10 targeted ES cells
with a 129/OLA genetic background were injected into E4.5 mouse blastocysts of the
C57/Black6 strain produced by natural matings.
Establishment of MEFs
E11.5 embryos were isolated and the head removed for genotyping. The embryos were passed
5 times through an 18 gauge syringe and 5 times through a 21 gauge syringe. The resulting
suspension was plated on in sterile tissue-culture dish (24 well) with medium (DMEM
medium supplemented with 10 % FCS, 1% penicillin-streptomycin, 1% glutamine) and
incubated O/N to allow cells to attach. The next day the medium was changed and cells
allowed to grow to confluency. The cells were passaged with 1:3 to 1:10 splitting.
4.2.7 Tissue sectioning
Tissue preparation and fixation
Fixation of mouse tissues, organs and whole embryos was performed differently depending on
whether the samples would be used for histology, Immunohistochemistry or in situ
hybridisation.
For histological analysis of tissues using paraffin sections, pituitary glands were isolated from
mice perfused in 4 % PFA and fixed 5 hours at 4°C in 4 % PFA. The pituitary glands were
subsequently washed in PBS for 10 minutes at 4°C and stored indefinitely in 70% ethanol at
4°C.
For analysis of gene expression by in situ hybridisation, organs from mice perfused in 10 %
formalin and embryos were properly dissected and stored indefinitely in 10% formalin.
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Cryosectioning
After fixation, embryos and organs were incubated O/N at 4°C in RNAse-free 20 %
Sucrose/PBS (w/v) solution O/N or until the tissue sank. OCT medium was placed in
embedding molds and the tissue sample was introduced in the medium. The molds were
placed in dry ice-cold ethanol to freeze the medium. Typically, 18 µm sections were cut on a
Leica Cryotome with a chamber temperature of -20°C. Tissue sections were transferred onto
glass slides and air dried for a minimum of 2 hours and stored at -20°C for later processing.
Paraffin embedding and mounting
Mouse organs preserved in 70% ethanol were dehydrated in a series of 85%, 96% and three
times 100% ethanol at least for 1 hour for each step at room temperature. The samples were
cleared in two changes of xylene for 30 minutes each and incubated O/N in xylene at room
temperature. The organs were carried through a series of four changes in paraffin 1hour each
at 60°C and embedded in the proper orientation in embedding molds. The molds were stored
at 4°C until sectioning. The microtome was set to cut 7 µm sections.
Vibrotome sectioning
Pituitary glands from mice perfused in 4 % PFA were fixed in 4 % PFA for 4 hours at 4 °C,
washed in PBS and embedded in 2 % Agarose in PBS. The agarose block was mounted on the
vibrotome, and 50 µm section were cut. The agarose was removed when possible with a brush
the tissue sections were stored in 0.5 % PFA in PBS at 4°C.
4.2.8 Histochemistry and Immunohistochemistry
Hematoxylene and Eosin staining
For hematoxylene and eosin staining of brain paraffin sections, slides were incubated twice
for 10 minutes in xylene followed by rehydration in a series of 100%, 96% and 70% ethanol.
After rinsing in distilled H2O, sections were stained in hematoxylene solution (Sigma) for 10
minutes and washed in water for 10 minutes. Sections were subsequently stained in eosin
solution (Sigma) for approximately 30 seconds, rinsed in distilled water, dehydrated in an
ascending ethanol series, cleared in xylene and mounted.
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Immunofluorescence
Imunofluorescence stainings were performed on 50 µm free floating vibrotomes sections
prepared as described. Sections were rinsed for 10 minutes in PBS. For blocking, the tissue
sections were incubated for 2 hours with 5 % (v/v) 2nd antibody species serum in TBS/0.4 %
Triton X-100 at room temperature. sections were washed twice with TBS/0.4% triton X-100
and incubated with the primary antibody at the appropriate dilution in TBS/0.4% triton X-100
O/N at 4°C. The slides were rinsed twice with TBS/0.4% triton X-100 and incubated with
fluorescent-labelled secondary antibody in TBS/0.4 % Triton X-100 for 1 hour at room
temperature in the dark. The slides were washed twice in 1xTBS/0.4% triton X-100 and
mounted with 60 µl of slow fade reagent (Prolong Antifade kit, Molecular Probes) according
to the manufacturer’s indications. Slides were stored at 4°C in the dark.
Immunohistochemistry
Immunohistochemical assays were performed on paraffin sections of embedded pituitary
glands. The sections were initially deparaffinated by incubation in xylene for 3x5 minutes
followed by rehydration in a series of 100%, 95% and 70% ethanol (3 minutes each). After
washing in TBS for 5 minutes, antigen was unmasked and endogenous peroxidases were
inactivated by one of two different methods.
1) Plain method. Sections were incubated for 10 minutes in 3 % H2O2/10 % MeOH in 1xTBS
followed by 5 minutes washing in 1xTBS with agitation
2) Microwave method. Sections were heated in 250 ml unmasking solution (Vector) for 2x5
minutes at 540W in microwave oven. After cooling for 20 minutes, the sections were rinsed in
water and then washed in 1xTBS for 5 minutes with agitation. The sections were then
incubated for 10 minutes in 3 % H2O2/10 % MeOH in 1xTBS followed by 5 minutes washing
in 1xTBS with agitation
The sections were incubated with blocking buffer (0.4 % Triton, 1 % Glycine, 3 % BSA, 10
% normal serum in 1xTBS) in a wet chamber for 2 hours at room temperature. After blocking,
the sections were incubated with primary antibody in blocking buffer in a wet chamber ON at
4°C. The slides were washed for 3x20 minutes in wash buffer (0.4 % Triton, 1 % Glycine, 3
% BSA in 1xTBS) with agitation. The sections were incubated with biotinylated secondary
antibody (vector) in was buffer in a wet chamber for 1 hour at room temperature and then
washed as after primary antibody. The staining procedure using the ABC reagent and DAB
substrate was performed according to the manufacturer’s recommendations. The sections were
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counterstained with methyl green stain (1:8 dilution from 2 % stock 10 minutes) dehydrated
2x10 minutes in 1-Butanol, cleared in xylene and mounted with 60 µl Eukitt.
4.2.9 In situ hybridisation
Generation of in situ probes by in vitro transcription
The radioactive labelling of RNA probes was performed using the Riboprobe® Combination
System-SP6/T7. An in vitro transcription labelling reaction was set up and incubated for 1
hour at 37°C:
4 µl of 5xtranscription buffer
2 µl of 100 mM DTT
0.6 µl RNasin
4 µl of A/G/C mix (2.5mM each nucleotide)
1 µg of linearised template
Nuclease free H2O to 14 µl
5 µl 35S-UTP (100 µCi)
1 µl of RNA polymerase
The labelling reaction was followed by a treatment with DNaseI at 37°C for 15 minutes. This
reaction was stopped by addition of 30 µl nuclease-free water and the labelled RNA was
recovered using ProbeQuant™ G-50 Micro Columns according to the manufacturer’s
protocol. A probe concentration of 5x106 cpm/ml was routinely used on the different tissue
sections. The calculated amount of 35S-labeled probe for 1 ml Hybridisation solution was
initially mixed with 50 µl tRNA, 10 µl 1M DTT and nuclease-free H2O to 200 µl. This
mixture was incubated at 65°C for 5 minutes to denature annealed strands in the labelled
probe and added to 800 µl Hybridisation solution (50 ml l Hybridisation solution: 25 ml
formamide, 10 ml 50 % dextran sulphate, 3 ml 5 M NaCl, 1 ml 1xDenhardt’s solution, 0.5 ml
1 M Tris-HCl pH 8.0, 0.1 ml 0.5 M EDTA pH 8.0, 0.4 ml nuclease free H2O). The
hybridisation mixture was stored at -20°C until the hybridisation step for a maximum of 1
week.
Hybridisation
18 µm frozen cryostat sections were used for in situ hybridisation. The tissue sections were
initially treated with Proteinase K (10 mg/ml) in proteinase digestion buffer (0.1 M Tris-HCl
pH 8.0, 50 mM EDTA pH 8.0) at 37°C for 30 minutes. Slides were rinsed briefly in dH20 and
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incubated in 0.1 M triethanolamine (TEA) pH 8.0 for 3 minutes at room temperature, and then
acetylated in acetylation buffer (625 µl acetic anhydrid, 250 ml 0.1 M TEA) for 10 minutes at
room temperature. Slides were then incubated in 2xSSC for 5 minutes and dehydrated through
an ethanol series of 50%, 70%, 90% and 2 times 100% ethanol for 3 minutes each step. The
slides were drained for 5 minutes and dried under vacuum in an exciccator for a minimum of
2 hours until hybridisation.
To hybridise the tissue sections with the a 35S-labelled probe, an aliquot of the hybridisation
mixture was placed at 65°C for 10 minutes and then centrifuged for 10 minutes at 3000 rpm to
eliminate any dextran sulfate precipitates that may have formed. 65 µl of hybridisation
mixture was applied to each slide (50x22 mm) and the tissue sections were then covered with
a coverslip and sealed with the application of a bead of liquid DPX mounting medium. For
hybridisation, the slides were incubated O/N on 60°C slide-warming tray. After hybridisation,
the slides were cooled and incubated four times 15 minutes with 4xSSC. The slides were
subsequently treated with RNaseA in RNase buffer (RNaseA 20 µg/ml, 25 ml 5 M NaCl, 2.5
ml 1 M Tris-HCl pH 8.0, 500 µl 0.5 M EDTA pH 8.0, dH2O to 250 ml ) for 37 minutes at
37°C. This was followed by a washing and gradual de-salting series of the following
solutions: 2xSSC, 1 mM DTT for 5 minutes at RT; 1xSSC, 1 mM DTT for 5 minutes at RT;
0.5xSSC, 1mM DTT for 5 minutes at RT; 0.1xSSC, 1mM DTT for 37 minutes at 65°C;
0.1xSSC, 1mM DTT for 3 minutes at RT. Slides were then dehydrated through an ethanol
series of 50 % ethanol (with 0.08xSSC, 1mM DTT), 70 % ethanol (with 0.08xSSC, 1mM
DTT), 95 % ethanol and 100% ethanol each step for 3 min. The slides were finally drained for
5 minutes and dried under vacuum in an exciccator for a minimum of 2 hours.
4.2.10 Mouse methods
Mice were housed in a specific pathogen free environment and under controlled light,
temperature (21°C) and humidity (50 % relative humidity) conditions. Water and food were
provided as needed. Mice were routinely weaned from their parents at the age of 3 weeks with
males and females being housed separately. Mice were tagged using six-digit number eartags
and tail biopsies were taken for genotyping.
For experiments with embryos, breedings were set up with one male and one female. Vaginal
plug-checks were performed daily, starting the morning following the set up of the breeding.
The presence of a plug was considered day 0.5 of pregnancy. Embryos were taken from the
mothers as previously described. For genotyping of embryos at day E12.5 or younger the yolk
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sacs were separated from the placenta and used for DNA extraction. With embryos older than
E12.5 tissue samples for genomic DNA were normally taken from the tail. The day of birth of
the new litters was considered P0.
4.2.11 Proteins
Cell-extracts
All extracts from cell-culture and mouse tissues were done in RIPA buffer (50mM Tris-HCl
pH 7.5, 150 mM NaCl, 1 % NP-40, 0.1 % SDS, 0.5 % Sodiumdeoxycholate, 0.05 % β-
mercaptoethanol, protease and phosphatase inhibitors).
Mouse pituitary glands were removed after perfusion with PBS, snap frozen in liquid nitrogen
and lysed in RIPA buffer in an eppendorf tube with a pestel. The extracts were sheared with a
pipette tip and insoluble debris spun down at 14000 rpm.
Mouse Embryo Fibroblast cultures were lysed on ice in RIPA buffer with a cell scraper and
the extracts treated as above.
Protein concentration meassurements
Protein concentrations were determined by Bio-Rad Bradford protein assay according to the
manufactures protocol. In all assays, BSA was used as a standard.
SDS-PAGE
All SDS-PAGE gels were run on the Mini Protean 3 system and the gels wereprepared as
follows:
Separation gel: 0.375 M Tris-HCl pH 8.8, 8-18 % acrylamide, 0.1 % SDS, 0.05 % APS and
TEMED (3 µl in 5 ml)
Stacking gel: 0.125 M Tris-HCl pH 6.8, 3.9 % acrylamide, 0.1 % SDS, 0.05 % APS and
TEMED (5 µl in 5 ml)
Extracts were heated to 90°C for 4 min. in Laemmli buffer (5xLeammli buffer: 0.15 M Tris-
HCl pH 6.8, 5 % SDS, 25 % glycerol, and 0.050 % Bromidephenolblue) with 3 % β-
mercapto-ethanol added freshly just before heating. The heated samples were spun at 14000
rpm for 2 minutes before loading on the gels. Gels were run at 100-200V in running buffer
(25 mM Tris, 192 mM Glycine)
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Western blotting
All blots weredone using the Mini Trans-Blot Cell. I all cases nitrocellulose membranes were
used. The mini-gels were blotted in a buffer containing 20 % Methanol (analytic grade), 0.1 %
SDS, 8.3 mM Tris, and 64 mM Glycine at 80 volts for 60-90 minutes at 4°C.
Probing
Membranes were blocked in PBS, 0.075% Tween20 + 5 % milk for an hour at room
temperature or overnight at 4°C. All primary antibodies were used in 1:1000 times dilution in
PBS, 0.075% + 1-5 % milk unless otherwise indicated in the figure legends. In all cases
incubations were for 2 hours at RT or overnight at 4°C. All washes were done in PBS, 0.075%
Tween20. All secondary antibodies were used in 1:5000 times dilution in PBS, 0.075%
Tween20 (washing buffer) + 1-5 % milk for 1 hour at RT. Western blot were developed using
ECL from Promega
Purification of GST-Menin
Bacteria transformed with pET-41a-Men1 were grown in 10 ml LB, 30 µg/ml Kanamycin
O/N. The culture was diluted to 4000 ml in LB, 30 µg/ml Kanamycin and grown to an OD600
of 0.6. 1mM IPTG were added and the bacteria grown for four additional hours. The bacteria
were spun down (4000 rpm, GSA) and resuspended in 50 ml PBS, 0,5 mM DTT + protease
inhibitors. The bacteria were sonicated 8-10 times 30 seconds and Triton X-100 was added to
1% followed by mixing for 30 minutes at 4°C. The bacterial lysates were spun at 10000 rpm
(SS34) for 10 minutes at 4°C to pellet insoluble aggregates. Glutathion-Sepharose was
washed three times in cold PBS, added to the cleared bacterial lysate and incubated for 2
hours 4°C on a wheel. The beads werespun down at low speed (1000g) and washed 4 times
with PBS- Triton X-100. GST-Menin was eluted in 2x1 ml of 20 mM reduced glutathione, 50
mM Tris-HCl, pH 8.0. Eluates were concentrated and the buffer changed to PBS using
Centricon filter devises.
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